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Abstract 
 
Transmissible spongiform encephalopathies (TSE), also known as 
prion diseases, are fatal neurodegenerative disorders present 
both in human and animals with different aetiology as they can 
occur genetically, spontaneously or by infection (Prusiner, 1998). 
TSE are caused by the presence of proteinacious aggregates, 
called ‘prions’, in brains of afflicted individuals. According to the 
‘protein-only’ hypothesis, the central event of prion pathogenesis 
is the conformational change of the cellular protein, PrPC, into its 
pathological counterpart, PrPSc in a process in which PrPSc acts as 
a template (Prusiner, 1998). Differently from PrPC, mainly 
constitutes of α-helices, PrPSc is enriched in β-sheets, 
aggregation-prone and resistant to treatment with proteinase K. 
Despite the intense research, many questions in prion biology are 
still open related to both the physiological functions of PrPC and 
mechanism of the disease caused by the misfolded form PrPSc. 
Thus, exploring some of these aspects at the molecular and 
cellular level is of fundamental importance for a better 
understanding of these fatal disorders and for developing 
potential therapeutical approaches. However, due to the lack of 
PrPSc-specific antibodies, PrPSc cellular trafficking, production and 
degradation are poorly defined.  
In the first part of my thesis I investigated the role of autophagy 
in prion disease. I demonstrated that although autophagic 
pathway is stimulated by prion infection, it is not involved in 
prion degradation. Furthermore, I showed that tamoxifen and its 
metabolite 4-hydroxil-tamoxifen (OHT) (previously shown to be 
autophagy inducers) reduce scrapie burden by redistributing 
cholesterol and PrP to lysosomes in an autophagy-independent 
manner. These data confirm the role of the lysosomal pathway in 
prion degradation and of cholesterol in prion formation. 
Furthermore, since tamoxifen is a wide-available pharmaceutical 
tool it might have potential application in therapy for prion 
disease. 
Another important question in prion biology is related to the 
spreading of PrPSc. At the different stages of its lethal journey to 
the central nervous system, PrPSc is transferred from one cell to 
another and this passage can involve several mechanisms. 
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Recently our laboratory has shown that PrPSc hijacks intercellular 
membranous channels, called tunneling nanotubes (TNT), for 
intercellular spread (Gousset et al., 2009; Langevin et al., 2010). 
Therefore, in the second part of my PhD work I have better 
characterized TNT-mediated trafficking of PrPSc between neuronal 
cells, as model of prion infection. I also identified factors that 
could be involved in TNT formation and in the resulting transfer 
of PrPSc between cells. These results will contribute to the 
characterization of both TNT formation and prion spreading and 
open the way to further investigations.  
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1. On the nature of prions: a brief overview 
 
Transmissible spongiform encephalopathies (TSE), also known as 
prion diseases, are fatal neurodegenerative disorders present 
both in human and animals with different aetiology as they can 
occur genetically, spontaneously or by infection (Prusiner, 1998). 
It is now well accepted that they are caused by the presence of 
proteinaceous aggregates, called ‘prions’, in brains of afflicted 
individuals deriving from a conformational change of the cellular 
protein PrPC, into its pathological counterpart, PrPSc (Prusiner, 
1998). But initially, the nature of the agent was highly debated 
for many years (Collinge, 2001). Alper and Griffith developed the 
theory that some transmissible spongiform encephalopathies 
were caused by an infectious agent consisting solely of 
proteins(Alper et al., 1967; GRIFFITH, 1967). This hypothesis was 
formulated to explain the fact that the mysterious infectious 
agent causing scrapie in sheep and goats and Creutzfeldt-Jacob 
(CJD) disease in humans (see below, Section2 of the 
Introduction) resisted to ionizing radiation and nucleases 
treatments, thus excluding the possibility that the infectious 
agent could have had a viral origin. As a follow up, in 1982 
Stanley B. Prusiner and its team at the University of California in 
San Francisco purified the infectious agent claiming that it 
consisted only of proteins. They named it ‘prions’ (pronounced 
"pree-ons") from “proteinaceous infectious particles” that are 
“resistant to inactivation by most procedures that modify nucleic 
acid’ (Prusiner, 1982). Prusiner was then awarded the Nobel Prize 
in Medicine in 1997 for his research on prions. 
Despite the fact that this ‘protein-only’ hypothesis formulated by 
Prusiner is now widely accepted and supported by a great 
number of data presented in the literature (Aguzzi and Calella, 
2009a; Aguzzi et al., 2008; Colby and Prusiner, 2011), other 
hypotheses across the years have been advanced on the nature 
of prions. 
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1.1 The ‘protein-only’ hypothesis vs the ‘virino’ hypothesis 
 
An alternative to the ‘protein-only’ hypothesis, the ‘virino’ 
hypothesis has been proposed in part to protect the ‘central 
dogma of biology’ (Crick, 1970). It claims that prions could be 
actually a ‘virino’, or slow virus, formed by a prion specific nucleic 
acid associated or coated by proteins encoded by the host. 
Firstly proposed by Dickinson and Meikle in 1971, it is based on 
the discovery of a single autosomal gene, that they named sinc 
(for scrapie incubator) that control scrapie incubation period in 
mice. This hypothesis proposed that the gene products of each 
sinc allele contributed to a multimeric protein structure, which 
then formed a 'replication site' for the scrapie agent (Dickinson 
and Outram, 1988). This hypothesis could also explain the 
absence of inflammatory response in prion diseases (Eklund et al., 
1967; Manuelidis, 2003). These small viruses would be able to 
escape inactivation by irradiation (Manuelidis, 2003). However, all 
experiments to purify a prion specific nucleic acid have failed to 
date (Caughey et al., 1997). Nevertheless some nucleic acids 
copurify with the infectious material, and in human brain-samples 
a highly infectious fraction containing little PrPSc together with 
nucleic acids can be separated from a less infectious fraction 
containing the majority of PrPSc (Akowitz et al., 1993; Sklaviadis 
et al., 1992). These results are in agreement with the 
observation that the rate of conversion of prions in vitro is higher 
in the presence of some DNA (Cordeiro et al., 2001) or RNA 
molecules (Deleault et al., 2003). Additionally, it has been 
recently shown that PrPC interacts with viral RNAs and is able to 
act as a chaperone (similar to the nucleocapsid proteins NCP7 of 
HIV-1) (Gabus et al., 2001a; b). 
Some evidences support a role for nucleic acids in prion 
conversion but additional studies will be necessary to assess their 
possible function and role in the disease. 
 
1.2 Prion protein gene 
 
Purification of the protease-resistant core PrP27-30 allowed the 
determination of its NH2-terminal amino acid sequence and the 
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following synthesis of an isocoding mixture of oligonucleotides 
that was subsequently used to identify incomplete PrP cDNA 
clones from hamster and mouse (Chesebro et al., 2005; Oesch et 
al., 1985).  
The prion protein gene (PRNP) belongs to the PRN gene family 
that consists of PRND, encoding the Doppel protein (Moore et al., 
1999), and SPRN, encoding Shadoo (Watts and Westaway, 
2007). PRNP is located in the short arm of the chromosome 20 
in humans and in a homologous region in mouse chromosome 2 
(Colby and Prusiner, 2011). The open-reading frame (ORF), 
responsible for the transduction of the PrPC protein, resides in a 
single exon in all known mammalian prions and avian genes PRNP 
(Westaway et al., 1987). However, the gene itself comprises two 
to three exons that contain untranslated sequences including the 
promoter and termination sequence (Hsiao et al., 1989; Gabriel 
et al., 1992). The PrP promoter contains multiple copies of GC-
rich repeats that represent a well-known binding site for the 
transcription factor Sp1 site driving expression in many different 
tissues (McKnight and Tjian, 1986). PRNP transcript is 
constitutively expressed in different tissues and especially within 
the brain of different animals but is highly regulated during 
development (Chesebro et al., 1985; Oesch et al., 1985). In 
addition, PRNP mRNA does not increase during the course of 
prion disease (Oesch et al., 1985).  
Furthermore, high levels of similarities in the PRNP sequence have 
been found by aligning more than 40 translated sequences from 
different species (Colby and Prusiner, 2011). This highlights the 
importance of PrPC protein functions and explains why the gene 
has been conserved through evolution. However, variations in PrP 
sequences exist both between species and between individuals 
within species (Figure 1), thus affecting their susceptibility to 
prion. 
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Figure 1 Variation in the prion protein gene. Species variations of the prion protein gene. 
The x-axis represents the human PrP sequence, with the five octarepeats and H1–H4 regions 
of the putative secondary structure shown, as well as the three !-helices A, B, and C and the 
two "-strands S1 and S2 as determined by NMR. Vertical bars above the axis indicate the 
number of species that differ from the human sequence at each position. Below the axis, the 
length of the bars indicates the number of alternative amino acids at each position in the 
alignment. From Colby and Prusiner 2011 
 
 
Besides, knock-out mice for PRNP gene (as Prnp 0/0, Zürich I and 
Prnp -/-, Edinburgh) have been generated from different 
laboratories (Manson et al., 1994; Büeler et al., 1992). These 
mice are vital, do not show particular signs of alterations and 
develop normally. In contrast, other mice models ablated of PRNP 
did show some dysfunction, afterwards attributed to abnormal 
expression of Doppel and due to the technique used to engineer 
these mice (Moore et al., 1999; Sakaguchi et al., 1996). But, in 
agreement with the ‘prion-only’ hypothesis all these mice are 
resistant to prion infection (Aguzzi et al., 2008). 
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1.3 Biochemical properties of PrPSc 
 
Purified full-length PrPSc is insoluble in non-ionic detergents and 
has partial protease resistance, with only the N-terminal third of 
the sequence being cleaved leaving a protease-resistant core, 
PrP27-30, which retains infectivity (Riesner, 2003). Indeed, limited 
protease digestion has been a convenient tool to detect PrPSc 
because the same treatment fully hydrolyzes the cellular protein 
PrPC thus allowing the discrimination between the two forms 
(Figure 2).  
 
 
 
Figure 2 Schematic representation of hamster Prnp gene and PrP isoforms. (A) The Prnp 
ORF encodes a protein of 254 residues, which is shortened to 209 residues during 
posttranslational processing. PrPSc is an alternate conformation of PrPC with identical primary 
structure. Limited proteolysis of PrPSc cleaves the amino terminus and produces PrP 27-30, 
composed of approximately 142 residues. (B) Western blotting of cell lysates from prion-
infected (lane 2) and uninfected  (lane 3) CAD cells. Samples in lanes 2 and 3 were digested 
with 50 #g/#l proteinase K for 30 min at 37°C, completely hydrolyzing PrPC, thus allowing to 
discriminate between the two isoforms of PrP. Blot developed with anti-PrP monoclonal 
antibody Sha31. Modified from Prusiner 2004 
!
Moreover, the increased propensity of PrPSc to aggregate 
correlates with its resistance to PK digestion. Also, cathepsin D 
can digest the C-terminus of PrPSc and liberates the 
glycosylphosphatidylinositol (GPI) anchor and the resulting PrPSc 
fragment retains prion infectivity (Lewis et al., 2006). Besides, 
transgenic mice expressing PrPC lacking a GPI anchor can 
propagate prions (Chesebro et al., 2005), thereby suggesting 
that the GPI anchor - which normally attaches PrP to the 
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membrane (see below in section 1.4 of the Introduction) - is not 
a prerequisite component of the infectious prion. Unlike PrPC, 
which can be readily cleaved from membranes by treatment with 
phosphatidylinositol-specific phospholipase C (PIPLC) (Stahl et al., 
1987), PrPSc is resistant to such treatment (Caughey et al., 
1990; Borchelt et al., 1993) suggesting that a conformational 
change prevents accessibility of PIPLC.  
Structural studies by Fourier Transform Infrared Spectroscopy 
(FTIR) and circular dichroism have demonstrated that unlike PrPC, 
which is predominantly α-helical, PrPSc is highly enriched in β-
sheets (Pan et al., 1993a; Gasset et al., 1992). β-sheet content 
in PrPSc comprises 45% compared to 3% in PrPC (Figure 3).  
 
 
Figure 3 Schematic representation of the structures of PrPC and PrPSc. Differently from 
PrPC (A), enriched in !-helices and fully digested upon PK treatment, PrPSc (B) is highly 
enriched in "-sheets, prone to aggregation and partially resistant to PK-digestion. (Picture from 
http://www.flickr.com/photos/ajc1/with/464066753/) 
 
The protease-resistant core of PrPSc has been shown to re-
arrange into amyloid rods, which stain with Congo red and show 
green-gold birefringence, typical of amyloids (Prusiner et al., 
1983). Interestingly, PrPSc deposits of varying sizes and 
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morphologies, including amyloid plaques, have been identified in 
scrapie-infected animal brain tissues (Merz et al., 1981). 
Nonetheless, no experimental evidence supports the presence of 
fibrils in human prion disease (Budka, 2003), although studies 
using synthetic fibrils have provided some insight into prion 
conformation (Tattum et al., 2006; Baskakov et al., 2002). 
Furthermore, although the nature of the self-propagating 
infectious agent is unknown, recent studies have demonstrated 
that small PrP oligomers of 14-28 molecules were maximally 
infective when compared to monomeric or fibrillar PrP (Silveira et 
al., 2005). 
 
1.4 Prion replication 
!
The use of transgenic mouse models has also provided genetic 
and biochemical evidences that the conversion of PrPC to PrPSc 
needs the formation of a PrPC-PrPSc complex in which probably 
PrPC is present in a partial unfolded state, named PrP* (PrP star) 
(Prusiner et al., 1990a; Meier et al., 2003). However, such a 
complex has never been isolated and this raises the possibility 
that one or more additional factors (generally termed as protein 
X) can be required for the conversion process (Prusiner, 1998). 
Indeed, supporting data towards the presence of other factors 
essential in prion conversion have shown that incubation of 
purified PrPC and PrPSc does not allow prion replication (Soto et 
al., 2002). Also, addition of the bulk of cellular protein, restore 
the conversion process, thus providing direct evidence that other 
factors present in the brain are essential to catalyze prion 
propagation .  
In addition, differences in the amino acidic sequence can influence 
the conversion efficiency (Scott et al., 1989) and also different 
levels of PrPC can be directly proportional to the rate of PrPSc 
formation and this inversely to the length of the incubation time 
(Soto et al., 2002). In some cases, the conversion process itself 
is impaired, a phenomenon known as ‘transmission barrier’ (see 
below in the paragraph 1.5). 
Two different conformational conversion models have been 
proposed to explain the phenomenon: the ‘template-directed 
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refolding’ model (Prusiner, 1998) and the ‘seeded nucleation’ 
model (Jarrett and Lansbury, 1993). In the ‘template-directed 
refolding’ PrPC to PrPSc conversion would occur through 
“instructions” given by PrPSc to PrPC in order to change the 
structure of the latter (Figure 4, A) in the pathological conformer 
of the protein.  
 
 
Figure 4 Model of prion replication. (A) The 'refolding' or template-directed assistance model 
postulates an interaction between exogenously introduced disease-associated prion protein 
(PrPSc) and endogenous cellular prion protein (PrPC), which is induced to transform itself into 
more PrPSc. A high-energy barrier might prevent the spontaneous conversion of PrPC to PrPSc. 
(B) The 'seeding' or nucleation–polymerization model proposes that PrPC and PrPSc are in a 
reversible thermodynamic equilibrium. So, only if several monomeric PrPSc molecules are 
mounted in a highly ordered seed can more monomeric PrPSc be recruited and eventually 
aggregate to form amyloid. In such a crystal-like seed, PrPSc becomes stabilized. Fragmentation 
of PrPSc aggregates increases the number of nuclei, which can recruit more PrPSc, and so 
seems to result in replication of the agent. In sporadic prion disease, fluctuations in the local 
PrPC concentration might (exceptionally rarely) trigger spontaneous seeding and self-
propagating prion replication. From Aguzzi et al 2001 
 
On the other hand, the ‘seeded nucleation’ model proposes that 
PrPSc could exist in equilibrium with PrPC shifted towards PrPC 
under physiological conditions. However the intrinsic instability of 
PrPSc could lead to aggregation of this conformer in more stable 
‘seeds’ that are prone to incorporate other monomers, thus 
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shifting the equilibrium towards an accumulation of the 
pathological isoform PrPSc (Figure 4, B). A precise knowledge of 
both PrPC and PrPSc structural features is necessary to support 
one or the other hypothesis. While both high-resolution nuclear 
magnetic resonance (NMR) and crystallographic structures are 
available for PrPC, a high-resolution 3D structure for PrPSc is still 
missing, thus slowing down the progress in the study of the 
conversion mechanism (Aguzzi and Polymenidou, 2004). 
Recently, an in vitro prion conversion system called PMCA 
(protein misfolding cyclic amplification) in a cell-free environment 
has been developed to mimic PrPSc autocatalytic replication in the 
presence of excess of PrPC and a minute quantity of PrPSc (Castilla 
et al., 2008, 2005).  In the amplification process, developed by 
Castilla and colleagues, PrPSc aggregates formed by the 
conversion of PrPC are subsequently disrupted by sonication in 
smaller ‘seeds’ that are then reused in further cycles of 
conversion (Figure 5) (Soto et al., 2006).  
 
                     
Figure 5 In vitro generation of infectious prions. Subjecting a solution of highly diluted brain-
derived PrPSc in an excess of PrPC to many cycles of protein misfolding cyclic amplification 
(PMCA) resulted in amplification of the amount of PrPSc at the expense of the normal protein (A) 
. When the in vitro generated PrPSc was inoculated into wild-type hamsters, all of the hamsters 
developed a disease with clinical, histological and biochemical characteristics typical of scrapie. 
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Control hamsters inoculated with the original diluted material (B) without amplification remained 
free of the disease.  From Soto et al 2006 
 
Further experiments using PMCA have then shown that PrPSc 
propagated in vitro led to a scrapie disease with similar 
pathological features than the brain-derived one, once inoculated 
in wild-type hamsters (Castilla et al., 2005). Moreover, Castilla 
and co-workers (2008) have reported that PMCA-replicated 
prions, derived from five different mouse and four distinct human 
prion strains, after injection into wild-type mice produced a 
disease with indistinguishable characteristics as the parental 
strain. Thus, confirming that PMCA could be used to replicate 
different types of prion. The use of PMCA reaction could be 
applied not only to detect prions in the brain in early pre-
symptomatic cases, but also to generate a test to diagnose living 
animals and people (Soto et al., 2002). Therefore, taken 
together, these findings support the ‘protein-only’ hypothesis 
and highlight the strong identity of the different prion strains 
present that are directly linked with their diverse biochemical, 
structural and biological properties (Castilla et al., 2008).  
 
1.5 Strains and transmission barrier 
 
Prion strains represent one of the most intriguing features of 
prion diseases. They are defined as infectious isolates that, when 
transmitted to identical host, exhibit distinct prion-disease 
phenotypes that are maintained unaltered for several passages 
(Aguzzi and Calella, 2009a). Phenotypic traits associated with 
different strains include distinct patterns of protein aggregate 
deposition, incubation times, histopathological lesion profiles and 
specific neuronal targets. The phenomenon was first noticed 
when goats where inoculated with “hyper” and “drowsy” isolates 
from sheep. Indeed, two different phenotypic traits of the 
disease were observed accordingly with the inoculated isolate 
deriving from infected animals with characteristic disease-
associated traits (PATTISON and MILLSON, 1961). Prion strains 
exhibit specific migration profiles of PrPSc fragment following PK-
assay on SDS-PAGE highlighting their conformational diversity 
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(Parchi et al., 1999). Also, they can be associated with different 
glycosylation patterns resulting in different ratios of the 
glycosylated forms (Prusiner, 1998; Collinge, 2001). Both PrPC 
and PrPSc exist in three different glycosylated forms: 
unglycosylated, mono-glycosylated and bi-glycosylated. For 
example, PrPSc fraction in immunoblots of brain extracts after 
digestion with PK deriving from individuals affected by variant 
CJD lead to a specific glycosylation pattern (type 4 pattern), 
similar to the one given by bovine spongiform encephalopathy- 
(BSE) affected brains and different to the one deriving from 
sporadic CJD and iatrogenic CJD (Type 1, 2 or 3 patterns) (Parchi 
et al., 1999; Hill et al., 1997a) (Figure 6).  
 
 
Figure 6 Representation of the three glycosylated PrPSc moieties (un-, mono-, and 
diglycosylated PrPSc) in immunoblots of brain extracts after digestion with proteinase K. 
Different inocula result in specific mobilities of the three PrP bands as well as different 
predominance of certain bands (top panel). These characteristic patterns can be retained, or 
changed to other predictable patterns after passage in wild-type mice (bottom panel). On the 
basis of the fragment size and the relative abundance of individual bands, three distinct patterns 
(PrPSc types 1–3) were defined for sCJD and iCJD cases. In contrast, all cases of vCJD and of 
BSE displayed a novel pattern, designated as type 4 pattern. From Aguzzi et al 2009 
 
It has been proposed that the prevalence of distinct glycoforms 
may determine the structure of infectious PrP seeds and thereby 
determine strain properties (Collinge, 2005a). These data 
strongly support the ‘protein-only’ hypothesis of infectivity and 
Page | #$"
suggest that strain variation is encoded by a combination of PrP 
conformation and glycosylation (Collinge, 2001).  
Prion strains display different organ tropisms. Some of them 
preferentially propagate in the central nervous system, as bovine 
prion causing BSE and some others are also detected in 
secondary lymphoid organs as many scrapie and vCJD strains 
(Aguzzi and Calella, 2009b). Yet, this different tropism suggests 
that cell-specific co-factors, such as RNA species, chaperones or 
lipids, are required for replicating prion in different physiological 
environment. 
‘Strain mutations’ are also observed upon transmission of prions 
to the same species carrying a different polymorphism in PrPC or 
to different species (Wadsworth et al., 2004; Bruce, 1993). Also, 
many of the inoculated animals have a delay in developing or do 
not develop the disease (Tateishi et al., 1996; Telling et al., 
1994; Carlson et al., 1989; Telling et al., 1995). This 
phenomenon is referred to as the ‘transmission barrier’ and was 
first noted by Ian Pattison in 1965 (Colby and Prusiner, 2011).  
It seems that the most important factor regulating the 
transmission barrier is the sequence homology between PrPC in 
the inoculum and PrPC expressed by the host. In fact, mice 
resistant to a different species prion strain became susceptible to 
the infection if artificially expressing PrPC of that species (Prusiner 
et al., 1990b). For example, transmission studies of human prion 
diseases have shown that while classical CJD prions may be 
efficiently transmitted to transgenic mice expressing human PrPC, 
they encounter a significant barrier for transmission to wild-type 
mice. On the other hand, vCJD prions transmit readily to wild-
type mice, whereas their transmission to transgenic mice 
expressing human PrPC is relatively inefficient (Collinge, 2001; 
Collinge and Clarke, 2007). 
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2. Human and animal prion diseases 
 
As already mentioned in the first section, transmissible 
spongiform encephalopathies (TSE) are fatal neurodegenerative 
disorders present both in human and animals that can occur 
genetically, spontaneously or by infection (Prusiner, 1998).  
Both animal and human conditions share common 
histopathological features (Figure 7) that include spongiform 
vacuolation (affecting any part of the cerebral grey matter), 
neuronal loss, and astrocytic proliferation that may be 
accompanied by amyloid plaques (Beck et al., 1982).  
 
 
 
 
Figure 7 Histopathological features associated with TSEs showing spongiform 
degeneration and astrocytic gliosis . Analysis of grey matter from brain sections of (A) a 
BSE-infected cow, (B) an individual affected from CJD, (C) sheep and (D) kuru-affected 
individual. Modified from http://www.biophys.uni-
duesseldorf.de/research/prions/index.html  
 
Also, no infiltration of lymphocytes and macrophages has been 
detected due to the absence of the immune response (Collinge, 
2001). The long pre-symptomatic period is a characteristic of 
TSE and is then followed by a rapid progression after the first 
symptoms that lead inevitably to death. Specific clinical signs are 
associated with each type of TSE but they include perturbations 
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of the locomotor and sensory system, lack of coordination and 
progressive dementia (Collinge, 2001). 
 
2.1 Animal 
 
Prion diseases occur in many animals and more frequently as 
infectious disorders (Table 1).  
 
    
Table 1 Animal and Human prion diseases.  
 
The most known are scrapie in sheep and goat, bovine 
spongiform encephalopathy (BSE) in cattle, transmissible mink 
encephalopathy (TME) (Marsh et al., 1991), chronic wasting 
disease (CWD) of mule deer and elk (Williams and Young, 1980) 
and the more recently described feline spongiform 
encephalopathy (Wyatt et al., 1991).  
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2.1.1 Scrapie 
 
Initially thought to be a muscle disease caused by parasites, such 
as amoeba by Girard in 1830, scrapie is the prototypic prion 
disease and has been the object of studies since the 19th century 
because of the importance of the wool textile business in the 
industrial revolution and its impact on the economy (Aguzzi and 
Polymenidou, 2004). Its name originates from the main clinical 
symptom, an itching sensation caused by the disease that 
induces the animal to scrape its fleece off (Figure 8, A).  
 
 
 
Figure 8 Scrapie and Kuru (A) The oldest known prion disease, was described 1759 (Leopold) 
and is characterized by the abnormal walk and scratching of infected sheep and goats. The 
srapie agent was adapted to mice and hamster, which are used as model systems in basic 
research. (B) Among the Fore people in Papua New Guinea the spread of kuru was caused by 
a ritual cannibalism. Besides the coordinative malfunctions the cerebellar deficits were often 
associated by uncontrollable and inapropiate episodes of laughter. Modified from 
http://www.pipevet.com/articles/Scrapie.htm and http://www.biophys.uni-
duesseldorf.de/research/prions/index.html  
 
Other symptoms include gait disorders and wool loss; death 
usually occurs between 6 weeks to 6 months after the onset of 
symptoms. Polymorphisms at codon 136 and 171 of the prion 
protein gene (PRNP) in sheep have been studied with respect to 
the occurrence of scrapie in sheep (Clouscard et al., 1995). At 
present, its routes of transmission remain unclear; however, a 
hereditary link has been suspected because of a strong genetic 
element (Parry, 1979). Initial transmissibility studies of scrapie 
infection were negative. The failure to recognise the long 
incubation times of the disease was overcome by the work of 
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Cuillé and Chelle in 1936 (“La maladie dite tremblante du mouton 
est-elle inocuable?” C. R. Acad. Sci. 203, 1552-1554) in which 
they demonstrated that scrapie can be transmitted into goats 
following injection of scrapie infected brain. The transmissibility 
of the infectious agent was further confirmed after scrapie was 
accidentally transmitted into sheep when a Scottish herd was 
inoculated against a virus with a brain, spleen and spinal cord 
extract from an infected animal (Collinge, 2001). Since then, 
scrapie has effectively been transmitted experimentally into other 
species including laboratory mice (CHANDLER, 1961), 
demonstrating that it can cross the ‘species barrier‘ and it is 
currently used as model in prion research. To date, scrapie has 
never been shown to pose a threat to human health (Collinge, 
2001). 
 
2.1.2 Bovine Spongiform encephalopathy 
 
BSE, also known as ‘Mad Cow disease’, has raised the attention of 
the public for the first time in 1986 in Great Britain where it 
appeared like an epidemic disease in which nearly one million 
cows were infected with prions (Anderson et al., 1996). Clinical 
symptoms include changes in temperament and movement 
disorders. Since the incubation time for BSE is around 5 years, 
infected cattle slaughtered at 2 or 3 years of age were in a pre-
symptomatic phase and therefore not recognized as afflicted by 
BSE (Stekel et al., 1996). The disease is caused by meat and 
bone meal (fed primarily to dairy cows) deriving from offal of 
sheep, cattle (probably affected by a rare sporadic BSE), pigs and 
chickens as they represent high sources of nutrients (Wilesmith 
et al., 1991; Nathanson et al., 1997). Changes in the feeding 
system eliminated the epidemic, that reached its peak in 1992 
but sporadic cases can still arise occasionally (Colby and Prusiner, 
2011). 
Also, brain extracts deriving from prion-infected cows can 
transmit the disease to mice, cattle, sheep and pigs after 
intracerebral inoculation (Aguzzi and Calella, 2009a; Fraser et al., 
1988). More importantly, and differently from scrapie, BSE can 
be transmitted to humans in a new variant, vCJD, by ingestion of 
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contaminated food (see below, paragraph 2.2). In 1994, the first 
cases of vCJD in teenagers and young adults occurred in Britain 
(Will et al., 1996a) and later one case was recognized in France 
(Chazot et al., 1996) presenting unusual neuropathological 
features that did not match with CJD cases.  
 
2.1.3 Transmissible mink encephalopathy 
 
Transmissible mink encephalopathy (TME) was the first TSE to be 
identified in non-domestic animals. It rarely develops in captive 
mink (Mustela vison) and it is thought to derive from ingestion of 
BSE-contaminated feed (Williams and Miller, 2003). Symptoms 
include aggression and loss of muscle coordination; animals die 
within 6 weeks following the onset of symptoms. TME has been 
experimentally transmitted to hamsters (Kimberlin and Marsh, 
1975).  
 
2.1.4 Chronic Wasting Disease 
 
CWD is the only disease found in free-ranging animals such as 
mule deer, white-tailed deer and elk and it is present in the US 
and in Canada. It was first described in 1967 in Colorado and only 
in 1978 classified as a form of prion disease by histopathological 
exam of infected brains (Colby and Prusiner, 2011). The shedding 
of prions from the feces has been identified as a likely source of 
infection for these grazing animals (Williams and Miller, 2002) but 
the route of infection is still unknown.  Afflicted animals develop 
the disease after 3-4 years from the TSE agent exposure and die 
very quickly in a period that goes from 2 weeks to 8 months. 
Symptoms include weight loss and excessive drinking (Gilch et al., 
2011). Experimental evidence has confirmed neuronal 
vacuolation (Williams and Young, 1980), accumulation of 
aggregated prion protein (Spraker et al., 2002) and prion 
infectivity in the brain (Browning et al., 2004). Moreover, prion 
protein aggregates are not only found in the central nervous 
system (CNS), but also in lymphoid tissues, skeletal muscles and 
other organs. Also, up to date there is no evidence for CWD 
transmission to humans. 
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Spongiform encephalopathies of a number of zoo animals 
(Kirkwood et al., 1990; Jeffrey and Wells, 1988) are also 
recognized as animal prion diseases. Many new species—including 
greater kudu, nyala, Arabian oryx, Scimitar horned oryx, eland, 
gemsbok, bison, ankole, tiger, cheetah, ocelot, puma, and 
domestic cats—have developed spongiform encephalopathies 
coincident with or following the arrival of BSE (Collinge, 1997; 
Bruce et al., 1997).  The majority of these subforms appear to 
be linked to the BSE epidemic (Sigurdson and Miller, 2003).  
 
2.2 Human 
 
Human prion diseases, traditionally classified into Creutzfeldt-
Jakob disease (CJD), Gerstmann-Straüssler-Scheinker disease 
(GSS) and Kuru, have been subsequently divided into three 
etiological categories: sporadic, acquired, and inherited (Table 1). 
 
2.2.1 Sporadic prion diseases 
 
The sporadic forms (sCJD) were the first to be described by 
Creutzfeldt-Jakob in 1920. They are the most frequent among 
CJD forms, accounting for 80 to 90% of the cases, and present 
worldwide without sexual preference with an annual incidence of 
one per million . The causes of sCJD are not known and probably 
derive from a spontaneous misfolding of PrPC into PrPSc (Prusiner 
1989; Hsiao et al 1991). Alternatively, it has been proposed that 
the disease could be due to a somatic mutation of PRNP or 
infrequent amplification of low levels of PrPSc that are part of 
“normal” protein homeostasis (Colby and Prusiner, 2011). 
Susceptibility to sCJD disease is influenced by a polymorphism at 
residue 129 of PRNP  (Prusiner, 1998) and homozygosity 
predisposes not only to sporadic but also the acquired forms of 
CJD. The onset of the disease is at ~ 60 years old which quickly 
progresses in 4-5 months leading to death (Johnson and Gibbs, 
1998). The pathology is limited to the central nervous system, 
where neuronal loss occurs with progressive vacuolization but in 
which no amyloid plaques are detected (Spero and Lazibat, 
2010). Also, infected sCJD brains can transmit the disease to 
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experimental animals by intracerebral injection (Brown et al., 
1994).  
 
2.2.2 Inherited prion diseases 
 
Around 15% of human prion disease is inherited and in all cases 
to date over 40 different mutations in PRNP are associated with 
genetic forms of prion disease (Colby and Prusiner, 2011). 
Accordingly with clinical symptoms, they have been classified as 
Gerstmann-Straüssler-Scheinker syndrome (GSS) (MASTERS et al., 
1981), familiar (f) CJD and fatal familiar insomnia (FFI) (Lugaresi 
et al., 1986).  
The first reports of Prnp mutations described insertion and 
missense mutations in families with dominantly inherited 
neurodegenerative disease (Owen et al., 1989). Over 40 different 
types of Prnp mutations have been found and Prnp analysis 
allows for pre-symptomatic diagnosis of inherited prion disease 
(Collinge, 2005b). They include point mutations leading to amino 
acid substitutions or premature stop codons mostly affecting the 
region between the second and the third helix of the carboxy-
terminus and octapeptide repeat insertions (OPRI) (Figure 9).  
 
 
 
Figure 9 The human PrPC protein and its mutants. The mature human PrPC protein contains 
208 amino acid residues. It features two positively charged amino acid clusters denoted CC1 
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and CC2 (blue boxes), an octapeptide repeat region (OR) (green boxes), a hydrophobic core 
(HC) (gray box), three !-helixes (H1-H3) (red boxes), one disulphide bond (S–S) between 
cysteine residues 179 and 214, and two potential sites for N-linked glycosylation (red forks) at 
residues 181 and 197. A glycosylphosphatidylinositol anchor (GPI) (yellow box) is attached to 
the C-terminus of PrP. This figure indicates in black framed boxes point mutations and 
insertions found in the human PRNP gene in patients with prion disease. The associated 
polymorphisms of codon 129 (methionine M or valine V) are indicated. Amino acids are given in 
single-letter code. The asterisk indicates a stop codon; therefore, this mutation results in a 
truncated protein.From Aguzzi et al 2008 
 
The pathology of this group of prion diseases can vary depending 
on the actual mutation, as well as on polymorphisms at codon 
129, that also represent a key determinant of genetic 
susceptibility to acquired and sporadic prion diseases (Collinge, 
2001). Also, given the heterogeneity in clinical signs, the 
importance of unidentified cellular modifiers and environmental 
factors should be taken into account (Kovacs and Budka, 2008). 
 
2.2.3 Acquired prion diseases 
 
Infectious forms of prion diseases include kuru, iatrogenic CJD 
(iCJD) and variant CJD (vCJD).  
Kuru was firstly described in research in the ’60 by Gajdusek and 
Zigas as an endemic disease among some tribes of New Guinea 
aborigines, particularly in the Fore Tribe and neighboring tribes 
(Figure 8, B). The route of transmission is attributed to the 
cannibalistic rituals through ingestion of the brains of their dead 
relatives in an attempt to immortalize them. The typical 
progression for kuru is progressive cerebellar ataxia, evolving in 
few months with a very broad incubation period of 4 to 40 years. 
With the end of cannibalism in Papua New Guinea, kuru is now 
eliminated (Aguzzi et al., 2008).  
Iatrogenic CJD is a rare form of prion disease deriving from 
accidental transmission during the course of medical or surgical 
procedures. In 1974, the first case of iCJD caused by corneal 
transplantation of a graft derived from a patient suffering from 
sCJD was reported (Duffy et al., 1974). Later on, other routes of 
transmission derived from prion-tainted human growth hormones 
and gonadotropin, dura mater grafts and blood transfusion were 
also reported. The incubation period ranges between 1 and 15 
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years and accordingly with the origin, death occurs around 15 
months from the onset of the symptoms (Prusiner, 1998; Colby 
and Prusiner, 2011).  
Among the infectious forms of prion diseases, the variant form 
(vCJD) is the one that has caught the attention of the public the 
most. Indeed, in 1996 a major epidemic of vCJD appeared in 
different countries, particularly in the UK, where the number of 
reported cases had the highest incidence (about 150)  (Will et 
al., 1996b). Patients are generally young at the onset of the 
disease (average onset is at 29 years), have a significant longer 
disease course, present florid plaque deposits (vacuolization) in 
the brain and are homozygous for methionine at position 129 in 
the PRNP gene that suggests a genetic susceptibility for vCJD. 
Interestingly, in experimentally infected mice, prions from 
patients with vCJD and prions from BSE-cattle gave similar 
pathological and biochemical characteristics (i.e. incubation 
period and localization in brain), leading researchers to conclude 
that the most likely cause for vCJD in humans is the consumption 
of BSE-contaminated beef (Hill et al., 1997b; Bruce et al., 1994). 
A single case of vCJD in a patient heterozygous at codon 129 
has also been reported, raising the possibility of a second wave 
of “mad cow”–related deaths . 
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3. Cell biology of prion disease 
 
3.1 The cellular protein: PrPC 
 
3.1.1 Structure and Functions 
 
PrPC is a ubiquitous glycoprotein expressed early in 
embryogenesis and present in high levels in the central nervous 
system in adult, particularly in neurons but also in glial cells 
(Manson et al., 1994; Harris, 2003). PrPC normally localizes at the 
extracellular site of the plasma membrane where it associates 
with cholesterol-enriched lipid rafts (see below, paragraph 3.2.1). 
In neurons, PrPC is predominant in axons and dendrites (Mironov 
et al., 2003). It seems to be excluded from synaptic vesicles but 
present within the synaptic specialization and perisynaptically, so 
its role at the level of the synapse is still controversial (Vassallo 
and Herms, 2003; Fournier et al., 1995). In addition, PrPC is 
widely expressed in the immune system, in hematopoietic stem 
cells and mature lymphoid and myeloid compartments (Isaacs et 
al., 2006). Also, many other tissues and organs like the spleen, 
intestines, the skin, muscles and the heart have been found 
positive for PrPC expression.  
The PrPC precursor is a protein of 254 amino acids (Figure 10, A). 
 
 
Figure 10 (A) Primary sequence and (B) tertiary structure of PrPC. OR= Octapeptide Region; 
CC= Charged Region; HR= Hydrophobic Region. 
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After cleavage of a 23 amino acids signal peptide in the 
endoplasmic reticulum (ER), a glycosylphosphatidilinositol (GPI) 
anchor, which mediates its anchoring to the membrane, is 
attached to the C-terminus of the protein (Stahl et al., 1987). 
The two Cys residues 179 and 214 are engaged in the formation 
of a disulphide bond essential for the stability of the protein. The 
protein exists as un-, mono- or bi-glycosylated, as one or two 
oligosaccharidic chains can be linked to two asparagines (N) 
(residues 181 and 197 in humans) in the C-terminal part of PrPC 
in the Golgi apparatus during the journey of the protein to the 
plasma membrane.  
At the 3D level, PrPC has a long, flexible N-terminal tail (residues 
23-128); it is present in most of the animal species studied, but 
not in elk and deer (Prusiner, 1998). It contains an octarepeat 
region (OR) consisting of 5 repeats of the sequence PHGGGWGQ 
(major binding site for divalent cations), a basic charged region 
(CC) important for PrPC trafficking and an hydrophobic domain 
(HR) that can be used by PrPC to assume different 
transmembrane topologies. Indeed, PrPC presents at least three 
distinct topological orientations: the fully extracellular form (or 
(sec)PrP) and two transmembrane isoform (called Ntm-PrP and 
Ctm-PrP) with opposite sequence orientations with respect to the 
lumen of the endoplasmic reticulum (Nicolas et al., 2009). 
Following the unstructured N-terminus is a globular C-terminal 
domain consisting of three α-helices interspersed with two-
stranded antiparallel β-sheets that flank the first α-helix (Figure 
10, B) (Zahn et al., 2000; Hornemann et al., 2004). The 
structure of several mature PrPC proteins in mice, cattle, humans 
and Syrian hamsters is very similar (Colby and Prusiner, 2011), 
thus suggesting a relevant evolutionary conserved function for 
this protein. 
 
A plethora of cellular functions have been attributed to PrPC but 
as already mentioned above its physiological role appears to be 
redundant, since PrP knock-out mice are vital and do not present 
severe abnormalities (Bueler et al 1992; Manson et al 1994). 
However, a growing number of studies implicates PrPC in diverse 
cellular processes (Nicolas et al., 2009) as cellular resistance to 
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oxidative stress (Milhavet and Lehmann, 2002), cell signalling 
(Mouillet-Richard et al., 2000), copper and zinc metabolism (Watt 
and Hooper, 2003; Pauly and Harris, 1998), synaptic 
transmission (Collinge et al., 1994) and cytoprotection through 
anti-apoptotic activity (Kuwahara et al., 1999; Bounhar et al., 
2001) (see below, paragraph 3.2). Recently, Bremer and 
colleagues have also demonstrated that PrPC is required for the 
maintenance of myelin sheath around peripheral nerves (Bremer 
et al., 2010). In addition, a role for PrPC as cellular receptor in the 
toxic effect of oligomeric forms of amyloid-β, implicated in 
Alzheimer's disease, has been described by Lauren and co-
workers (2009). In contrast, other reports have shown that 
amyloid-β toxicity is independent from PrPC (Balducci et al., 
2010). Therefore, its role in Alzheimer's disease is still 
controversial. Besides, it has been shown that PrPC is implicated 
in cell adhesion (Malaga-Trillo, 2009), focal adhesion formation 
and filopodia extention (Schrock et al., 2008). These findings 
point out towards an additional role of PrPC in cytoskeleton 
dynamic and remodeling and cell-to-cell communication.  
Furthermore, the identification of interacting partners of PrPC is 
of fundamental importance not only to provide new insights into 
its role in physiological conditions but also to better understand 
the basic mechanism of PrPC-PrPSc conversion that leads to 
neuropathology. In a recent report, a series of interacting 
partners for PrPC has been found by using a proteomics approach 
(Zafar et al., 2011). The results have confirmed 15 interacting 
partners already shown to interact with both PrPC and PrPSc but 
28 new proteins were also identified. A functional categorization 
of these proteins (Figure 11) confirmed many of the assigned 
roles for PrPC in highlighting its multi-faceted functionality and 
involvement as a biological platform for diverse cellular 
processes. 
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Figure 11 Functional categorization of putative PrPC binding partners. Modified from Zafar 
et al 2011. 
 
3.1.2 Localization  
 
After being synthetized in the rough endoplasmic reticulum (ER), 
immature PrPC transit in the Golgi compartment before reaching 
the plasma membrane similarly to other surface or secreted 
proteins (Harris, 2003) (Figure 12).  
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Figure 12 Cellular localisation and trafficking of PrPC and PrPSc. Intracellular pathway of 
PrPC and PrPSc is depicted together with the Rab proteins controlling dfferent pathways. 
 
Specifically, during its journey, PrPC undergoes a number of post-
translational modifications in the endoplasmic reticulum and at 
the Golgi level including cleavage of the N-terminal signal peptide, 
addition of N-linked oligosaccharide chains, formation of a single 
disulphide bond, and attachment of the GPI anchor (Haraguchi et 
al., 1989; Turk et al., 1988). The N-linked oligosaccharide chains 
added in the ER are of the high-mannose type and are sensitive 
to digestion by endoglycosidase H. In the Golgi they are 
subsequently modified to more complex oligosaccharides that 
contain sialic acid and are resistant to endoglycosidase H 
(Caughey et al., 1989). PrPC is attached on the external leaflet of 
the plasma membrane by its GPI-anchor which mediates its 
segregation within specific domains of the membrane known as 
detergent resistent microdomains  (DRMs), or lipid rafts. 
Association to lipid rafts is thought to occur at the level of the 
Golgi (Naslavsky et al., 1997a), but it has also been shown that it 
can take place earlier in the ER with the immature PrPC, and may 
be implicated in facilitating the proper folding and stability to the 
protein (Sarnataro et al., 2004). Additionally, PrPC has been 
Page | $)"
detected at the cell surface in caveolae and caveolae-like 
domains (CLDs) in cells expressing caveolin (Mouillet-Richard et 
al., 2000; Peters et al., 2003; Harmey). Phosphatidylinositol-
specific phospholipase C (PIPLC) treatment of cells in culture has 
shown that with an accumulation of PrPC in the medium, due to 
the cleavage of the GPI-anchor by PIPLC, a progressive loss of 
PrPC is detected. This demonstrates that the majority of this 
protein is localized at the plasma membrane through its GPI-
anchor (Stahl et al., 1987). Indeed, different reports have shown 
that the GPI-anchor mediates PrPC raft-association (Taraboulos et 
al., 1995a; Kaneko et al., 1997). However by using cells 
expressing various PrPC mutants lacking the GPI-anchor 
(transmembrane-anchored form of PrPC, PrP-TM) it has been 
shown that the N-terminal flexible domain contains a raft-target 
domain between amino acids 23-90 that is sufficient to confer 
rafts association of PrP-TM (Walmsley et al., 2003). Moreover, 
the highly charged region of the N-terminal consisting of residues 
23-28 (-KKRPKP-) are known binding sites for 
glycosaminoglycans (GAGs) (Warner et al., 2002; Pan et al., 
1993b). Recently it has been described that the major neuronal 
heparin sulphate proteoglycan GPI-anchored glypican-1 is 
involved in the recruitment and stabilization of PrPC in lipid rafts 
by interacting with the ectodomain of PrPC (Taylor et al., 2009). 
Also, depletion of glypican-1 significantly reduced the raft 
association of PrP-TM and displaced PrPC from rafts, promoting its 
endocytosis (Taylor et al., 2009). Altogether, these results 
support that both GPI-anchor and N-terminal ectodomain of PrPC 
mediate raft-association and stabilization (Campana et al., 2005).  
 
3.1.3 Internalization 
 
At the cell surface, PrPC is then constitutively internalized and 
recycles back to the plasma membrane (Harris, 2003).  Both 
clathrin coated pits and caveolae mediated endocytosis have 
been shown to be involved in PrPC internalization (Campana et al., 
2005). In particular, some experimental evidences have shown 
that PrPC does cycle between the plasma membrane and early 
endosomes via clathrin coated pits dependent pathway 
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(Taraboulos et al., 1995a; Shyng et al., 1994). In order to be 
internalized by a classic clathrin-mediated manner, PrPC should 
translocate outside lipid raft domains and this occurs upon Cu2+ 
binding to the protein (Taylor and Hooper, 2007). 
Transmembrane proteins that are internalized through clathrin-
coated pits interact through their cytosolic domain with 
cytoplasmic clathrin-coated pits accessory proteins that mediate 
internalization (Bonifacino and Traub, 2003). Therefore, since 
PrPC is anchored on the external leaflet of the plasma membrane, 
its presence in these structures should involve adaptor proteins, 
probably interacting with the polybasic region of the N-terminus 
of PrPC. For example, low-density lipoprotein receptor-related 
protein-1 (LRP1) has been shown to mediate PrPC endocytosis in 
neuronal cells (Taylor and Hooper, 2007; Parkyn et al., 2008) but 
other proteins could be involved. Sunyach et al.  have shown that 
endogenous PrPC expressed on the surface of adult sensory 
primary neurons recycle every few minutes via clathrin coated 
pits between the cell surface and recycling endosomes (Sunyach 
et al., 2003). Similarly, this was also shown for N2a and SH-SY5Y 
cells, both neural cell lines (Taylor et al., 2005; Shyng et al., 
1994; Sunyach et al., 2003). Alternatively, caveolae-mediated 
internalization and trafficking of PrPC from late endosomes to 
lysosomes have been described (Peters et al., 2003). For 
example, PrPC has been found in caveolae, but not in clathrin-
coated pits and vesicles, in Chinese hamster ovary cells, which 
express caveolin-1 (Peters et al., 2003). Caveolae are flask-
shaped invaginations at the cell surface that are decorated by a 
caveolin 1 (Cav1) coat (Anderson, 1998). However, the role of 
caveolae in prion trafficking on neurons is irrelevant, as caveolae 
have not been shown to occur on adult mammalian neurons. 
However, caveolae-mediated PrPC endocytosis may present a 
distinct trafficking pattern in non-neuronal cells (Sarnataro et al., 
2004).  
 
3.1.4 Trafficking  
 
Intracellular trafficking of proteins required vesicle transport 
between different membrane compartments (Maxfield and 
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McGraw, 2004). By characterizing endosomes and transport 
vesicles, in particular through the presence of specific Rab 
proteins, precise information about the traffic of a certain protein 
can be achieved. Rab proteins are small GTPases that regulate 
vesicular transport in endocytosis and exocytosis (Zerial and 
McBride, 2001). Different Rab proteins were found to be 
associated specifically with different endosomes (Figure 12). 
Briefly, Rab5 is associated with clathrin-coated pits and early 
endosomes (Bucci et al 1992; Bucci et al 1994; Stenmark et al 
1994; Bucci et al 1995). Rab4 couples early in recycling 
compartments promoting fast recycling to the plasma membrane 
(van der Sluijs et al 1991; van der Sluijs et al 1992; Daro et al 
1996). Rab11 is concentrated in recycling endosomes and also 
provide a pathway for recycling of proteins to the membrane 
(Ullrich et al 1996). Rab7 and Rab9 are found in late endosomes. 
Rab7 seems to be essential for the transport of molecules from 
early to late endosomes and lysosomes (Feng et al 1995; 
Meresse et al 1995) and Rab9 from late endosomes to trans-
Golgi (Lombardi et al 1993). Finally, Rab6 is involved in 
retrograde trafficking from the Golgi to the endoplasmic 
reticulum (Martinez et al 1997; White et al 1999). A number of 
different studies have analyzed the trafficking of PrPC in cell 
cultures and it appears that PrPC trafficking may vary from 
neurons to neuroblastoma cell lines or glia cells (Prado et al 
2004).  Indeed, PrPC has been shown to localize to different 
compartments depending on the cell type. For example it has 
been reported that PrPC predominantly localizes in late 
endosomes in neuroblastoma-derived (N2a) and hypothalamic 
gonadotropin releasing (GT1-7) cell lines (Pimpinelli et al., 2005); 
other studies reported that in primary neurons and in N2a cells 
very little portion of PrPC resides in lysosomes (Shyng et al., 
1994; Sunyach et al., 2003). Furthermore, experiments with a 
GFP-tagged form of PrPC (GFP-PrPC) expressed in different cell 
lines and studies using immunolabelling to detect endogenous 
PrPC have shown that PrPC is present in the Golgi (Marijanovic et 
al., 2009; Magalhães et al., 2002), early endosomes (EEs) and in 
the endosomal recycling compartment (ERC) (Magalhães et al., 
2002; Marijanovic et al., 2009). Also, in hippocampal neurons, 
PrPC is found mainly at the plasma membrane (Galvan et al., 
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2005) and on vesicles resembling early endocytic or recycling 
vesicles (Godsave et al., 2008).  
 
The fate of PrPC after passage through endocytic compartments 
is still poorly understood. However, it has been shown that it can 
be degraded through the endo-lysosomal pathway after reaching 
the lysosomes (Campana et al., 2005; Sunyach et al., 2003; 
Magalhães et al., 2002). Also, approximately 10% of wild type 
PrPC is subject to retrograde transport through the ER-associated 
degradation (ERAD), probably due to incorrect processing or an 
excess of PrP and it is subsequently delivered to the cytosol and 
degraded in the proteasome (Ma et al., 2002; Parizek et al., 
2001; Yedidia et al., 2001; Vetrugno et al., 2005). Additionally, 
PrPC shedding from the cell surface in the extracellular medium 
can occur, suggesting proteolysis of the GPI-anchor. Indeed, 
soluble PrPC has been found in conditioned media of cells in 
culture as well as in human cerebrospinal fluid (Parizek et al., 
2001; Tagliavini et al., 1992) and within the lumen of exosomes 
(Fevrier et al., 2004; Vella et al., 2007).  
And yet, Gilch and colleagues have shown that the perturbation 
of PrPC but also PrPSc trafficking could result in a delay of the 
onset of the disease in mice, by using the chemical compound 
Suramin (Gilch et al., 2001). Insights from the mechanisms of 
internalization and trafficking of PrPC can also help in better 
characterizing where PrPC to PrPSc conversion occur and how PrPSc 
spread, by dissecting possible pathways and finding interacting 
partners for both PrP isoforms.  
 
 
3.2 PrPC to PrPSc conversion site: a secret “rendez-vous” 
 
Differently from PrPC localization, PrPSc detection is very difficult 
to assess because of the lack of specific antibodies.  However, 
several studies suggest that it has a wide distribution inside cells 
and importantly it also appeared associated with DRMs but not 
necessary in the same raft domains as PrPC (Vey et al., 1996; 
Naslavsky et al., 1997a). Indeed, some earlier reports have 
shown that the majority of PrPSc is intracellular (Taraboulos et al., 
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1990), sequestered within lysosomes of prion-infected N2a cells 
(McKinley et al., 1991; Caughey and Raymond, 1991; Borchelt et 
al., 1992) with little localization at the cell surface (Vey et al 
1996). In infected brains, PrPSc has been reported to accumulate 
at the plasma membrane and occasionally in late 
endosome/lysosome-like structures (Jeffrey et al 2006). More 
recent reports describe accumulation of PrPSc either in the 
perinuclear Golgi region of neurons in scrapie-infected transgenic 
mice, in the late endosomal compartment of infected GT1-7, N2a 
and CAD neuronal cells (Gousset et al., 2009; Pimpinelli et al., 
2005; Marijanovic et al., 2009) or at the cell surface and on early 
endocytic and recycling vesicles in hippocampal neurons (Jeffrey 
et al., 1994). Also, the mechanism of internalization of PrPSc is 
not well understood but a recent work suggests the possibility of 
clathrin-mediated endocytosis, as its cellular counterpart (Veith 
et al., 2009).  
Due to the disparate sub-cellular localizations of both PrPC and 
PrPSc, several possible sites for conversion have been postulated, 
but this process is still far from being fully understood. As 
already mentioned above, this is the process in which cellular PrPC 
is converted into its pathological counterpart, PrPSc. Certainly, a 
better understanding of the compartments in which PrPC-PrPSc 
conversion occurs is of fundamental importance to develop 
potential therapeutics for prion disease.  
Several papers have reported that PrPc has to reach the plasma 
membrane before conversion (Gilch et al., 2001; Taraboulos et 
al., 1995a; Caughey et al., 1991; Borchelt et al., 1992) (Figure 
13).  
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Figure 13 Possible sites of PrPC-PrPSc conversion. Dotted lines and circles represent 
intracellular pathways and site for conversion. (A) Initiation of conversion at the cell surface 
after direct contact between uninfected and infected cells. (B) Lipid raft clustering, enabling 
interaction of otherwise separated PrPC and PrPSc. (C) Non-raft associated PrPSc promoting 
conversion of contiguous raft associated PrPC. (D) Conversion of PrPC to PrPSc in endocytic 
vesicles.  
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Recently, Goold and co-workers (2011) have shown that the 
plasma membrane is an initial site of prion conversion. This could 
be the case of acquired forms of prion disease in which an 
exogenous introduced PrPSc converts the cellular endogenous 
PrPC. In this work by using a neuroblastoma cell line knocked-
down for endogenous PrPC and expressing an epitope-tagged PrPC 
the earliest events in cellular prion infection have been 
characterized, giving new insights on PrPSc dynamics. In particular 
they found that prion conversion occurs very rapidly at the cell 
surface within 1 minute of prion exposure (Goold et al., 2011).  
This new finding does not preclude a role for intracellular 
compartments in prion conversion, that have already been shown 
to be important, and may continue and accelerate the process 
following PrPSc initially synthesized at the plasma membrane. Both 
PrPC and PrPSc localize to vesicles of the endosomal and lysosomal 
pathways. PrPSc is trimmed at its N-terminus by endogenous 
proteases in acidic compartments immediately after its 
generation (Borchelt et al., 1992; Caughey et al., 1989) 
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suggesting that its conversion to a protease-resistant state 
occurs prior to reaching the lysosomal compartment. Moreover, 
inhibition of endocytosis using a temperature block or release of 
nascent PrP from the cell surface using PIPLC prevented PrPSc 
synthesis (Borchelt et al., 1992; Campana et al., 2005). 
Recently, Marijanovic and colleagues (2009) selectively inhibited 
PrP trafficking through the different endocytic compartments 
using both pharmacological and reverse genetic approaches in 
infected cells and analyzed PrPSc levels under the different 
experimental conditions. They demonstrated that early and late 
endosomes are not involved in PrPSc replication. However 
inhibition of the trafficking from the early endosomes to the 
endocytic recycling compartment by over-expression of Rab22 
dominant-negative would block prion conversion (Marijanovic et al 
2009). Moreover, they have shown that PrPSc accumulates in the 
endosomal recycling compartment (ERC) upon inhibition of PrP 
exit from this compartment by overexpressing a Rab11 
dominant-negative mutant, which impairs recycling from the ERC 
back to the plasma membrane (Marijanovic et al., 2009). These 
data suggest that PrPC has to reach the ERC to be converted and 
stimulate PrPSc production, thus pointing towards a role for the 
recycling compartment as an intracellular site for prion 
conversion. This finding is also supported by the recent evidence 
that PrPSc is present in the ERC of primary hippocampal neurons 
derived from infected brains (Godsave et al., 2008). Also, as will 
be described below (paragraph 3.2.1), cholesterol has been 
shown to be involved in prion conversion (Taraboulos et al., 
1995). Interestingly, ERC membranes are enriched in cholesterol 
in different cells (Hao et al., 2002; Maxfield and McGraw, 2004). 
Therefore, a cholesterol-dependent retention mechanism in the 
ERC could facilitate the efficient conversion of the native prion 
protein into its pathological counterpart. The involvement of the 
ER compartment in prion conversion is suggested by the 
observation that forcing the retrograde transport of PrPC to the 
ER by overexpressing a constitutively active form of the GTPase 
Rab 6, is sufficient to increase scrapie production in infected cells 
(Beranger et al., 2002). In the ER, high amounts of newly 
synthesized PrPC could be available as substrate for the 
conversion reaction. In addition, PrPC can be found in this 
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compartment in a partially unfolded state that could make it 
easier for PrPSc to impress its conformation to PrPC. Furthermore, 
the first step in the misfolding of mutants of PrPC associated with 
hereditary forms of prion diseases, has been shown to occur in 
the ER. In addition it has been shown that dissociation of PrPC 
from DRMs by cholesterol depletion, induce its misfolding in the 
ER (Sarnataro et al., 2004). Therefore, while in the infectious 
diseases PrPSc could catalyze prion amplification in this 
compartment even if conversion is occurring elsewhere, in the 
hereditary diseases the ER could represent the propitious 
environment where the conformational transition of mutated PrPC 
can take place spontaneously. More recently by inducing ER-
stress or inhibiting the proteasome some researchers have found 
that both conditions significantly affect total PrP level resulting in 
accumulation of aggregated PrP forms, still able to reach the 
plasma membrane and be a substrate for PrPSc conversion in 
other cellular sites. These results confirm a role for the ER in 
hereditary forms of the prion disease (Nunziante et al 2011). 
 
3.2.1 Role of lipid rafts in prion conversion 
 
Lipid rafts are membrane microdomains enriched in cholesterol 
and glycosphingolipids in which lipids of specific chemistry can 
dynamically associate with each other to form platforms that 
segregate specific membrane proteins (Simons and Ikonen 2002; 
Lingwood and Simons 2010). One of the main methods used to 
prove the existence of rafts domains in cell membranes has been 
the extraction by non-ionic detergents such as Triton X-100, 
therefore detergent resistant microdomains (DRMs) represent 
cellular lipid rafts (Edidin 2003; Zurzolo et al 2003).  
Although still quite unclear, recent studies suggest a role for lipid 
rafts in prion conversion (Lewis and Hooper, 2011; Taylor and 
Hooper, 2006; Campana et al., 2005). Interestingly both PrPC and 
PrPSc localize in these particular domains but they seem to be 
able to associate to different DRMs. Indeed, purified DRMs 
containing PrPC can be biochemically separated by DRMs 
containing PrPSc (Naslavsky et al., 1997a). Moreover, DRMs seem 
to be involved in prion uptake), like other pathogens and toxins, 
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and their destabilization (Sarnataro et al 2009) can induce 
altered PrPC exocytic trafficking in neuronal cells and a slow down 
of PrPC maturation in epithelial cells (Campana et al., 2005). 
Furthermore, insertion of PrPC in lipid rafts has an impact on its 
conformation stability both in vitro and in cell culture (Sarnataro 
et al., 2004). These data suggest a protective role for DRMs 
against the occurrence of prion conversion. Interestingly, it has 
been demonstrated that cholesterol depletion impairs PrPSc 
production (Taraboulos et al 1995; Bate et al 2004) while 
sphingolipid depletion increase it (Naslavsky et al., 1997b). More 
recently, Gilch and colleagues have shown that inhibition of 
cholesterol recycling impairs cellular PrPSc propagation. 
Cholesterol is one of the main components of lipid rafts (Gilch et 
al., 2009). The content of free cholesterol in the cell is tightly 
regulated by endogenous synthesis, uptake by low-density 
lipoprotein (LDL) and level of esterification, which allows storage 
of cholesterol in cytoplasmic lipid droplets (Ikonen, 2008). 
Recycling of cholesterol is achieved by the controlled action of 
two proteins, NPC-1 and NPC-2 whose loss-of-function mutations 
lead to Niemann-Pick type C disease (NPC), a lysosomal storage 
disorder associated to neurological symptoms, characterized by 
accumulation of cholesterol in late endosomes and lysosomes 
(Maxfield and Tabas, 2005). In prion-infected N2a cells, knock-
down of NPC-1 led to a drastic loss of PrPSc (Gilch et al., 2009) 
and treatment with the drug U18666A, producing a phenocopy 
of NPC disease exerts the same effect (Klingenstein et al., 2006; 
Hagiwara et al., 2007; Gilch et al., 2009; Marijanovic et al., 
2009). These data support a role for cholesterol in prion 
conversion. Moreover, perturbation of cholesterol recycling and 
trafficking could alter intracellular trafficking of both PrP 
isoforms, thus slowing down the conversion process and shifting 
the balance of PrPSc production/degradation towards the latter. In 
addition, it has been shown that impairment of prion conversion 
can be achieved by forcing PrPC to localize outside DRMs (i.e. 
substituting the GPI anchor attachment signal with a 
transmembrane domain in the coding sequence of PrPC) even 
though the anchor seems to be dispensable for the conversion 
process itself (Baron and Caughey, 2003; Lawson et al., 2001; 
Kocisko et al., 1994). These results suggest that a specific lipid 
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environment can be necessary for the conversion process. In this 
view, rafts could provide a favorable environment for 
conformational conversion of PrPC to PrPSc, by concentrating 
proteins in specific membrane regions allowing their mutual 
interaction and by providing accessory molecules required for the 
process (Campana et al., 2005; Taylor and Hooper, 2006). 
Finally, rafts could be able to traffic the two isoforms to the 
compartments where prion conversion occur. Indeed, membrane 
rafts are present not only at the plasma membrane level but also 
in vesicles of the endocytic compartments, thus constituting a 
conversion-prone environment (Taylor and Hooper, 2011). 
Despite the fact that several advancements have been reached in 
understanding the mechanisms involved in PrPC-PrPSc conversion, 
the role of lipid rafts, other critical factors and particular 
endocytic pathways participating in the process need further 
investigations to fully understand prion diseases at a molecular 
level and develop new drugs for therapy.  
 
3.3 From PrPC – PrPSc conversion to neurotoxicity: what is the 
link? 
 
Understanding how PrPSc formation actually leads to 
neurodegeneration following neurotoxicity is still an open 
question in prion biology. Despite the fact that apoptosis and 
oxidative stress have been shown to contribute to TSE pathology 
(Milhavet and Lehmann, 2002), little is known about damage 
causing primary events (Aguzzi et al., 2008). In principle, it is still 
unclear weather PrPSc toxicity represents a gain of function or a 
loss of PrPC function and which is the main responsible factor for 
the neuropathological changes induced by prions. Some reports 
that have addressed this question rather support a loss of PrPC 
function (Nazor et al 2007). But, based on the mild phenotype of 
PrPC knock-out mice, other groups think that a gain of function is 
more conceivable (Westergard et al., 2007; Aguzzi et al., 2008). 
However, it is also possible that a normal neuroprotective role for 
PrPC needed during prion-induced brain damage could be missing 
due to its conversion in the pathological counterpart. A third 
possibility could be that in presence of PrPSc, the cellular PrPC 
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could trigger toxic signals through pathways not related with its 
physiological function (subversion of function) (Figure 14). 
 
 
Figure 14 PrP-mediate neurotoxicity. (A) Toxic gain-of-function mechanism. PrPSc 
possesses a novel neurotoxic activity that is independent of the normal function of PrPC. (B)  
Loss-of-function mechanism. PrPC possesses a normal, physiological activity, in this case 
neuroprotection, that is lost upon conversion to PrPSc. (C)  Subversion-of-function mechanism. 
The normal, neuroprotective activity of PrPC is subverted by binding to PrPSc. 
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To date, several reports suggest that these three possibilities 
might co-exist to different extent in the diverse forms of prion 
diseases and they all lead to neurodegeneration. 
 
3.3.1 Gain of function through formation of PrPSc 
 
Although the presence of PrPSc is the hallmark of prion diseases, 
it is highly debated whether prion pathology could really be 
attributed only to a toxic gain of function. In this context, newly 
formed PrPSc presents novel properties unrelated with the 
physiological role of PrPC and PrPSc deposits might interfere with 
synaptic transmission or block of the axonal transfer (Westergard 
et al., 2007). Some reports have suggested that both full-length 
PrPSc (Hetz et al., 2003) and shorter PrP peptides are toxic to 
primary neuronal cultures in vitro (Forloni et al., 1993), but their 
relevance to in vivo pathogenesis is under debate. Nonetheless, 
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from some other experimental evidences it is unlikely that 
accumulation of extra-neuronal PrPSc aggregates is the only 
responsible factor for neurotoxicity. Indeed, when neural tissue 
over-expressing WT PrPC is grafted into mice lacking PrP, prion 
infection of the mice leads to PrPSc levels increase and 
neurodegeneration only in the PrPC-expressing graft (Brandner et 
al., 1996). Furthermore, absence of endogenous PrPC in prion-
infected mice has been demonstrated to reverse early 
spongiform change preventing neuronal loss and progression to 
clinical disease, even in presence of extra-neuronal PrPSc (Mallucci 
et al., 2003). 
Moreover, prion-infected transgenic mice expressing PrPC without 
a GPI anchor produce infectious prions, accumulate extracellular 
PrP amyloid plaques, but do not succumb to the disease 
(Chesebro et al., 2005).  
Finally, it has also been described that in some cases PrPSc 
accumulation does not lead to clinical symptoms (Hill and 
Collinge, 2003; Race et al., 2000, 2002; Hill et al., 2000). 
 
3.3.2 Loss or subversion of PrPC function 
 
As already described (paragraph 3.1.2), PrPC seems to be 
implicated in diverse physiological activities even if its presence is 
not essential. A loss in any of these functions could theoretically 
lead to neurodegeneration. In particular, loss of its anti-apoptotic 
role could directly be related to toxicity and neuronal death. For 
example, neurons derived from mice lacking PrPC were originally 
reported to be more susceptible to apoptosis mediated by serum 
deprivation and this phenotype could be rescued by over-
expressing either PrPC or B-cell lymphoma protein 2 (Blc2) 
(Kuwahara et al., 1999). Also, overexpression of Bax, a 
stimulator of the apoptotic pathway, together with PrPC leads to 
a decrease in the rate of apoptosis in human neurons (Bounhar et 
al., 2001). 
A third possibility is that alteration in PrPC normal function is 
achieved by contact with PrPSc, thus leading to a toxic signal 
cascade and inducing a subversion of its normal activity. 
Consistent with this hypothesis, cross-linking of PrPC at the cell 
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surface with anti-PrP antibodies induces apoptosis of the CNS 
neurons in vivo (Solforosi et al., 2004). Additionally, binding of 
PrPSc could interact with specific region of PrPC necessary for its 
normal function, thus stimulating altered activities. Accordingly, 
transgenic mice overexpressing PrP harboring a deletion in a 
portion in the N-terminal tail (Tg(PrPΔ105-125)) exhibit a severe 
neurodegenerative illness that is lethal within one week of birth 
(Li et al., 2007). Indeed, this highly conserved region could be an 
important binding site for a putative cell-surface receptor 
mediating PrPC function that in presence of PrPSc is masked 
(Westergard et al., 2007). Besides, abnormal topology or altered 
trafficking of PrPC could in part explain PrP-related neuronal 
toxicity in the absence of PrPSc formation (Aguzzi and Calella, 
2009). For example, targeting of PrPC to the cytosol results in 
rapid lethal neurodegeneration (in the absence of PrPSc) and 
proteasome inhibition induces a slightly protease-resistant PrP 
species in cultured cells (Ma et al., 2002). Although numerous 
studies have provided important information about the function 
of PrPC, this issue has not been clarified. Until we have a clear 
understanding of the function of PrPC it will be difficult to 
understand the mechanism that leads to the pathogenesis of the 
disease. Therefore more studies at single cell level to understand 
the cell biology of PrPC and PrPSc are needed.  
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4. Prion degradation: is autophagy an option? 
 
PrPSc persistence in cultured cells is thought to be maintained by 
a balance between its formation following the conformational 
change of PrPC into PrPSc (as described in the previous section) 
and its degradation. A better understanding of PrPSc metabolism 
and particularly how to shift the equilibrium between PrPSc 
production and degradation is very important to understand the 
pathogenesis of the disease. Different degradation pathways 
might be involved in reducing intracellular PrPSc burden. For 
example, a role for the lysosomal compartment in PrPSc 
degradation has been described in several reports which have 
shown that in different infected neuronal cell lines PrPSc is 
sequestered in lysosomes where can be degraded (Borchelt et al., 
2002; Caughey et al., 1991; McKinley et al., 1991; Jeffrey et al., 
2006; Marijanovic et al., 2009; Gousset et al., 2009; Veith et al., 
2009). Furthermore, upon block of the proteasome activity 
significant changes in total PrP level that result in accumulation 
of aggregated PrP forms in the cytosol, have been observed in 
N2a cells (Nunziante et al., 2011). Macroautophagy (hereby 
referred to as autophagy) is another cellular degradation system 
for long-lived proteins and organelles, normally activated upon 
starvation for energy supply (Yang and Klionsky, 2009a). 
Recently, autophagy has been described to play an important role 
in diverse physiological and pathological processes and, in 
particular, in neurodegenerative diseases associated with protein 
aggregation (Wong and Cuervo, 2010). The role of autophagy in 
prion disease in controversial and it will be discussed in the 
paragraph 4.3 of this section. 
 
4.1 Molecular overview of the autophagic pathway 
 
Autophagy, literally “self-eating”, is a highly conserved cellular 
degradation system present in all tissues delivering long-lived 
proteins and cytoplasmic components to lysosomes and is 
normally induced by starvation. This process leads to the 
breakdown and eventual recycling of the macromolecules 
targeted to this pathway (Yang and Klionsky, 2009a; Ana, 2004; 
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Levine and Klionsky, 2004). Three different types of autophagy 
are present in eukaryotic cells: macroautophagy, microautophagy 
and chaperone-mediated autophagy (CMA) (Figure 15).  
 
 
 
Figure 15 Different types of autophagy present in eukaryotic cells. During 
Macroautophagy, a double-membrane structure, the phagophore, arises from the cytosol and 
engulfs part of the cytoplasm containing different proteins and organelles; the phagophore then 
closes to form the autophagosome, a vacuole with a double-membrane that subsequently fuses 
with a lysosome, originating an autolysosome in which the content is degraded. Microautophagy 
involves direct sequestration of proteins and organelles by invaginations of the lysosomal 
membrane that pinch off into the lumen; Chaperone-mediated autophagy (CMA) targets and 
delivers cytosolic proteins containing a consensus peptide sequence across the lysosomal 
membrane via a specific receptor binding. 
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Microautophagy involves direct sequestration of proteins and 
organelles by invaginations of the lysosomal membrane that 
pinch off into the lumen (Mijaljica et al., 2011). CMA targets and 
delivers cytosolic proteins containing a consensus peptide 
sequence across the lysosomal membrane via a specific receptor 
binding. During the process, a chaperone complex mediates the 
substrate protein translocation in the lumen of the lysosome 
where degradation takes place (Li et al., 2010). 
Upon stimulation of macroautophagy, hereafter simply referred 
to as autophagy, a double-membrane structure, the phagophore, 
arises from the cytosol and engulfs part of the cytoplasm 
containing different proteins and organelles; the phagophore then 
closes to form the autophagosome, a vacuole with a double-
membrane (Figure 15). The origin of the phagophore, also called 
isolation membrane, is still debated. However, it has recently 
emerged that both the endoplasmic reticulum and the 
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mitochondria may provide the source of membranes for the 
autophagic vacuole (Tooze and Yoshimori, 2010).  During the 
maturation of the autophagosome, fusion events with endosomes 
or multivesicular bodies (MVBs) can occur leading to the 
formation of amphisomes containing endocytic organelles. Their 
contents are then targeted to lysosomes, via autophagosome, 
for further degradation (Eskelinen, 2004). Either autophagosome 
or amphisome eventually fuse with lysosomes to form the 
autolysosome. After fusion, the inner membrane of the 
autophagosome is exposed to lysosomal hydrolases and its 
content is degraded. This final step ends with the release of 
degraded material into the cytosol for recycling (Figure 15) (Xie 
and Klionsky, 2007). 
The autophagosome-lysosome fusion is a critical step for the 
progression of autophagy (also referred to as autophagic flux). 
For example, inhibition of the vacuolar ATPase (v-ATPase) with 
bafilomycin A1 or concanamycin A blocks the lysosomal pumping 
of H+ and consequently inhibits lysosomal proteases activity.  It 
has been shown that bafilomycin A1 can also block the 
autophagic flux (Mousavi et al., 2001; Yamamoto et al., 1998), 
and this can lead to both an increase in the number of 
autophagosomes and inhibition of degradation of the autophagic 
cargoes (Eskelinen, 2004; Beau et al., 2011).  
 
To date, more than 30 Autophagy-related Genes (Atg genes), 
firstly described by Yoshinori Ohsumi’s group in the early 1990s, 
have been identified from genetic screens in yeast model 
systems (Xie and Klionsky, 2007; Huang and Klionsky, 2002a). 
Homologues of many Atg genes in yeast have been found in 
higher eukaryotes, including humans, highlighting the fact that 
the molecular machinery of autophagy is evolutionally conserved 
among species (Mizushima and Yoshimori, 2007; Klionsky et al., 
2008). 
The ‘core’ autophagy machinery responsible for the formation of 
the autophagosome is composed of four main functional groups: 
(1) Atg12-Atg5 and Atg8-phosphatidilethanolamine conjugation 
systems (Ohsumi 2001); (2) the Atg1-Atg13-Atg17 kinase 
complex; (3) the class III phosphatidylinositol 3-kinase (PtdIns3K) 
complex I and, (4) Atg9 and its cycling system (Xie and Klionsky, 
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2007). A fifth group includes proteins needed for the last step of 
autophagy in which the degradation products are recycled back in 
the cytosol (Yang and Klionsky, 2009b).   
 
The identification of the Atg8 mammalian homologue 
Microtubule-Associated Protein 1 light chain 3 (MAP1LC3, simply 
known as LC3) opened up a new era in the study of mammalian 
autophagy (Kabeya et al., 2000). LC3 was originally described as 
a protein that co-purified with microtubule-associated protein 1A 
and 1B from rat brain (Mann and Hammarback, 1994); Kabeya 
and co-workers (2000) have shown by subcellular fractionation 
and immunogold electron microscopy that LC3 localizes on 
autophagic vacuoles. To date, LC3 represents a widely used 
marker that specifically associates with these structures thus 
allowing the development of a series of LC3-based assay to 
monitor autophagy (Kimura et al., 2009; Huang and Klionsky, 
2002b). 
LC3 exists in two different forms: LC3-I that is cytosolic and LC3-
II that is membrane bound and associated with autophagic 
vacuoles (Figure 16).  
 
 
 
Figure 16 LC3 and autophagic vacuoles assembling. The protein LC3 is a known specific 
marker of autophagic vacuoles and it is widely used to measure autophagy. Two forms of LC3 
are produced post-traslationally, LC3-I (cytosolic) and LC3-II (membrane bound). LC3-II is 
bound on the outer face of the outer membrane and inner face of the inner membrane. When 
the autophagosome matures into an autolysosomes, LC3 on the outer membrane is liberated 
into the cytosol, whereas the one facing the lumen of the organelle is trapped inside and finally 
degraded by lysosomam proteases. 
 
LC3-I results from the cleavage of the pro-LC3 form (LC3 
translated from mRNA) at the level of a glycine in the C-tail. 
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During autophagy, LC3-I is post-translationally modified by a 
combination of enzymatic activities that ultimately add a 
phosphatidylethanolamine (PE) to the C-terminal of LC3-I, 
generating the LC3-II form (Kimura et al., 2009). LC3-II is bound 
on the outer layer of the outer membrane and inner layer of the 
inner membrane of the double-membrane autophagosome. When 
the autophagosome matures into an autolysosomes, LC3-II on 
the outer membrane is liberated into the cytosol as LC3-I, 
whereas the one facing the lumen of the organelle is trapped 
inside and only in the final stage of the autophagic flux is 
degraded by lysosomal proteases (Figure 16) (Xie and Klionsky, 
2007). Therefore, the measurement of LC3-II turnover by 
different biochemical and microscopy approaches is a good 
indicator of the state of autophagy in a given condition (Kimura 
et al., 2009). 
 
Regulation of autophagy is complex and a comprehensive view of 
regulatory mechanisms is still missing (Reggiori and Klionsky, 
2002). Despite this, it is possible to identify different levels of 
autophagy regulation: (1) signalling pathways acting up-stream 
of the autophagy machinery regulating induction/inhibition of 
autophagy, (2) formation of autophagosome and, (3) maturation 
and fusion of autophagosomes with lysosomes (Esclatine et al. 
2009).  
Historically, mTOR (mammalian Target Of Rapamycin) has been 
considered the central regulator of autophagy. Indeed, the 
inhibition of this serine/threonine kinase (acting as a nutrients 
sensor) induces autophagy under starvation for energy supply 
and this process is an evolutionarily conserved response to stress 
in eukaryotes (Yang and Klionsky, 2009a). It has been shown by 
Blommaart and colleagues (1995) that rapamycin induces 
autophagy in rat hepatocytes; therefore rapamycin, by inhibiting 
the mTOR pathway, represents a well-known inducer of mTOR-
dependent autophagy (Noda and Ohsumi, 1998). Several other 
mTOR-independent pathways are involved at the different levels 
mentioned above and their modulation with different compounds 
might have potential therapeutic application in disease-related 
autophagy de-regulation (Rubinsztein et al., 2007a).  
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Beyond its classical role in energy supply under starvation and 
turnover of organelles and proteins, autophagy plays a wide 
variety of roles in different physiological processes and 
pathological conditions as depicted in figure 17 (Beau et al., 
2011; Yang and Klionsky, 2009a; Mizushima et al., 2008).  
 
 
 
Figure 17 Role of autophagy in different physiological (in green) and pathological (in 
orange) conditions.  
 
4.2 Autophagy and Neurodegenerative Diseases 
 
Recently, autophagy has been described as an important process 
in the pathogenesis of neurodegenerative diseases of protein 
aggregation such as Alzheimer's disease (AD), Parkinson's 
disease (PD), tauopathies and polyglutamine expansion diseases 
like Huntington's disease (HD) (Cherra III et al., 2010). As post-
mitotic cells that must endure for the lifetime of an organism, 
neurons must have efficient mechanisms to avoid accumulating 
toxic protein aggregates that otherwise could not been diluted in 
the daughter cells by cell division. It has been proposed that 
autophagy could have a protective role in neurodegeneration 
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acting as a quality control system in neurons for the turnover of 
malfunctioning proteins and organelles. Recently it has also been 
shown that dysfunction in the autophagic pathway is common to 
numerous neurodegenerative diseases leading to the 
accumulation of toxic mutant aggregate-prone proteins (Figure 
18) (Wong and Cuervo, 2010).  
 
 
Figure 18 Autophagy in neurodegeneration. Mutant aggregate-prone proteins can block the 
autophagic pathway and lead to neurodegeneration. Alternatively, autophagy can have a 
protective effect against neurodegenerative disease and stimulation of the autophagic flux can 
enhance this effect. 
!
For example, conditional knockout of the essential autophagy 
genes Atg5 or Atg7 in mouse brains, results in a 
neurodegenerative phenotype accompanied by massive protein 
aggregate accumulation that leads inexorably to death within the 
first few months of life (Hara et al., 2006; Komatsu et al., 2006). 
On the other hand, aggregate-prone proteins could also inhibit 
autophagy at different stages of the process. Winslow and co-
workers (2010) have recently shown that a-synuclein 
overexpression compromises autophagy via Rab1a in both 
mammalian cells and transgenic mice, and that this phenotype 
could be rescued by overexpressing Rab1a in the autophagy-
defective cells. Another study, in which the status of the 
autophagic system was analyzed in different cell types (primary 
neurons and striatal cell lines) deriving from HD mouse models 
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and from lymphoblasts derived from HD patients, showed a 
defect in cargo recognition mediated by p62 resulting in a lower 
and inefficient clearance of substrates that led to the 
accumulation of toxic cytosolic aggregates (Martinez-Vicente et 
al., 2010). 
Moreover, up-regulation of autophagy has been shown to 
efficiently counteract the accumulation of aggregate-prone 
protein deposits both in vitro and in vivo models. Therefore, an 
enhancement of autophagy with different compounds with the 
aim to reduce the produced toxic species might has a potential 
therapeutic use in neurodegenerative diseases because of its 
protective role (Figure 18) (Rubinsztein et al., 2007b).  
 
4.3 Autophagy and Prion Disease: an open debate 
 
The role of autophagy in prion disease is still controversial and 
highly debated (Heiseke et al. 2010). Autophagic vacuoles were 
detected in cell models chronically infected with prions (Figure 
19) (Schätzl et al., 1997).  
 
 
 
Figure 19 Ultrastructural signs of autophagic vacuolation and apoptosis in ScGT1-trk 
cells. (A) An uninfected (GT1-trk) cell showing a normal heterochromatic nucleus, well-
developed Golgi system, intact mitochondria, small secretory granules, and regular-size dense 
lysosomes. (B) Electron micrograph demonstrates typical cytopathologic changes in ScGT1-trk 
cells (present in about 20% of cells). Note the cytoplasmic accumulation of autophagic vacuoles 
representing different stages of degeneration, giant, swollen vacuoles, and peripheral clumping 
of dense chromatin in the nucleus. Modified from Schatzl et al., 1997 
More recently, it was found that autophagic vacuoles are formed 
in neuronal perikarya, neurites and synapses in experimentally 
induced scrapie, Creutzfeldt-Jakob disease (CJD) and Gerstmann-
Sträussler-Scheinker (GSS) syndrome (Liberski et al., 2008) and 
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autophagic vacuoles were identified in synapses in various forms 
of human prion disease (Sikorska et al., 2004). It was then 
proposed that autophagy could play a disease-promoting role by 
contributing to the formation of spongiform changes, a 
pathological hallmark in prion-affected brains (Liberski and 
Jeffrey, 2004; Liberski et al., 2008). On the other hand, it has 
been demonstrated that a number of autophagy-inducing 
compounds such as lithium salts, trehalose and rapamycin are 
effective at reducing PrPSc burden in cultured neuroblastoma cells 
(N2a) and delay the onset of symptoms in prion-infected mice in 
prophylactic treatment models (Heiseke et al., 2009; Aguib et al., 
2009). Thus, the induction of autophagy has been proposed as a 
novel approach in the treatment of prion diseases. However, a 
more systematic analysis of the role of autophagy in prion 
infection is needed, because the molecular mechanisms by which 
autophagy would be protective are still not understood.  
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5. Invasion and Spreading: PrPSc body tour 
 
Understanding how exposure to TSE agents, present in the 
environment, leads to invasion and spreading to the brain of a 
particular host is of fundamental importance in many different 
aspects of prion diseases, including the control of the infection, 
diagnosis, prophylaxis and identification of therapeutic 
approaches. 
 
From several studies, it is now well accepted that prion infection 
starts mainly with the uptake of prions by the alimentary tract or 
through scarification of gums, skin and conjunctiva (Beekes and 
McBride, 2007). It is interesting to note that the spreading of 
prions in naturally acquired prion diseases, such as scrapie, CWD, 
BSE and vCJD may also depend on their site of entry, strain and 
species, dose and PrPC genotype of the host (Kovacs and Budka, 
2008). This highlights the urgency of a more systematic study of 
the pathogenesis at the cellular level to better characterize 
pathways and major players involved in prion diseases. 
Despite the number of variables involved in prion spreading, from 
substantial data present in the literature reviewed in great detail 
by Beekes and Mc Bride (2007), it is possible to dissect the 
routing of TSE agents through the body in precise characteristic 
stages, summarized in Figure 20.  
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Figure 20 Different stages of prion infection. 1) accumulation of prions in lymphoid tissues; 
(2) neuroinvasion, consisting in the spread from the lymphoid tissues to the peripheral nervous 
system (PNS); (3) dissemination within the brain and spinal cord (central nervous system, 
(CNS)) and, (4) centrifugal spread from the CNS to further peripheral sites such as muscles. 
 
Particularly: (A) accumulation of prions in lymphoid tissues; (B) 
neuroinvasion, consisting in the spread from the lymphoid tissues 
to the peripheral nervous system (PNS); (C) dissemination within 
the brain and spinal cord (central nervous system, (CNS)) and, 
(D) centrifugal spread from the CNS to further peripheral sites 
such as muscles (Beekes and Mc Bride, 2007).  
 
 
5.1 From the periphery to the central nervous system: which is 
the route to follow? 
 
Following ingestion, prion reaches the lymphoid organs. The 
mechanism by which prion spreads from the gastrointestinal tract 
after exposure to the lymphoid tissues is still not well understood 
but different players with specific roles has been identified. 
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From early studies in mice fed with scrapie or BSE agent, it was 
observed that the first prion deposition may occur in Peyer’s 
patches and mesenteric lymph nodes prior to infection to other 
lymphoid tissues (Kimberlin and Walker, 1989) and that the 
spleen does not play a major role in neuroinvasion (Maignien et 
al., 1999). Instead, gut-associated lymphoid tissue (GALT) and 
GALT-draining lymph nodes appear to play a more significant role 
in early pathogenesis (Beekes and Mc Bride, 2007).  
Once prion gets in the lymphoid follicles, its replication and 
transport involve different cell types such as microfold cells (M 
cells), follicle-associated epithelium (FAE), follicular dendritic cells 
(FDCs), dome and tangible body macrophages (TBMs) and 
dendritic cells (DCs) (Beekes and McBride, 2000). In addition, it 
has been shown that B cells and complement system can have a 
supporting role that appears not to be essential (Mabbott et al., 
2001; Klein et al., 1997, 2001). Also, at later stages of 
infection, lympho-reticular system (LRS) components seem to 
accumulate the scrapie agent (McBride et al., 2001; Beekes et 
al., 1996). A schematic representation with the main players that 
are thought to be involved in the uptake of prion from the gut to 
the lymphoid tissues is depicted in figure 21. 
 
 
 
 
Figure 21 Possible cells involved in the uptake of prion from the gut to the lymphoid 
tissues. The intestinal epithelium is protected by a single layer of epithelial cells bound by tight 
junctions. How TSE agents cross this protective barrier is not known, but several mechanisms 
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have been proposed. Within the epithelium, microfold (M) cells are specialized for the 
transepithelial transport of macromolecules and particles. One study suggests that M cells are 
also plausible sites for the transport of TSE agents across the intestinal epithelium. TSE agent 
transport across the intestinal epithelium might also occur independently of M cells. 
Alternatively, dendritic cells (DCs) can also acquire antigens directly from the intestinal lumen 
by opening up the tight junctions that join the epithelial cells and inserting their dendrites 
between them. Once across the intestinal epithelium, current data suggest that the TSE agent 
might be acquired by migratory DCs and macrophages. Although DCs are plausible candidates 
or the delivery of TSE agents to lymphoid tissues, macrophages seem to phagocytose and 
sequester them (Mabbott and McPherson 2006). 
 
A consistent number of studies have shown that mainly GALT 
and, in minor part, other lymphoid tissues play a pivotal role in 
amplifying prions and acting as a bridge towards the CNS (Aguzzi 
and Calella, 2009). Nevertheless a direct infection of the nervous 
system could also take place after oral exposure, as observed in 
rodent models lacking a detectable lymphoid infection (Bartz et 
al., 2005; Oldstone et al., 2002; Fraser et al., 1996). 
Of particular interest, the involvement of FDCs, as GALT 
components, has been comprehensively investigated for their 
ability to both accumulate PrPSc, as demonstrated by Kitamoto 
and colleagues (Kitamoto et al., 1991) and spread it to the CNS 
(Mabbott et al., 2003; Montrasio et al., 2000). FDCs are immobile 
stromal-differentiated cells that highly express PrPC (Brown et al., 
1999) residing in the follicles and germinal centres (Shortman 
and Liu, 2002; Kapasi et al., 1993). They have many fine 
dendritic processes used for the trapping and retention of 
antigen in a native state. In the case of prion, some evidences 
show that FDCs capture and accumulate the infectious agent and 
are then able to transfer it to different cells allowing the 
spreading of the infection. 
But how can immobile FDCs make a link between the intestinal 
barrier and the peripheral nerves? 
Heppner and colleagues (2001) have shown in an in vitro system, 
consisting of a CaCo-2 epithelial cells monolayer (Heppner et al., 
2001), that microfold cells (M cells) are able to actively 
transcytose the scrapie agent through the basolateral site of the 
epithelium as happens for some pathogenic microorganisms 
(Neutra et al., 1996). M cells are localized between the villus 
epithelium and the follicle-associated epithelium of the Peyer’s 
patches and are specialized in transcytosis of macromolecules 
Page | '%"
and particles. Therefore, PrPSc can cross the gut epithelium by 
this particular cell type even if not in an exclusive manner. 
Migratory bone-marrow dendritic cells (BMDC) can then be 
possible candidates for the passage of PrPSc to FDCs and from 
FDCs to the PNS (Figure 22) (Gousset and Zurzolo, 2009).  
 
 
 
 
Figure 22 Schematic representation of the passage of TSE agent from the gut lumen to 
the PNC. Migratory bone-marrow dendritic cells (DC) can then be possible candidates for the 
passage of PrPSc to FDCs in lymphoid tissues and from FDCs to the PNS.  
 
Indeed, dendritic cells (DCs) are situated beneath the M cells in 
the intraepithelial pocket where they can uptake antigens that 
has been transcytosed by the M cells; therefore they are 
specialized in the capture of antigens in the periphery, followed 
by delivery to the lymphoid organs (Shortman and Liu, 2002). 
Alternatively, DCs can directly uptake antigens from the intestinal 
lumen by opening the tight junctions of the intestinal barrier 
(Rescigno et al., 2001). Huang and co-workers have shown that 
DCs are indeed able to transport PrPSc from the gut to the prion-
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replicative lymphoid tissue (Huang et al., 2002). Also, PrPSc 
deposits have been detected in DCs from Peyer's patches, 
mesenteric lymph nodes or spleen (Dorban et al., 2007). 
Moreover, in mice lacking DCs, neuroinvasion is partially impaired 
because accumulation of PrPSc does not take place following 
peripheral prion infection (Raymond et al., 2007; Cordier-Dirikoc 
and Chabry, 2008; Aucouturier et al., 2001). More recently, 
Langevin and colleagues (2010) have characterized the role of 
BMDCs in the transfer of prions to primary neurons using an in 
vitro system in which BMDCs were loaded with prion and then co-
cultured with cerebellar primary neurons (CGNs) (Langevin et al., 
2010). BMDCs deriving from both PrPC-overexpressing and knock-
out mice (lacking PrPC) were able to uptake and degrade PrPSc, 
demonstrating that these processes are PrPC-independent, as 
previously shown (Dorban et al., 2007). Moreover, a direct cell-
to-cell contact, mediated by tunneling nanotubes (Langevin et 
al., 2010), that have been found to have a major role in prion 
spreading (Gousset and Zurzolo, 2009), between BMDCs and 
CGNs in PrPSc transfer seems to be necessary for the process to 
occur similarly to what was recently shown with dorsal root 
ganglion neurons (Dorban et al., 2010). These results clearly 
point out towards a major role of dendritic cells in prion 
spreading from the periphery to the CNS and a further 
characterization of the mechanism could allow a better 
understanding of their role in vivo. 
 
On the way to the CNS, passing mainly from the lymphoid 
tissues, PrPSc get access to the peripheral nerves prior to 
reaching the brain.  
Studies from Mc Bride and co-workers (1999 and 2001) suggest 
that efferent fibres of both sympathetic (as the splanchnic 
nerve) and parasympathetic nerves (as the vagus nerve) can 
direct prions to the CNS in a retrograde direction from the 
enteric nervous system. In the case of parasympathetic nerves, 
the entry in the CNS occurs independently from the spinal cord 
highlighting the fact that different routes may be responsible for 
prion spreading to the CNS (Baldauf et al., 1997).  
Once the infection has reached the brain, it can spread along it in 
both anterograde and retrograde directions (Beekies et al 1996). 
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For example, from a study in hamsters orally challenged with 
scrapie, it was observed that substantial amount of PrPSc was 
present in different muscles, including the tongue, providing the 
first evidence of a centrifugal spread of infection from the CNS to 
peripheral locations (Bosque et al., 2002).  
 
5.2 Cell-to-cell spreading  
 
At the different stages of its lethal journey to the CNS (Figure 
20), PrPSc is transferred from one cell to another and this passage 
can involve several mechanisms not mutually exclusive probably 
depending on cell types, strains infecting and hosts.  
As depicted in figure 23, prion transmission may occur (A) by 
cell-to-cell contact through the conversion of recipient PrPC 
without internalization of donor PrPSc; (B) in association with 
exosomes; (C) through the release in the medium of a C-terminal 
truncated form of PrPSc followed by uptake in the recipient cell; 
(D) by “GPI-painting” mode and, (E) spreading through tunneling 
nanotubes (TNTs).  
 
 
 
Figure 23 Possible ways of cell-to-cell prion spreading. Proposed mechanisms of cell-to-
cell spread of prion infectivity. (A) Prion transmission through direct cell-to-cell contact 
(conversion of recipient PrPC without internalization of donor PrPSc). (B) Transmission of prions 
through exosomal PrPSc association; both a direct interaction of exosome-associated PrPSc with 
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cell-associated PrPC and incorporation of exosomal membrane with recipient cell membrane 
are represented. (C) C-terminal truncation of PrPSc allowing release from an infected cell and 
movement to an uninfected recipient cell. (D) "GPI-painting" mode of prion transfer. (E) PrPSc 
spread through tunnelling nanotubes, in association with small vesicles of lysosomal origin. 
Mode (A) is represented by lipid raft associated PrP, but could involve non-raft associated PrP. 
Mode (D) is depicted by transfer of cell surface PrPSc, but could potentially occur with 
exosomal PrPSc (From Lewis and Hooper 2011).  
 
A brief description of the different means of PrPSc transmission is 
presented below:  
 
• Cell-to-cell contact 
From the works of Kanu and co-workers (2002) and 
Paquet and colleagues (2007), it has been shown that, in 
some cases, prion transmission needs a close cell-to-cell 
contact to occur and that contact with only the medium of 
infected cells or the physical separation between infected 
and uninfected cells abrogate infectivity (Paquet et al., 
2007; Kanu et al., 2002). However, in both reports, the 
authors have not postulated a model of transmission. The 
mechanism could involve, for example, PrPC conversion in 
trans in the recipient cell by contact with PrPSc present on 
the plasma membrane of an infected cell. Moreover, a 
transfer of infected apoptotic bodies in uninfected cells 
could not be totally excluded since dead infected cells are 
still able to pass the infectivity to naïve cells (Kanu et al., 
2002). 
 
• Exosomes 
Exosomes are small vesicular carriers with a diameter of 
40-100 nm generated within the lumen of the endosomal 
system and released in the extracellular space following the 
fusion of the endosome with the plasma membrane. These 
vesicles are involved in intercellular communication by 
transferring not only transmembrane proteins but also 
nucleic acids and other cytosolic components (Simons and 
Raposo, 2009). It has been shown that cells can release 
prions in association with exosomes (Fevrier et al., 2004; 
Vella et al., 2007); moreover, intracerebral injection of 
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purified prion-containing exosomal particles resulted in the 
infection of healthy mice (Fevrier et al., 2004). 
 
Microvesicles 
• Besides vesicles of exosomal origin, a recent report 
describes the involvement of microvesicles (MVs) in prion 
spreading as well (Mattei et al., 2009). MVs are sub-micron 
membrane-bound vesicles released by healthy or damaged 
cells, whose number can increase upon injury, apoptosis or 
inflammation and are normally present in the blood 
(Ratajczak et al., 2006). Mattei and colleagues (2009) 
have shown that PrPSc is released from infected murine 
neuronal cell in association with MVs, resulting in infection 
both in vitro and in vivo. Moreover, it has been 
demonstrated that blood as well as plasma of animals 
experimentally infected with TSEs can transmit TSE 
infection by transfusion (Ludlam and Turner, 2006; 
Cervenakova et al., 2003). In these cases, MVs could be 
the vehicles for prion transmission through infected blood.  
 
• Shedding 
Alternatively, it has also been reported that around 15% of 
PrPSc is present in a C-terminal truncated form in hamster 
brains (Stahl et al., 1990). This form results from the 
cleavage at the level of Gly228, part of sequence Gly-Arg-
Arg that is a target for proteolysis and release of bioactive 
peptides (Stahl et al., 1990). The presence of this C-
terminal truncated form of PrPSc in the medium following 
the actions of a phospholipase- or protease-like activity 
could also allow the spreading of PrPSc in neighboring 
uninfected cells (Lewis and Hooper, 2011). 
 
• GPI painting 
GPI painting phenomenon consists in the transfer from one 
cell to another by re-insertion of a functional GPI-anchored 
protein in the plasma membrane of the recipient cell and 
seems to occur both in vitro and in vivo (Legler et al., 
2005; Kooyman et al., 1995). Baron and co-workers 
(2002) have suggested that GPI-painting could be one of 
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the possible mechanisms of PrPSc transfer between cells, as 
described for PrPC in a co-culture system using a PrPC 
expressing cell line (M17-PrP) and the cell line IA lacking 
PrPC (Liu et al., 2002). 
 
• Tunneling nanotubes (TNTs)  
Tunneling nanotubes (TNTs) are thin membranous bridges 
containing actin that serve as long-range form of 
intercellular communication that can easily form between 
different cell types in culture (Rustom et al., 2004). It has 
been shown that these structures can traffic both PrPC and 
endogenous and exogenous PrPSc between various cell 
types of both neuronal and non-neuronal origins (Gousset 
et al., 2009). TNTs and their role in prion spreading will be 
described and discussed largely in the next chapter 
(chapter 6), as this mechanism of prion spreading is one of 
the subjects of my PhD work. 
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6. Tunneling Nanotubes (TNTs) 
 
The ability of cells to communicate with each other is essential 
for the life of a multicellular organism and is evolutionarily 
conserved between species. Without cell-to-cell communication, 
processes such as remodeling of tissues and organs, 
differentiation during development, growth, cell division and 
responses to stimuli could not take place. Therefore, a great 
number of cellular genes and their products are implicated in 
intercellular communication and their deregulation leads to the 
establishment of pathological conditions associated with many 
diseases (Alberts, 2004). 
Recently, long-range forms of intercellular communication 
consisting of different types of membrane bridges have been 
described in a wide variety of cell types in in vitro cell culture 
system.  Similar connections have also been found in vivo . The 
discovery of these new types of communication highways has 
opened up new ways of viewing how cells interact with one 
another, leading to the reconsideration of the traditional view of 
the cell as a basic unit of structure, function and organization 
originally postulated by Schleiden and Schwann (1839). 
 
Tunneling nanotubes (TNTs), initially described by Rustom and 
co-workers (2004), are long thin actin-containing bridges 
connecting PC12 cells in culture that do not contact the 
substratum, extending up to 100 μm in length with diameters 
ranging from 50-200 nm. Since then, TNTs have been found in 
many cell types in culture, from immune to neuronal cells and 
primary cells, acting as conduits for cytosolic and membrane-
bound molecules, organelles and spreading of pathogens (Gerdes 
and Carvalho, 2008) (Figure 24).  
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Figure 24 (A) Schematic representation of cargo transported along a TNT-like structure. Red 
arrowhead correspond to F-actin cytoskeleton. Identified cargo in TNT-like structures is 
displayed in box drawn with dotted line. (B) Three-dimensional reconstruction of a network of 
TNTs in CAD cells (modified from Gousset et al 2009). 
 
This and other examples of intercellular contacts established by 
different type of mammalian cells as filopodial bridges, viral 
cytonemes and EP bridges together with plasmodesmata found in 
plant cells, bacterial and parasite networks reveal a high 
heterogeneity in both structure and functions of these 
fascinating new routes of communication that need a further 
characterization and classification. 
 
6.1 Mechanism of TNTs formation  
 
As mentioned above, TNT-like structures were first described in 
PC12 neuronal cells (Rustom et al., 2004).  In these cells, de 
novo actin-driven formation of TNTs was observed.  Further 
examination of PC12 cells and TNT formation suggested that 
while the majority of tubes formed via de novo formation, from 
directed filopodia-like protrusions, a small subset (7%) were also 
able to form after cells in close contact detached from one 
another (Figure 25). 
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Figure 25 Model of TNT formation. (A) One cell forms an actin-driven protrusion directed 
towards the target cell (top). Fusion of the cell protrusion with the membrane of the target cell 
results in TNT formation (bottom). (B) TNTs may form between adjacent cells, which 
subsequently diverge. Red line, F-actin; arrows, direction of filopodium  (A) and cell (B) 
movement, respectively.  From Gerdes et al 2007 
 
In the mouse neuronal CAD cell line, both types of TNT formation 
are observed (Gousset et al 2009).  However, the significance 
and the differences between these various structures remain 
unclear.  Similar to other cell types, TNT-like structures in CAD 
cells present a high degree of heterogeneity in the diameters 
(Gousset et al., 2009). Furthermore, as previously described in 
PC12 cells (Rustom et al., 2004), neuronal TNTs formed between 
CAD cells contained actin filaments but no microtubules (Gousset 
et al., 2009).  The fact that most TNTs in neuronal cells arise 
from the extension of filopodia-like protrusions toward 
neighboring cells suggested that actin polymerization plays an 
important role in this type of TNT formation.  Rustom and 
colleagues demonstrated that using the F-actin depolymerizing 
drug latrunculin no TNTs were detected in PC12 treated cells 
(Rustom et al., 2004). This type of treatment could thus be used 
to selectively block TNT formation and look at the effect of the 
presence or absence of nanotubes in various cultures. Using 
nanomolar concentrations of Cytochalasin D (CytoD), another 
actin-depolymerizing drug, Bukoretshliev and colleagues went 
further and examined the effects of this drug during the lifetime 
of TNTs (Bukoreshtliev et al., 2009).  They showed that as 
expected, low levels of CytoD abrogated both filopodia formation 
and TNT formation.  Interestingly, they also demonstrated that 
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once formed, CytoD had little effects neither on the stability of 
these tubes and their ability to transfer material from one cell to 
another.  Thus, most neuronal TNTs arise from filopodia-like 
structures, detached from the substratum.  Once formed 
however, they are no longer sensitive to low levels of actin-
depolymerizing drugs, demonstrating that functional TNTs are 
distinct from filopodia in both structure and function. TNT-like 
structures have also been described in immune cells, such as B-
cells, Natural killer cells and macrophages (Onfelt et al., 2004).  
In macrophages, two types of nanotubes were also described 
(Onfelt et al., 2006).  The thin nanotubes were found to contain 
actin filament only, whereas thicker nanotubes, with diameters 
larger than 0.7 μm, contained both F-actin and microtubules.  
These different structures also had distinct functions, with the 
thicker structures being able to transport in a bi-directional 
manner vesicles and various organelles in a microtubule 
dependent mechanism.  Similarly, long nanotube connections 
between Jurkat T-cells and primary T cells were also described 
(Sowinski et al., 2008). Finally, numerous networks of TNT-like 
structures were observed between dendritic cells and THP-1 
monocytes (Watkins and Salter, 2005).  These connections 
varied greatly in length and diameter but were able to quickly 
transfer calcium fluxes and small dyes to interconnected cells. In 
Urothelial cell lines, two types of TNT-like structures were 
described (Veranic et al., 2008).  The shorter but more dynamic 
structures, described as Type I nanotubes, were found to contain 
actin.  These structures did not collapse after micromolar 
concentrations of CytoD.  On another hand, the longer and more 
stable structures, or type II nanotubes, no longer had actin 
filaments and were composed instead of cytokeratin filaments. 
These examples show the disparity in the various cytoskeleton 
requirements and formation mechanisms in naturally occurring 
TNT-like structures in neuronal, immunological or epithelial cells.  
The type of formation however (de novo actin-driven versus cell-
to-cell contact) might arise from the nature and role that these 
cells play in vivo.   
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6.2 Signal and molecules involved in TNTs formation 
 
In order to better understand the role that TNTs may play in 
intracellular transfer of materials, a better characterization of the 
initiation steps of TNT formation, the signals that guide the 
extension of these structures toward a neighboring cell and the 
mechanisms of binding and fusion need to be elucidated. 
Recently, the effects of stress on TNT formation have been 
analyzed in different cell types (Wang et al., 2011; Yasuda et al., 
2011, 2010). Wang and colleagues (2010) have shown that 
stress induced by hydrogen peroxide (H2O2) treatment led to an 
increase in TNT formation in both astrocyte and neurons. They 
also observed transfer of various organelles, such as ER, Golgi, 
endosomes and mitochondria via TNTs in astrocytes cultures.  
For both astrocytes and neurons, it was always the cells 
undergoing stress that developed TNTs and transferred cellular 
materials in a uni-directional fashion to the non-activated cell.  
Thus, suggesting that TNT formation might be directly induced 
by stress.   
Interestingly these authors showed that p53 activation, which is 
critical in apoptosis, led to an increase in TNT formation 
independently of stress stimulation, and that down-regulation of 
p53 blocked TNT formation. Furthermore, EGF receptor up-
regulation was also shown to be necessary for TNT initiation. 
Since the EGF receptor can activate the Akt/PI3K/mTOR 
pathway, they used various mutants and inhibitors to selectively 
block or activate each protein and found that this pathway was 
indeed up regulated in H2O2 activated cells leading to an increase 
in TNT development.  In another study, looking at a macrophage 
cell line and HeLa cells, it was demonstrated that the interaction 
between m-Sec and the Ral/exocyst complex was also critical for 
TNT formation (Hase et al., 2009).  Thus, to see if m-Sec might 
also be important for TNT formation in astrocytes, Wang and 
colleagues looked by RT-PCR at the levels of mSec in astrocytes 
and found a positive relationship between H2O2 treatment and the 
levels of m-Sec expression (Wang et al., 2010).  They concluded 
that m-Sec might be regulated by p53 activation. Interestingly, in 
another study Yasuda and colleagues analyzed the transfer of 
mitotracker-labeled vesicles via TNTs between endothelial 
Page | (&"
progenitor cells (EPC) and human umbilical vein endothelial cells 
(HUVEC) (Yasuda et al., 2010). They observed both TNT 
formation between the two cell types and transfer of 
mitochondrial material from the EPC to the HUVEC.  Upon 
treatment of the HUVEC with adriamycin, they observed a large 
increase in the transfer of mitotracker particles from the non-
stressed EPC to the adriamycin-stressed HUVE in an uni-
directional fashion. Further characterization in these co-cultures 
could determine whether the stressed cells might release some 
signals that might attract filopodia-like protrusions from the EPC 
to the HUVEC or whether the HUVEC might initiate formation and 
allow for a reverse transfer of material from the receptor cell to 
the initiator cell.  This is exactly what the authors next set out to 
demonstrate.  Indeed, in a follow-up study, they looked more 
precisely at the TNT formation mechanisms between these cells 
(Yasuda et al., 2011).  First the authors showed that co-cultures 
of EPC with collagen I (GC)-stressed HUVEC led to a rescue of 
HUVEC viability.  However, when the EPC were pre-treated with 
nanomolar levels of CytoD to block TNT formation prior to co-
culture with the HUVEC, the rescue effects were almost entirely 
abrogated, pointing toward the importance of TNT formation 
from EPC to HUVEC for cell survival.  Using both fluorescence 
microscopy and FACS analyses they showed the existence of 
basal levels of transfer of lysosomes between the two cell types 
in a bi-directional manner under non-stressed conditions.  
However, the transfer was much more efficient as it increased in 
speed and frequency and was found preferentially between non-
stressed EPC and GC-stressed HUVEC, suggesting that the 
stressed-cells were able to signal and guide filopodia-like 
protrusions for the formation of de novo TNTs to occur.  Further 
examinations suggested that surface-exposed 
phosphatidylserines (PS) in HUVEC might be able to guide TNT 
formation from the EPC to the stressed- HUVEC.  Indeed, when 
PS on HUVEC were blocked by binding of Annexin V, the selective 
TNT formation and transfer from EPC to HUVEC was also blocked.    
Overall, these studies suggest that transfer of materials via TNTs 
in most cell types occurred from the cell type that initiated TNT 
formation to the receptor cell.  However, while certain stress 
conditions might increase the formation of TNTs between cells, it 
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doesn’t affect all cells the same way.  Indeed, while in astrocytes 
and neurons, stress appears to increase TNT formation in the 
stressed cells leading to an increase in transfer of material, in 
endothelial cells stress increase the guidance signals from the 
stressed cells leading to an increased formation of TNTs from the 
non-stressed cells.  Thus, once more the analysis of these two 
studies brings forward the disparities that exist in formation and 
nature of TNTs between different cell types.  It suggests that 
even within an identical type of TNT formation (i.e., de novo 
extension of filopodia-like protrusions) the mechanisms might be 
very distinct from one another (activation of attractive guidance 
signals versus activation of initiation of filopodia-like protrusions).  
However, these studies open up the doors for more general 
signaling pathways by pointing key elements critical for TNT 
formation.  For example, the role of m-Sec, which was found to 
be important in macrophages, HeLa cells and astrocytes could be 
of general importance in TNT formation, independently of cell 
type.  In addition, since filopodia-like protrusions are critical for 
TNT formation in neuronal cells (Bukoretshliev et al., 2009), 
molecules that are involved in filopodia formation and dynamic 
have to be taken into account. In particular, in my PhD thesis I 
focused my attention to the role that the actin molecular motor 
protein, Myosin-X might play in both the formation of TNT-like 
structures and its function in transfer of materials in neuronal 
cells (described largely below, section 7).   
In addition, the search for guidance signals and the role that lipids 
might play in TNT formation might also bring up a better 
consensus in TNT formation in general. 
 
6.3 TNTs-mediated transfer  
 
Tunneling nanotubes have revealed a high degree of 
heterogeneity also from a functional point of view, as different 
components seems to be selectively transferred by different cell 
types. First, further investigation is needed to understand why 
some cargoes are uni-directionally or bi-directionally transported. 
Uni-lateral transfer occurs in the case where a donor cell 
transfers material to an acceptor cell, whereas bi-lateral transfer 
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happens when both cells mutually exchange materials. The 
reasons for these different transport mechanisms can depend on 
the structural components (actin-only versus both actin- and 
microtubules-containing TNTs) or on specific signals that 
stimulate nanotube formation and are responsible for directing 
the traffic in one or two ways.  
Up to now several reports have shown that calcium signals could 
propagate between remote cells through tunneling nanotubes. 
This is especially important for remote cells that are unable to 
propagate calcium-mediated signalling to cells in close proximity 
using gap junctions. Initially, Watkins and Salter (2005) 
demonstrated that myeloid cells can respond to stimulation 
through soluble factors or mechanical stress and are able to 
amplify the cellular response by calcium signalling through 
membrane connections. Since then, propagation of calcium flux 
has been shown in many other cell types able to make 
connections between each other. More recently, the transfer of 
IP3 receptor (IP3R) and endoplasmic reticulum has been 
described along TNTs in SH-SY5Y neuroblastoma and HEK cell 
lines (Smith et al., 2011). Overall, calcium spreading through 
nanotubes appears to be a good option for different type of cells 
to quickly spread calcium signalization under physiological 
conditions, leading to fast responses in connected neighboring 
cells. Particularly fascinating and newly discovered is the 
spreading of death signals by nanotubes occurring in Jurkat and 
primary T cells (Arkwright et al., 2010). The authors have 
observed FasL and active caspase-3 passage from Fas-activated 
cells in neighboring non-activated ones was detected, thus 
resulting in the spreading of apoptosis through fratricide, 
highlighting that this might be an efficient way to shut down 
cellular responses (Arkwright et al., 2010). Tunneling nanotubes 
can be in certain cases be highways for diverse organelle transfer. 
Labelling with membrane-specific dyes, markers of the endo-
lysosomal pathway, or other dyes specific to organelles such as 
mitochondria, has revealed sub-cellular organelles traveling 
between cells along these connections (Hurtig et al., 2010). Also, 
a rescue function of TNT-mediated organelle transfer might be 
associated with other cell types that undergo injuries as well 
(Plotnikov et al., 2010; Yasuda et al., 2011). Smaller particles, 
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named nanoparticles, have also been shown to travel within 
nanotubes (He et al., 2010). Tunneling nanotubes could be either 
actively hijacked from different pathogens or transport them as 
“Trojan horses”, along the membrane or inside, leading to the 
spreading of infection. Hijacking of these structures can be 
preceded by induction of TNT formation, thus optimizing 
pathogen transfer, as has been shown for HIV particles spreading, 
both surfing on or inside TNTs in primary macrophages (Eugenin 
et al., 2009).  The HIV virus can use these highways to spread as 
an alternative to the other means already mentioned above. 
Additional investigations on the trafficking of HIV have shown 
that HIV specifically traffics in TNTs associated with endocytic 
compartments and so these organelles could be responsible for 
viral spread between macrophages (Kadiu and Gendelman, 
2011a; b). Finally, Onfelt and colleagues (2006) have shown that 
M. bovis BCG or clusters of several bacteria can surf on thin 
membrane nanotubes between macrophages before being 
internalized by receptor-mediated endocytosis, pointing towards 
a possible role of these structures in bacterial infection by 
concentrating the pathogen on the entry site for a more efficient 
invasion. 
 
6.4 TNTs and PrPSc spreading  
 
As described in the section 6, the mechanisms of prion spreading 
from the periphery to the central nervous system (CNS), and 
subsequently within the CNS, remain questionable and a number 
of mechanisms, such as cell-to-cell contact, exosomes and GPI-
painting, have been proposed (Kanu et al., 2002; Fevrier et al., 
2004; and Baron et al., 2006). It has been shown that TNTs 
readily formed in neuronal CAD cells (Figure 24) (Gousset et al., 
2009) were able to transfer lysosomal organelles, the cellular 
GPI-anchor prion protein PrPC, as well as fluorescently labeled 
infectious prion particles, PrPSc. Using various co-culture 
conditions, Gousset and colleagues (2009) have shown that 
these infectious particles were efficiently transferred to non-
infected cells only in the presence of TNTs. Since the prion 
protein is a GPI-anchored protein, it has the possibility of 
Page | (*"
traveling via TNTs either at the surface or within vesicular 
structures. Finally, it has also been demonstrated that the 
transfer via TNTs of infectious prion particles resulted in the 
transfer of infectivity to the recipient cell.  This transfer was not 
confined to neuronal co-cultures but was also efficiently 
transferred between loaded Bone-Marrow dendritic cells and 
primary neurons (Gousset et al., 2009; Langevin et al., 2010).  
Altogether these studies suggested that TNTs might play a 
critical role in vivo in the spreading of prions within the central 
nervous system (CNS) and at the periphery (Figure 26). 
 
   
 
Figure 26 Transport of PrPSc via TNTs, an alternative spreading mechanism during 
neuroinvasion. Studies in our laboratory suggest that TNTs allow for the intracellular transport 
of PrPSc between dendritic cells and neurons and between neurons (see inset). The exact 
mechanism of transport remains to be determined. For instance, it is still not clear, whether 
PrPSc is strictly transported within endocytic vesicles, or whether it can slide along the surface 
or be transported as aggregosomes within the tubes. Similarly, the types of motors used, as 
well as the possible gated mechanisms to enter the recipient cells are not known. Because of 
the high propensity of DCs to form TNTs with different cell types, we propose that TNTs could 
play important roles in delivering PrPSc to the proper cell types along the neuroinvasion route. 
For instance, DCs could deliver PrPSc  from the peripheral entry sites to FDCs in the secondary 
lymphoid tissues (2) or in a less efficient manner, they might occasionally directly transport 
PrPSc to the PNS (1). They could also bridge the immobile FDC networks and the PNS (3), 
since we have shown that DCs can form TNTs with nerve cells. Finally, once PrPSc has 
reached its final destination within the CNS, TNTs might play a final role in the spreading of 
PrPSc within the brain between neurons and possibly between neuronal cells and astrocytes 
(4). 
 
Like prion diseases, neurodegenerative diseases such as 
Alzheimer, Parkinson and Huntington appear as the result of 
Page | )+"
protein misfolding and aggregation, it is tempting to wonder 
whether these diseases might share some common spreading 
mechanisms.  Recently, Wang and colleagues have analyzed 
whether intracellular A" particles could spread through TNTs in 
astrocytes and neurons (Wang et al., 2010).  Microinjection 
experiments demonstrated that intracellular A"-fusion proteins 
were indeed able to quickly spread from cell-to-cell via TNTs.  In 
addition, they looked at the transfer of A" toxicity in co-cultures 
of infected astrocytes and neurons.  They showed that increasing 
the number of TNTs between the cells by H2O2 treatment led to 
an increase in neuronal cell death in co-cultures with infected 
astrocytes compared to the control GFP or non-stressed cells.  
Thus suggesting that A" particle spreading via TNTs within the 
cultures resulted in an increase in neuronal toxicity leading to cell 
death.  Such observations are very similar to what we found with 
PrPSc and infectivity and suggest that prion diseases and other 
neurological diseases might use TNTs as a spreading mechanism.  
If these types of studies can be further extended to Parkinson or 
Huntington, they might open up new ways of looking at these 
diseases and could lead to new strategies to fight them. 
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7. MyoX: an unconventional molecular motor for an 
unconventional function? 
 
Myosins form a large family of actin-based motor proteins 
implicated in diverse cell processes, such as cell locomotion, 
division and organelle transport (Sellers, 2000). Also, myosins 
mutations are linked to serious pathologies like myopathies, 
blindness, and hearing loss (Oliver et al., 1999; Toyoshima and 
Nishida, 2007). They share a general structure that consists of a 
head, neck and tail. The head is the motor domain that binds to 
actin and generate force in an ATP-dependent fashion to move 
along tracks of filamentous actin. The neck can interact with 
specific light chains or calmodulin. The tail is responsible for 
binding to specific targets or regulatory factors (Hartman et al., 
2011). Myosins superfamily can be divided in at least 20 
structurally and functionally distinct classes based on 
phylogenetic analysis of their conserved heads (Berg et al., 2001; 
Foth et al., 2006). However, a distinction between ‘conventional’ 
myosins, involved in muscle contraction and cytokinesis  (class 
II), and ‘unconventional myosins’, that include all the rest, is 
generally accepted (Sousa and Cheney, 2005).  
Myosin-X (Myo-X) is the founding member of a new class of 
unconventional myosins with a unique tail domain structure that 
includes multiple pleckstrin homology (PH) domains (Berg et al., 
2001). It was initially discovered in a PCR screen to identify new 
myosins expressed in the inner ear. It appears to be vertebrate-
specific and widespread in different tissues (Sousa et al., 2006) 
but not present in either C. elegans or Drosophila (Sousa and 
Cheney 2005). At the cellular level, Myo-X is detected in regions 
of dynamic actin, particularly along the leading edge of 
lamellipodia but more frequently at the tips of filopodia (Berg et 
al., 2000; Sousa and Cheney, 2005). It is also recruited to 
phagocytic cups in a phosphoinositide 3-kinase (PI3K)-dependent 
manner (Cox et al., 2002) and plays a role in spindle formation 
during cell division (Woolner et al., 2008; Toyoshima and Nishida, 
2007; Weber et al., 2004). Full-length Myo-10 is a protein of ~ 
240 kDa (Figure 25).  
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Figure 27 Schematic representation of the different domains of Myosin-X. See the text for 
a detailed description. 
!
The head at the N-terminal is the motor domain interacting with 
actin bundles that binds to ATP and generates force for 
movement ; this region is followed by three isoleucine-glutamine 
(IQ) motifs that serve as calmodulin or calmodulin-like light-chain 
binding sites (Homma et al., 2000). After the IQ domain, there is 
a predicted coiled-coil of 10-20 nm probably needed for 
dimerization (Lupas et al., 1991). The C-terminal globular tail 
contains binding sites for several cytoskeletal components, 
plasma membrane, signaling molecules and other factors (Sousa 
and Cheney, 2005). It consists of different sub-domains: a PEST 
domain, three PH domains, a myosin tail homology 4 (MyTH4) 
domain and a FERM domain (Berg et al., 2000). The PEST region 
(enriched in proline, glutamate, serine and threonine) is often the 
site of proteolysis by the Ca2+-dependent enzyme calpain; the 
cleavage of Myo-X at this site could serve to permanently 
‘unhitch’ the head domain from the tail and, so, stop the activity 
of the protein (Berg et al., 2000; Sousa and Cheney, 2005). The 
presence of the three PH domains that follow the PEST domain is 
a unique feature of Myo-X as these domains are frequently used 
as binding sites for inositol phosholipids. They have an unusual 
organization because the first PH domain is split by the insertion 
of the second one (Cain and Ridley, 2009). The PH2 domain of 
Myo-X binds with high affinity to PIP3 (Isakoff et al., 1998) and 
makes it a potential direct molecular target of PI3K, a master 
regulator of cell motility . 
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Following the PH domains, there is a myosin tail homology 4 
domain (MyTH4) that is a short (~150 amino acids) but well-
conserved domain common to other myosins (IV, VII, X, XII and 
XV) (Chen et al., 2001; Liang et al., 1999) and a plant kinesin 
(Reddy et al 1996). It has been shown by Weber et al (2004) 
that the MyTH4 domain of Myo-X in Xenopus serve as a 
microtubules binding site, thus highlighting a possible role in 
bridging the actin cytoskeleton with microtubules (Weber et al., 
2004) . 
The tail domain of Myo-X ends with a FERM domain (band 4.1, 
ezrin, radixin, moesin) connected to the MyTH4 by a short linker. 
The FERM domain seems to require the N-term MyTH4 domain for 
its cellular funtions (Bohil et al., 2006; Tokuo and Ikebe, 2004; 
Zhu et al., 2007) and it has recently been shown by 
crystallographic structural studies that these two domains form 
an integral structural supramodule (Wei et al., 2011). The FERM 
domain has been shown to bind to β-integrins (Zhang et al., 
2004), Mena/VASP actin-capping proteins (Tokuo and Ikebe, 
2004), axonal guidance receptor netrin-1 (Zhu et al., 2007) and 
VE-cadherin (Almagro et al., 2010). The capacity of Myo-X to 
interact with several cargo proteins allows it to participate in 
diverse cellular functions. FERM domains consist of three 
subdomains, the lobes F1, F2 and F3 (Pearson et al., 2000). It 
has recently been shown that both lobes F2 and F3 strongly 
interact with a NPXY motif in the cytoplasmic domain of integrin 
β5 but they are also required for binding to β1 and β3 (Zhang et al., 
2004). The direct interaction between Myo-X and integrins is 
important in localizing these cargo proteins to the tip of filopodia 
where they can anchor the cell to the extracellular matrix.  
The role of Myo-X in initiating filopodia formation and regulation is 
largely studied and its critical involvement has been 
demonstrated by many reports (Tokuo and Ikebe, 2004; Sousa 
and Cheney, 2005; Zhang et al., 2004; Berg et al., 2000; Bohil et 
al., 2006). Filopodia are cellular extensions acting as cell sensors 
for the extracellular environment and they are implicated in 
several fundamental physiological processes, mainly cell migration 
but also wound healing, development and cell signalling (Gupton 
and Gertler, 2007). These protrusive structures are thin (0.1-0.3 
μm), finger-like and filled with tight parallel bundles of 
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filamentous (F)-actin (Mattila and Lappalainen, 2008). The length 
of filopodia is controlled by a dynamic balance between actin 
polymerization at the barbed ends of a filament (the rapidly 
growing filament end) and the retrograde flow (by which the 
actin filament slowly slides backwards to the cell body 
(Mallavarapu and Mitchison, 1999).  
Myo-X is strikingly enriched at filopodial tips, a major site for 
signal transduction cascades regulating filopodial extension, 
retraction and adhesion (Berg and Cheney, 2002). It undergoes a 
new form of motility within filopodia named ‘intrafilopodial 
motility’ that consists of fast forward movements by using its 
motor domain (towards the tip) and slower rearward movements 
(towards the cell body) together with actin retrograde flow (Berg 
and Cheney, 2002) (Figure 26).  
 
 
 
 
Figure 28 Myosin-X intrafilopodial motility. A hypothetical model of M10 function in filopodia. 
Actin subunits (<) (left arrow). M10 is hypothesized to transport an as yet unidentified cargo, 
such as cell surface molecules or cytoplasmic signalling complexes (question mark) towards the 
tip of the filopodium (top) and to move rearward by binding to actin filaments,which are 
undergoing retrograde flow (bottom). 
 
It has been shown that a GFP-tagged heavy meromyosin (HMM)-
like fragment (GFP-MyoX-HMM) consisting of only the head motor 
domain, neck and coiled-coil is sufficient for tip localization while 
GFP-MyoX-tail only or GFP-MyoX-Headless (containing neck, coiled 
coil and tail regions) are both diffused in the cytosol and unable 
to reach filopodial extremities (Berg and Cheney, 2002). Taken 
together these experiments show that Myo-X needs its N-
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terminal actin-binding motor for filopodial tips localization. More 
importantly, it has been reported that Myo-X overexpression 
induces filopodial protrusion (Tokuo and Ibeke, 2004; Berg and 
Cheney, 2002; Zhang et al., 2004) and this finding raised the 
possibility that Myo-X could play a role in filopodia formation. 
Moreover, a recent work has shown that Myo-X without the tail 
domain can initiate filopodia upon dimer formation but these 
newly formed filopodia appeared to be short and unstable, 
differently from the over-expression of the full-length protein 
(Tokuo et al., 2007). This suggests that the tail domain is 
necessary to bring the right components to the growing site of 
filopodia, thus stabilizing and elongating these structures .  
In addition, Bohil and colleagues have shown that Myo-X 
overexpression is a great inducer of dorsal filopodia, that do not 
contact the substratum, in COS-7, HEK-293 (human embryonic 
kidney), HUVEC (human umbilical vein endothelial cells) and CAD 
(mouse neuronal cell line) cells. Also, by knocking-down the Myo-
X gene, they have shown that in absence of Myo-X there is a 
substantial loss of dorsal filopodia indicating that this protein is 
necessary for their formation (Figure 27).  
 
 
                    
 
Figure 29 Effect of Myosin-X over-expression and knock-down. (A) The dorsal surfaces of 
control COS-7 cells transfected with GFP alone are smooth and lack dorsal filopodia. (C) Cells 
transfected with GFP-Myo10, however, exhibit a massive increase in dorsal filopodia (B) SEM 
of a HeLa cell treated with control siRNA showing the numerous dorsal filopodia normally 
present on HeLa cells. (D) SEM of a HeLa cell from the same experiment treated with Myo10 
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siRNA showing the loss of dorsal filopodia induced by Myo10 siRNA (Modified from Bohil et al 
2006). 
It is interesting to note that the implication of Myo-X in the 
formation of dorsal filopodia highlights the fact that the 
anchoring to the substratum is not necessary for Myo-X function. 
Accordingly, the deletion of the FERM domain did not impair the 
ability of Myo-X to induce filopodia (Bohil et al., 2006) even if the 
attachment to the substrate by integrin binding could facilitate 
substrate-attached filopodia formation (Zhang et al., 2004). 
It has been also demonstrated that Myo-X can act downstream of 
Cdc42 that is a master regulator in filopodia formation (Bohil et 
al., 2006). However, it remains unclear how Myo-X could promote 
filopodia formation. Also, PIP3 has been shown to play an 
important role in filopodia induction by regulating Myo-X 
localization and function (Plantard et al., 2010). Indeed, the PH2 
domain of Myo-X binds to the membrane lipid PtdIns(3,4,5)P3 and 
no other PI and disrupting this interaction causes the 
redistribution of Myo-X in Rab7-positive endosomal vesicles that 
could be involved in trafficking and recycling of the protein 
(Plantard et al., 2010). Myo-X mutants lacking the PIP3 binding 
site do not promote induction of filopodia as the HMM-MyoX 
(Berg and Cheney, 2002). The mechanism of regulation is not 
clear but it could be possible that PIP3 binding to Myo-X is 
necessary to anchor the protein on the membrane; alternatively it 
can also be possible that PIP3 is a cargo for Myo-X that after 
reaching filopodial tips promote actin polymerization and thus 
filopodia growth (Plantard et al 2010).  
Besides, it has been recently shown by using a series of 
truncation mutants of myosin-X that the tail domain (PH-FERM) 
directly interacts with the motor domain to inhibit its activity in a 
phospholipid-dependent and Ca2+- independent manner (Umeki et 
al., 2011). Based on this finding, Umeki and co-workers propose 
that this intramolecular interaction is responsible for maintaining 
the motor domain in an inhibited state preventing it from free 
movement in physiological ionic condition, thus regulating the 
activity of Myo-X. The binding of PIP3 to the PH domain disrupts 
the interaction between the head and the tail domains and this 
activates both the motor activity and dimer formation of Myo-X 
allowing the transport of its cargo complex (Umeki et al., 2011). 
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As already mentioned above, the distribution of Myo-X is 
widespread and expressed at low level in different tissues. In the 
brain, the function of Myo-X is still not clear but it has been 
shown, for example, that its mRNA increases seven-fold upon 
peripheral nerve crush, thus indicating that it can be involve in 
nerve regeneration after injury  (Tanabe et al., 2003). mRNA for 
Myo-X protein is expressed in neurons, such as Purkinje cells, and 
in non-neuronal cells such as astrocytes and ependymal cells. In 
these cells, Myo-X localized at neuronal extensions, in neuronal 
filopodia, growth cones, neurites but also in the cell body (Sousa 
et al., 2006). Also, in undifferentiated CAD neuronal cell lines (Qi 
et al., 1997), Myo-X exhibits a punctuate pattern at the filopodial 
tips, confirming a role for this protein in filopodia dynamic (Sousa 
et al., 2006). 
Moreover, a short form of Myo-X of ~ 165 kDa lacking the motor 
domain is also expressed in adult brains with the exception of the 
cerebellum where it is present only at early stages of 
development and then it disappears. This ‘headless’ Myo-X 
localizes in the cell body and is unable to undergo intrafilopodial 
motility (Sousa et al., 2006). Regarding its role in the brain, it 
could act as ‘dominant negative’, regulating Myo-X full-length 
activity in neurons or can have independent functions in other 
cell processes (Sousa et al., 2006). It is interesting to note that, 
while in the cerebrum, both Myo-X full-length and headless forms 
are expressed at similar levels, in the cerebellum, only the full-
length form is increasing upon time and it appears to be highly 
regulated during development (Sousa et al., 2006). More 
recently, it has also been shown that Myo-X is highly expressed in 
the cranial neural crest (CNC) cells in embryos of Xenopus laevis 
where it is required for head and jaw cartilage development and 
has an essential function in migration (Hwang et al., 2009). An 
interesting recent report from Singh and colleagues (2010) have 
shown that Myo-X is implicated in a new model of melanin 
transfer named ‘filopodial-phagocytosis model’ in between 
melanocytes (MCs) to keratinocytes (KCs) crucial for the 
protection of the skin against UV radiations (Singh et al., 2010). 
Accordingly with these findings Myo-X drives filopodia formation 
and elongation in a Cdc42-dependent manner in MCs, creating 
conduits for melanosomes (specific organelles containing 
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melanin). Filopodial protrusions containing the melanosomes are 
then anchored to the membrane of KCs by integrin-binding and 
the help of Myo-X. In this model, the motor activity of Myo-X 
present at the tips could facilitate the phagocytic uptake of 
melanosomes by the KCs (Singh et al., 2010). 
In the second part of my results I have analyzed the role of Myo-
X in the formation and transfer function.  
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Aims of the study 
 
Prion diseases are neurodegenerative disorders characterized by 
the conformational change of a cellular protein, PrPC, in its 
pathological counterpart, PrPSc (Prusiner, 1998). Differently from 
PrPC, PrPSc is enriched in β-sheets, prone to aggregation, 
proteinase K-resistant. It represents the main component of 
prions, which are the infectious particles associated with the 
disease (as already described in the introduction, section 1.1). 
Despite the intense research, many questions in prion biology are 
still opened related to both the physiological functions of PrPC 
and mechanism of the disease caused by the misfolded form 
PrPSc. Thus, exploring some of these aspects at the molecular and 
cellular level is of fundamental importance for a better 
understanding of these fatal disorders and for developing 
potential therapeutical approaches. 
 
My PhD work has been focused on two major projects: 
 
• PROJECT 1 Role of autophagy in in vitro models of prion 
disease 
• PROJECT 2 Characterization of PrPSc spreading from cell-to-
cell by Tunneling Nanotubes (TNTs) in a prion infected 
neuronal cell model 
 
 
PROJECT 1:  
Role of autophagy in in vitro models of prion disease 
 
The role of protein degradation systems in protecting cells from 
aberrant, misfolded proteins has been in the spotlight due to its 
emerging relevance to human neurodegenerative diseases (Wong 
and Cuervo 2010). Autophagy is a cellular process responsible 
for the degradation of long-lived proteins, organelles and for 
maintaining steady amino acid pools when the cell is starved. 
Indeed, autophagy has been recently described as an important 
process in the pathogenesis of neurodegenerative diseases of 
protein aggregation such as Alzheimer disease, Parkinson disease, 
tauopathies and Huntington disease (Cherra et al. 2010). As 
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already mentioned before (Introduction, section 1.4) the role of 
autophagy in prion disease is still controversial and highly 
debated (Heiseke et al. 2010). Initially, autophagic vacuoles were 
detected in cell models chronically infected with prions (Schatzl 
et al., 1997) and in neuronal perikarya, neurites and synapses in 
experimentally induced scrapie, Creutzfeldt-Jakob disease (CJD) 
and Gerstmann-Sträussler-Scheinker (GSS) syndrome (Liberski et 
al., 2004). It was therefore proposed that autophagy could play a 
disease-promoting role by contributing to the formation of the 
spongiform changes, a pathological hallmark in prion-affected 
brains (Liberski et al., 2004 and 2008). More recently, it has 
been demonstrated that a number of autophagy-inducing 
compounds such as lithium salts, trehalose and rapamycin are 
effective in reducing PrPSc burden in cultured neuroblastoma cells 
(N2a) and delay the onset of symptoms in prion-infected mice in 
prophylactic treatment models (Aguib et al., 2009; Heiseke et al., 
2009).  
Therefore, a more systematic analysis of the role of autophagy in 
prion infection is needed because the molecular mechanisms by 
which autophagy would be either protective or co-responsible for 
the disease are not well understood yet.  
 
In this context, I divided this part of my PhD work in three 
specific objectives: 
 
a. To investigate the state of the autophagic pathway 
in different model of prion infected cells compared to 
non infected cells; 
 
b. To examine whether induction of autophagy has a 
role in prion degradation by clearing PK-resistant 
prion protein (PrPSc) in different infected neuronal 
cell models; 
 
c. To investigate possible drugs and alternative 
pathways involved in prion clearance. 
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This first part of my work has been submitted to Molecular 
Biology of the Cell as a paper in which I am the first author (See 
Results section 1).  
 
 
 
PROJECT 2:  
Characterization of PrPSc spreading from cell-to-cell by 
Tunneling Nanotubes (TNTs) in a prion infected 
neuronal cell model 
 
In variant Creutzfeldt-Jakob disease, prions PrPSc enter the body 
with contaminated foodstuffs and can spread from the intestinal 
entry site to the central nervous system (CNS) by intercellular 
transfer from the lymphoid system to the peripheral nervous 
system (PNS) (Mabbott 2006). Although several means and 
different cell types have been proposed to have a role, the 
mechanism of cell-to-cell spreading remains elusive (Introduction, 
section 1.6).  
TNTs have been identified between cells, both in vitro and in vivo, 
and may represent a conserved means of cell-to-cell 
communication (Introduction, section 1.7). Gousset et al. (2009) 
have shown that TNTs allow transfer of exogenous and 
endogenous PrPSc between infected and naïve neuronal CAD cells. 
Significantly, transfer of endogenous PrPSc aggregates was 
detected exclusively when CAD cells chronically infected with 
139A mouse prion strain were connected to CAD cells by means 
of TNTs, thus identifying TNTs as an efficient route for PrPSc 
spreading in neuronal cells (Gousset et al 2009).   
Therefore, to characterize the intercellular trafficking of PrPSc via 
TNTs and to investigate the mechanisms of TNT formation and 
function is of fundamental importance in prion biology and could 
lead to a better understanding of prion invasion and spreading to 
the brain of a particular host. 
 
In this context, I divided the second part of my PhD work in the 
following objectives: 
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a. Characterization of the sub-cellular compartments 
allowing the vesicular trafficking of PrPSc inside TNTs 
connecting CAD cells;  
 
b. Role of both cellular and pathological PrP isoforms on 
TNT formation and transfer; 
 
c. Role of Myosin-X in TNT formation, TNT-mediated 
transfer and PrPSc spreading from cell-to-cell.  
 
This second part of my results has been performed in 
collaboration with a post-doc in the lab and will be submitted 
beginning of 2012 in a paper in which I will be second author.  
 
In addition I have contributed to a review as first co-author that 
will be submitted by December 15 to Frontiers in Membrane 
Physiology and Biophysics (see ANNEX 1). 
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Material and Methods 
 
Cell l ines 
 
GT1-1 cells (gift of Dr. Mellon P., University of California, San 
Diego, USA) were infected with RML prion strain (gift of Dr. Korth 
K., Heinrich Heine University, Dusseldorf, Germany). N2a cells and 
scN2a cells (infected with 22L prion strain) were provided by 
Dr.Korth K. Non-infected and prion-infected GT1-1 and N2a cells 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(Invitrogen) supplemented with 10% of fetal calf serum (FCS). 
CAD and scCAD (infected with 139A prion strain) were both gifts 
of Dr. Laude H. (Institut National de la Recherche Agronomique, 
Jouy-en-Josas, France) and were cultured in Opti-MEM 
(Invitrogen) with addition of 10% FBS. 
 
Chemicals and antibodies 
 
Rapamycin, Tamoxifen, HO-Tamoxifen and Bafilomycin A1 were all 
purchased from Sigma. Puromycin dihydrochloride used for stable 
selection, 25% glutaraldehyde solution and 1M HEPES solution 
were from Sigma.  
 SAF32 and Sha31 anti-prion antibodies were purchased from 
SpiBio. Anti-tubulin monoclonal antibodies and anti-ATG7 were 
from Sigma. Anti-MyosinX rabbit polyclonal antibody was 
purchased from Sigma. Myosin X shRNA (m) lentiviral particles, 
control shRNA lentiviral particles and Polybrene® reagent were 
from Santa Cruz Biotecnology, INC. Anti-LAMP1 antibodies were 
purchased from BD Pharmingen™. Anti-LC3 monoclonal antibody, 
used for western blotting, was from nanoTools and anti-LC3 
polyclonal antibody, used for immunofluorescence, was 
purchased from MBL International. Anti-EEA1 and anti-Vamp1, 2, 
3 antibodies were from Synaptic Systems, Germany.  All the 
fluorescently labelled secondary antibodies as well as 
Lysotracker® green were purchased from Invitrogen (Molecular 
Probes). HCS CellMask™ Blue stain, Vybrant® DiD cell-labeling 
solution (DiD), wheat germ agglutinin tetramethylrhodamine 
conjugate (WGA-rhodamine) were purchased from Molecular 
Probes (Invitrogen). Fluorescently-labelled PrPSc (Alexa546-PrPSc) 
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was prepared as previously described (Gousset et al., 2009). 
 
Plasmids, siRNAs and transfection procedures 
 
The tandem fluorescently- tagged (with both GFP and RFP) LC3 
(Tf-LC3) and GFP-LC3 plasmids were a kind gift from Dr. Ballabio 
A. (Telethon Institute of Genetis and Medicine (TIGEM), Naples, 
Italy) and Dr. Yoshimori T. (Research Institute for Microbial 
Diseases, Osaka University, Osaka, Japan). The GFP-LC3 plasmid 
was provided from Dr. Yoshimori T. (Research Institute for 
Microbial Diseases, Osaka University, Osaka, Japan). ATG7 siRNA 
predesigned ON TARGETplus SMARTpool and siGENOME RISC-Free 
Control siRNA were both purchased from Dharmacon. GFP-MyoX 
full-length, GFP-MyoX-Headless, GFP-MyoX-HMM constructs were 
a kind gift from Dr. Cheney R. E. (University of North Carolina, 
Chapel Hill, NC, USA). GFP-MyoX-ΔF2, GFP-MyoX-ΔF3, mCherry-
MyoX full-length were provided by Dr.Strömblad S. (Center for 
Biosciences, Department of Biosciences and Nutrition, Karolinska 
Institutet, 14183 Huddinge, Sweden). eGFP-vector CFP-vector 
and mCherry-vector were from Clontech. GFP-PML was a kind gift 
of Dr. Enninga J. (Dynamique des interactions hôte-pathogène, 
Institut Pasteur, Paris, France). 
GT1-1 and scGT1 cells were transfected at 50% confluence using 
FuGENE6 (Roche Diagnostic) for DNA constructs according to 
manufacturer’s protocol.  To downregulate ATG7, 100 nM 
concentration of oligo was used with 10 µl of HiPerFect 
(Quiagen) per 60 mm dish. Hyperfect reagent was mixed with 
siRNA in DMEM without FBS, incubated for 10 min at room 
temperature and added to the cells. 
Transfection of both non-infected and infected CAD and N2a cells 
with DNA constructs was done using Lipofectamine 2000 
(Invitrogen), according to producer’s protocol.  
When detection of PrPSc levels was performed, downregulation 
and overexpression of the proteins were maintained for 5-day 
period. Therefore in all the experiments siRNA and plasmids, 
except of pEGFP were transfected twice (a second round of 
transfection was performed 3 days post-transfection). 
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MyoX shRNA lentiviral particles transduction and stable 
clones selection 
 
CAD cells (40000) were plated in a 12-well plate 24h prion 
transduction. Transduction protocol was performed accordingly 
to manufacturers’ instructions (lentiviral particles transduction 
protocol). Stable clones expressing both control and MyoX shRNA 
were selected and maintained in culture by adding 5 μg/ml of 
puromycin dihydrochloride to kill non-transduced cells. Western 
blotting was used to evaluate the percentage of MyosinX gene 
downregulation after cell lysis and Bradford protein colorimetric 
assay to measure protein content. 
 
Treatment of ScGT1, scCAD and scN2a cells with 
different drugs 
 
Rapamycin, Tamoxifen, HO-Tamoxifen were reconstituted 
according to manufacturer’s instructions. All the drugs were used 
in DMEM + 10% FCS at the final concentration of 2 µM for 
Rapamycin, and 5 µM concentration for Tamoxifen and HO- 
Tamoxifen. During the 3 or 5 day-treatment, medium containing 
the different drugs was changed every 2 days. 5M stock 
concentration of NH4Cl from powder (Sigma) was prepared in 
sterile Ultra-pure MilliQ water. 
When needed, Bafilomycin A1 or NH4Cl, respectively at 100 µM 
and 15 mM concentration were added to the Rapamycin, 
Tamoxifen or HO-Tamoxifen 5 day treatment for 2 days starting 
from the 4th day of the different treatments. 
 
Protein analysis by western blotting 
 
Cells grown in 60 mm dishes after the different treatments were 
lysed in 500 µl of Lysis buffer (0,5% triton X-100, 0,5% DOC, 
100 mM NaCl, 10 mM Tris-HCl pH 8). To analyze PrPSc levels, 250 
µg of protein/lysate were treated with 5 µg of Proteinase K (PK) 
for 30 min at 37°C. This step allows detecting PrPSc content only, 
because of its partial resistance to PK. The protein content was 
then methanol-precipitated overnight at -20°C and centrifuged at 
13000g for 30 minutes. After drying at 100°C, the pellet was 
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resuspended and denatured in Laemmli buffer before SDS-PAGE 
and western blot with the Sha31 anti-PrP antibody. All the other 
proteins, including total PrP, were analysed by western blotting 
from 20 or 40 µg of total lysate. HRP-conjugated secondary 
antibodies and ECL™ reagents from Amersham (GE Healthcare) 
were used for detection. 
 
Immunofluorescence 
 
For immunofluorescence analysis cells grown on coverslips into a 
24 well plate or on µ-Dish35mm, high (35 mm Petri dish with a thin 
bottom for high end microscopy, from Ibidi ®) were carefully 
washed with PBS, fixed with 2% PFA for 30 minutes and 
permeabilized with 0,1% of Triton X-100/PBS. A denaturation 
step with 6M guanidine-hydrochloride (Gnd-HCl) was performed 
for 10 minutes after permeabilization to detect PrPSc in infected 
cells (Taraboulos et al., 1990), when needed. Cells were then 
blocked in 2% BSA/PBS, immunolabelled with primary and 
secondary antibodies and mounted with Aqua/Poly Mount 
(Polysciences). Additionally, CAD cells were stained for 30 
minutes with HCS CellMask™ Blue stain (1:10000) and 
rhodamine-conjugated WGA (1:300) in PBS solution, when 
needed.  
In order to label endogenous LC3, cells were differently treated 
as previously described (Kimura et al., 2009). 
When filipin staining was used, cells were fixed with 4% PFA for 
60 min and blocked with 0,2% BSA/PBS. Filipin (250 µg/ml) was 
added to blocking solution and additional 30 min incubation was 
performed after incubation with secondary antibodies.  
 
Fluorescence Microscopy 
 
Immunofluorescences were analysed by high-resolution wide-field 
microscope Marianas (Intelligent Imaging Innovations) using 63x 
oil objective. All Z-stacks were acquired with Z-steps of 0.27 μm. 
The auto-scaling (min/max) of signal detection was used to 
record only maximal signal intensities when PrPSc was analyzed 
(Marijanovic et al., 2009). For colocalization studies of PrPSc in 
different organelles in tunnelling nanotubes of CAD cells 
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fluorescence images were acquired with a Perkin Elmer (PE) 
UltraView® laser spinning disk confocal imaging system using a 
63x immersion-oil objective. All Z-stacks were acquired with Z-
steps of 0.3 μm. 
In the live experiments, CAD cells plated on ibidi dishes were 
either transfected with GFP-LC3 plasmid or incubated with of 
LysoTracker (1:1000 dilution) for 30 min at 37 °C prior to be 
challenged with 1 ul/dish of sonicated Alexa546-PrPSc. The time-
lapse movies were acquired with Biostation IM (from Nikon) and a 
widefield microscope (Zeiss Axiovert 200M) controlled by 
Axiovision software.  
 
Tunneling nanotubes (TNT) detection by Fluorescence 
Microscopy 
 
To evaluate the number of TNT-connected cells TNT structures 
were analyzed by fluorescence microscopy. Cells were plated on 
µ-Dish35mm, high and maintained at 37 °C ON. Then cells were fixed 
for 30 minutes at room temperature (RT) with fixative solution 1 
(2% PFA, 0.075% glutaraldheide, 0.2M Hepes in PBS) and 
additionally for other 30 minutes at RT with fixative solution 2 
(4% PFA and 0.2M Hepes in PBS). Then cells were carefully 
washed in PBS and labeled for 20 minutes at RT with WGA-
rhodamine (1:300 in PBS solution) and 20 minutes at RT with 
HCS CellMask™ Blue stain (1:10000 in PBS solution).  WGA and 
HCS CellMask™ cell stainings permit cell segmentation and TNT 
detection. Image stacks covering the whole cellular volume were 
acquired with a widefield microscope (Zeiss Axiovert 200M) 
controlled by Axiovision software.  
 
Transfer of PrPSc from scCAD to CAD through TNTs by 
Fluorescence Microscopy assay 
 
Cocultures of scCAD cells (donor cells) transfected with either 
pGFP-vector or GFP-MyoX full-length and GFP-PML transfected 
CAD cells (acceptor cells) were plated plated on µ-Dish35mm, high in 
ration 1:1 and maintained ON at 37°C. Cells were then fixed with 
2% PFA for 30 minutes, permeabilized for 4 minutes with 0.1% 
Triton X-100 (Sigma), denatured for 10 minutes with 6 M Gnd-
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HCl. After extensive washes in PBS, cell were immunostained with 
Sha31 (1:500 in PBS) and AlexaFluor 546-conjugated secondary 
antibody. Additionally, cells were stained with HCS CellMask™ Blue 
stain (1:10000 in PBS solution) for 30 minutes at RT before 
mounting. Image stacks covering the whole cellular volume were 
acquired with a widefield microscope (Zeiss Axiovert 200M) 
controlled by Axiovision software. The auto-scaling (min/max) of 
signal detection was used to record only maximal signal 
intensities when PrPSc was analyzed (Marijanovic et al., 2009). 
 
DiD-vesicle transfer in CAD cells by Flow Cytometry 
(FACS) 
 
For quantitative analyses of intercellular organelle transfer, 
cocultures of CFP-vector transfected CAD cells (acceptor 
population) and DiD-labelled CAD cells transfected with 
alternatively GFP- or mCherry-tagged contructs harboring 
proteins of interest (donor population) were plated at a ratio of 
1:1 on 35 mm dishes (each experiment has been performed in 
triplicate). Notably, the DiD staining was performed as following. 
After counting, cell were centrifuged for 4 minutes at 1000 rpm 
and incubated with 1:3000 DiD solution in complete medium for 
30 minutes at 37°C. Then, cells were centrifuged for 4 minutes 
at 1000 rpm and washed in complete medium 30 minutes at 
37°C. Analysis of organelle transfer was performed at 16h after 
cell plating (overnight, ON). For this purpose, cells were scraped 
with 500 μl of PBS and passed through sterile 40 µm nylon cell 
strainers (BD Falcon™) in order to obtain single cell suspensions. 
Cell were then mixed with 500 μl of 4% PFA solution and let in 
fixation at 4°C, overnight (ON). For FACS analysis, DiD-labeled 
donor cells and CFP-vector transfected acceptor cells were 
analyzed at 633 nm and 488 nm excitation wavelengths, 
respectively. Flow cytometry analysis of organelle transfer (DiD-
vesicle) was performed on a CyAn ADP flow cytometer (Dako 
Cytomation, Beckman Coulter, Inc.).  
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Image processing and quantification 
 
Raw data (both images and movies) were processed with Image J 
software. The constrained iterative algorithm in Slidebook 4.2 
software (Intelligent Imaging Innovations) was used deconvolve 
the images acquired with the high-resolution wide-field 
microscope Marianas. Also, in these experiments, colocalization 
was quantified by intensity correlation coefficient-based (ICCB) 
analysis using JACoP (Bolte and Cordelières, 2006). Statistical 
analysis of the correlation of the intensity values of both green 
and red pixels or blue and red pixels in dual-channel image was 
performed using Pearson’s and Menders’s coefficient and Van 
Steensel’s approach (van Steensel et al., 1996).  
To evaluate the number of TNT-connected cells, a manual 
analysis was performed independently by two different people 
and each experiment was made at least in triplicate.  
To detect PrPSc particles in CAD cells (acceptor cells) in coculture 
experiments and to quantify the percentage of PrPSc particles in 
different organelles in TNTs of CAD cells a dedicated version of 
the QUIA (QUantitative Image Analysis) software 
(http://www.bioimageanalysis.org/) provided by the Quantitative 
Image Analysis unit (headed by J.-C. Olivo-Marin, Institut Pasteur, 
Paris, France) was used. FACS raw data were analysed by 
Kaluza® Flow Cytometry software (Beckman Coulter, Inc.).  
 
Statistical analysis 
 
Standard error was used to test the difference between the 
means of two or more independent experiments. All data were 
statistically validated by Student’s T-test. The differences were 
considered significant when p<0.05. 
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PROJECT 1: 
Role of autophagy in in vitro models of prion disease  
 
The Manuscript related to this first part of my results has been 
submitted to the journal “Molecular Biology of the Cell” and is 
appended at the end of this section. 
 
1.1 Objectives 
 
a. To investigate the state of the autophagic pathway 
in different model of prion infected cells compared to 
non infected cells; 
 
b. To examine whether induction of autophagy has a 
role in prion degradation by clearing PK-resistant 
prion protein (PrPSc) in different infected neuronal 
cell models; 
 
c. To investigate possible drugs and alternative 
pathways involved in prion clearance. 
 
1.2 Specific Background 
 
Although PrPC and PrPSc proteins share the same primary 
structure, PrPSc diverges from PrPC insofar as it acquires a greater 
content of β-sheets compared to the predominantly α-helical 
secondary structure of the normally folded protein. The 
accumulation of this protease-resistant, aggregate-prone form is 
associated with neuronal death and pathological features in 
affected individuals (Prusiner 1998). PrPSc persistence in cultured 
cells is thought to be maintained by a balance between its 
formation following the conformational change of PrPC into PrPSc 
and its degradation (as described in the Introduction, section 
1.1). A better understanding of PrPSc metabolism and particularly 
how to shift the equilibrium between PrPSc production and 
degradation is very important to understand the pathogenesis of 
the disease. Furthermore it could help in developing therapeutic 
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strategies for prion disease. However, due to the lack of PrPSc-
specific antibodies, PrPSc cellular trafficking, production and 
degradation are poorly defined. Both the plasma membrane and 
the endosomal recycling compartment (ERC) have been 
demonstrate to be sites were PrPC-PrPSc conversion occurs 
(Marijanovic et al 2009; Goold et al 2011). Moreover, recent 
studies suggest a role for lipid rafts in prion conversion (Campana 
et al., 2005; Taylor and Hooper, 2006; Taylor and Hooper, 
2011). Indeed, it has been reported that both PrPC and PrPSc 
localize in these particular domains, enriched in cholesterol and 
glycosphingolipids (Simons and Ikonen 2002; Lingwood and 
Simons 2010). Interestingly, it has been demonstrated that 
cholesterol depletion impairs PrPSc production (Taraboulos et al 
1995; Bate et al 2004). More recently, Gilch and colleagues 
(2009) have also shown that inhibition of cholesterol recycling 
impairs cellular PrPSc propagation. On the other hand, different 
degradation pathways might be involved in reducing intracellular 
PrPSc burden. For example, a role for the lysosomal compartment 
in PrPSc degradation has been described in several reports which 
have shown that in different infected neuronal cell lines PrPSc is 
sequestered in lysosomes where can be degraded (Borchelt et al 
2002; Caughey et al 1991; McKinley et al 1991; Jeffrey et al 
2006; Marijanovic et al 2009; Gousset et al 2009; Veith et al 
2009). More recently it has been shown that macrophages, 
involved in early stages of prion infection, might degrade PrPSc via 
the lysosomal and proteasomal pathways (Sassa et al 2010). 
Furthermore, upon block of the proteasome activity significant 
changes in total PrP levels that result in accumulation of 
aggregated PrP forms in the cytosol, have been observed in N2a 
cells (Nunziante et al 2011). Finally, several studies have shown 
that the ER-associated degradation pathway (ERAD) is involved in 
the degradation of pathogenic PrP mutants linked with familial 
prion diseases and is responsible for the degradation of misfolded 
PrP isoforms (Zanusso et al 1999; Nunziante et al 2011).  
Macroautophagy (hereby referred to as autophagy) is another 
cellular degradation system for long-lived proteins and organelles, 
normally activated upon starvation for energy supply (Yang and 
Klionsky, 2007). Recently, autophagy has been described to play 
an important role in diverse physiological and pathological 
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processes and, in particular, in neurodegenerative diseases 
associated with protein aggregation (Wong and Cuervo 2010). 
The role of autophagy in prion disease in controversial. Early 
works indicated the presence of autophagic vacuoles in prion-
infected GT1 (scGT1) cells and in murine models of induced 
scrapie, Creutzfeldt-Jakob disease (CJD) and Gerstmann-
Sträussler-Scheinker (GSS) syndrome as hallmarks of 
cytopathology upon prion infection (Schazl et al 1997; Liberski 
et al., 2004; Sirkosa et al 2004). This suggested that the 
activation of the autophagic pathway could contribute to the 
pathogenesis of the disease. On the contrary, more recently it 
has been shown that a number of autophagy-inducing 
compounds such as lithium salts, trehalose and rapamycin can 
reduce PrPSc burden in cultured neuroblastoma (N2a) cells (Aguib 
et al 2009; Heiseke et al 2009), pointing towards a protective 
role of autophagy in prion infection. Hence, in order to shed light 
on this still controversial open question in prion biology we 
decided to further characterize of PrPSc metabolism at cellular 
level and investigate the possible role of autophagy in PrPSc 
clearance.  
 
1.3 Summary of the results 
 
In order to investigate the role of autophagy in prion infection, 
we first evaluated the autophagic flux in prion-infected cells by 
comparing it with uninfected cells. For this purpose, we used two 
well-established in vitro cell models, named murine neuronal 
hypothalamic GT1 and mouse neuroblastoma N2a cells, 
permissive for prion replication and widely used in prion biology 
(Villette 2008). As already described before (section 1.5 of the 
Introduction), the autophagic flux is an index of the progression 
of autophagy and includes the formation of the autophagosome 
containing organelles and proteins to degrade, and the 
subsequent fusion with lysosomes. This final step leads to 
formation of autolysosome in which the cellular components 
undergo degradation upon the action of lysosomal proteases in a 
pH-dependent manner (Yang and Klionsky 2009). Measurement 
of the autophagic flux is largely used to evaluate the autophagy 
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status in a given condition (Kimura et al 2009). In particular, we 
used the tandem fluorescent tagged LC3 construct (tfLC3), that 
encodes for LC3 linked to both GFP and RFP proteins, to monitor 
potential changes in the autophagic flux upon prion infection in 
both uninfected and prion infected GT1 and N2a cells. LC3 is a 
well-known autophagic marker protein and specifically associates 
with autophagosome membranes (Kabeya et al., 2000).   This 
tool is based on the different sensitivity of GFP and RFP 
fluorophores to the acidic pH of the lysosomes (Mizushima and 
Yoshimori, 2007). As illustrated in Figure 30, while both GFP and 
RFP signals are present in autophagosomes, following the 
maturation process to phagolysosome only the RFP signal 
remains due to the quenching of the GFP-linked molecule (Kimura 
et al., 2009).  
 
 
 
Figure 30 tf-LC3 tool.  
By quantifying the number of both green and red and only-red 
vesicles per cell, we found that uninfected GT1 and N2a cells 
possess similar percentage of autophagosomes and 
phagolysosomes, indicating that both neuronal cell lines in culture 
have a basal activation of the autophagic pathway (see Figure 1, 
A and B, in the annex manuscript). We then assessed the 
autophagic flux in infected GT1 and N2a cells (scGT1 and scN2a 
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cells) and found a substantial increase in the number of 
phagolysosomes compared to uninfected cells (see Figure 1, A 
and B, in the annex manuscript). We concluded that chronic 
scrapie infection causes an increase of the autophagic flux in 
both scGT1 and scN2a cells, in agreement with previous findings 
in N2a cells (Aguib et al., 2009; Heiseke et al., 2009). We could 
also confirm these findings by monitoring the LC3-II levels (the 
post-translationally modified form of LC3 associated with 
autophagosome membranes) in uninfected and prion-infected 
GT1 and N2a cells in the presence or absence of lysosomal 
protease inhibitors (see Figure 1, C, in the annex manuscript).  
Treatment with lysosomal protease inhibitors partially inhibits the 
degradation of LC3-II delivered to lysosomes during organelle 
fusion, thus facilitates the monitoring of the state of the 
autophagic flux in a given condition (Mizushima and Yoshimori, 
2007). Because of the combined use of these two approaches 
gives a good estimation of the autophagic flux (Kimura et al 
2009), we could conclude that autophagy was activated upon 
prion infection.  
 
However, both cell lines could still be infected and were able to 
replicate PrPSc (see Supplementary Figure 2 in the annex 
manuscript) (Villette 2008), indicating that autophagy is not 
sufficient to impair the establishment of prion infection. 
Therefore, we asked whether further stimulation of the 
autophagic flux by using well-known autophagy inducers could 
lead to degradation of PrPSc. In this case, scGT1 and scN2a cells 
were treated with rapamycin, tamoxifen and 4-hydroxil-tamoxifen 
(OHT). Then by western blot with anti-PrP antibodies, we 
evaluated PrPSc levels upon the different drug treatments, 
compared to untreated cells used as control. As already 
described before (section 1.1 of the Introduction), differently 
from PrPC, PrPSc is resistant to proteinase K (PK) treatment 
(Schatzl et al 1997). This property is widely used as a tool to 
detect PrPSc levels in infected cells (see Figure 2 in the annex 
manuscript). Interestingly, we found that tamoxifen and, its more 
potent derivative OHT, efficiently reduced PrPSc levels in both 
scGT1 and scN2a cells (around 80-90%). Next, we evaluated the 
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autophagic flux upon the different drugs treatments to further 
analyze the involvement of the autophagy in PrPSc clearance. For 
this purpose, we transfected scGT1 and scN2a cells with tf-LC3 
construct and we counted the number of autophagosomes and 
autolysosomes upon rapamycin, tamoxifen and 4-hydroxil-
tamoxifen (OHT) treatment. Surprisingly, we found that none of 
the drugs used was able to increase the autophagic flux in 
infected cells (see Figure 3, A and B, in the annex manuscript). 
We could confirm these results by measuring LC3-II levels in 
presence or absence of lysosomal proteases inhibitors, as 
previously discussed (see Figure 3, C, in the annex manuscript). 
This led us to speculate that, due to the increased autophagic 
flux upon infection, further stimulation of autophagy-mediated 
degradation is not effective in these cells. Moreover, we analyzed 
PrPSc localization in control cells and upon rapamycin, tamoxifen 
and OHT treatment to evaluate its presence in autophagosomes 
at steady state and upon stimulation of autophagy. To this aim, 
we used an immunofluorescence approach, in which 
immunolabelling with both anti-LC3 and anti-PrP antibodies were 
performed after treatment with Gnd-HCl to expose PrPSc epitopes 
(as described in the Material and Methods section). We found 
that only a minor fraction of PrPSc colocalized with endogenous 
LC3 in permanently infected scGT1 cells. Furthermore, the 
amount of PrPSc in LC3-positive vesicles did not significantly 
increase upon rapamycin, tamoxifen or OHT treatments (see 
Figure 4 in the annex manuscript). Then to rule out the possibility 
that the lack of PrPSc detection in autophagic structures was due 
to a fast lysosomal degradation in this compartment, we blocked 
the activity of lysosomal proteases using Bafilomycin A1. Also 
upon this treatment, we could not observe any increase in 
localization of PrPSc in autophagosomes in scGT1 cells (see Figure 
4 in the annex manuscript). These data indicate that the 
reduction in PrPSc observed upon the different treatments is 
unlikely due to autophagy. Additionally, mouse catecholaminergic 
neuronal CAD cells (Qi et al 1997), another well-established cell 
line for prion-replication, was used in the same set of experiments 
to verify the involvement of autophagy in prion degradation. The 
results obtained in this cell lines corroborated our previous 
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findings in GT1 and N2a cells (see Supplementary Figure 3 in the 
annex manuscript). 
To definetely rule out the role of autophagy in PrPSc clearance, we 
performed an RNA interference experiment in scGT1 cells in 
which we down-regulated Atg7 gene, codifying for an essential 
autophagy protein, and then treated the cells with rapamycin, 
tamoxifen or OHT. After treatment with siRNA Atg7, down-
regulation of ~80% was achieved and under these conditions, 
LC3-II could not be detected, suggesting that the autophagic 
pathway was efficiently inhibited (see Figure 5 in the annex 
manuscript).  We then treated the cells with the different drugs 
and we compared PrPSc levels in Atg7 down-regulated cells with 
control cells subjected to scrambled siRNA. Strikingly, we found 
that both tamoxifen and OHT treatments were still able to 
decrease PrPSc levels in absence of activated autophagy (see 
Figure 5 in the annex manuscript).  
 
Overall, these findings argue against a role for autophagy in prion 
degradation. Notwithstanding, we found that tamoxifen and (in 
greater extend) OHT were able to efficiently reduce PrPSc levels in 
all the cell model systems used (see Figure 2 in the annex 
manuscript), pointing towards a potential therapeutical 
application of these drugs for prion disease.  
Therefore we decided to analyze the possible mechanism of 
action of these drugs. From data presented in literature, it is 
known that tamoxifen and OHT modulate cholesterol metabolism 
by reducing its levels (de Medina et al 2004). Furthermore, these 
compounds disturb cholesterol trafficking by inhibiting the egress 
of LDL-derived cholesterol from lysosomes and causing a 
Niemann-Pick type C disease type phenotype (Suarez et al 
2004). As already mentioned above, it is well documented that 
prion replication is sensitive to perturbation of lipid metabolism, 
and specifically, that cholesterol depletion leads to PrPSc 
reduction (Taraboulos et al 1995; Campana et al 2005). 
Therefore we investigated whether tamoxifen- and OHT 
treatment had an effect on cholesterol distribution in our system. 
To this aim, we treated scGT1 cells with tamoxifen and OHT and 
evaluated cholesterol distribution compared to untreated cells by 
filipin staining and lysosomes immunolabelling with anti-LAMP1 
Page | !!+"
antibodies. While in untreated scGT1 cells we could observe 
diffuse filipin staining, both tamoxifen and OHT treatments 
resulted in a punctate staining pattern that partially colocalizes 
with LAMP1 (see Figure 6 in the annex manuscript), thus 
suggesting an accumulation of cholesterol in late endosomal 
compartments upon these drugs treatment. Subsequently, we 
asked whether cholesterol accumulation in lysosomes could also 
increase PrPSc sequestration in lysosomes, and, so, enhance PrPSc 
degradation in this compartment. To test this hypothesis, we 
examined PrPSc distribution in lysosomes by immunofluorescence 
with both anti-PrP and anti-LAMP1 antibodies in the presence of 
tamoxifen and OHT in comparison with untreated control. We 
could observe a large fraction of PrPSc in lysosomes following OHT 
drug treatment. Indeed by quantify the percentage of 
colocalisation of PrPSc with LAMP1, we found that upon treatment 
with both these drugs PrPSc colocalisation with LAMP1 increases 
up to 30% compared to control cells (10%) (see Figure 7 in the 
annex manuscript).  Finally, to demonstrate that PrPSc rerouting 
to lysosomes led to degradation in this compartment, we treated 
scGT1 cells with OHT (in the presence or absence of lysosomal 
inhibitors) and we evaluated PrPSc levels, compared to untreated 
control by PK assay (as already described in the Material and 
Methods section). We were able to demonstrate that lysosomal 
inhibitor treatment counteracted the effect of OHT in PrPSc 
clearance and restored PrPSc levels equal to untreated cells (see 
Figure 8 in the annex manuscript). These data confirmed that 
OHT and tamoxifen reduce PrPSc levels by increasing prion 
degradation in lysosomes. 
In parallel to determine whether PrPC is also relocated to 
lysosomes upon these drugs treatment we also evaluated PrPC 
distribution in lysosomes upon OHT treatment. We reasoned that 
in this case one of the effects of tamoxifen and OHT treatment 
would be also to reduce the substrate for PrPSc production, thus 
impairing prions formation. Interestingly, upon OHT treatment, a 
major fraction of PrPC colocalised with LAMP1 (we found around 
25% colocalisation compared to 9% colocalisation of the 
control). This suggests that OHT could increase also decrease 
PrPC degradation thus reducing the substrate of PrPSc production.  
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In summary, in this first part of my work, by using different 
approaches I demonstrated that autophagy is not involved in 
PrPSc degradation. Interestingly, I found that tamoxifen and OHT, 
two drugs used to enhance the autophagic flux, efficiently 
reduced PrPSc levels in autophagy independent manner. Then I 
exploited the possible mechanism of action of these drugs and I 
found that tamoxifen and OHT alter cholesterol trafficking and 
cause a redistribution of both PrPSc and PrPC to lysosomes, thus 
shifting the equilibrium between prion production and 
degradation towards the latter.   
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1.4 Discussion  
 
Accumulation of misfolded protein deposits in affected brain 
regions is a characteristic feature of many neurodegenerative 
diseases (Agorogiannis et al 2004; Nijholt et al 2011), 
suggesting that in these pathological conditions the degradative 
capacity of the cell fails in reducing proteins burden. Experimental 
evidence suggests that neuronal death may be associated with 
the ubiquitin-proteasome system (UPS) impairment, although 
whether this is a cause or consequence of neurodegeneration is 
still unclear. Also, UPS impairment is thought to be important in 
prion disease (Ma and Lindquist, 2002; Ma et al., 2002; Kang et 
al., 2004; Kristiansen et al., 2005). In contrast, the role, if any, 
of the alternative major protein degradation pathway, autophagy, 
in prion disease is still unclear and highly debated (Heiseke et al 
2009) (see also section 1.5 of the Introduction and paragraph 
1.1 of this chapter).  
Thus the aim of my study was to investigate the role of 
autophagy in prion disease and, so, to look more closely into the 
molecular interplay between autophagy, prion propagation, 
trafficking and clearance. In order to do so, I used both 
fluorescence microscopy and biochemical approaches and 
different neuronal cell culture models. Our results indicate that 
autophagy is up regulated in prion-infected cells. Indeed, as 
already mentioned above, in prion diseases an increased number 
of autophagosomes have been reported in infected neuronal cells 
and brain tissue (Liberski et al., 2008; Sikorska et al., 2004; 
Schätzl et al., 1997). Here I have confirmed and extended these 
findings by showing that chronic scrapie infection induces 
autophagic flux at higher levels but that uninfected neuronal cells 
already possess a basal level of autophagy. These results were in 
contrast with previous reports in which basal levels of autophagy 
could not be detected in non-infected N2a cells (Liberski et al., 
2008; Sikorska et al., 2004; Schätzl et al., 1997). The most 
likely reason for this discrepancy was the different tool used in 
this study to monitor autophagy, namely, tandem fluorescent 
LC3 (tf-LC3) containing both GFP and RFP (Figure 1.1). This 
construct enables one to distinguish autophagosomes from 
phagolysosomes based on the presence of only red fluorescence 
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in the acidic phagolysosomal compartment (Aguib et al., 2009; 
Heiseke et al., 2009). Therefore, earlier studies reporting no 
basal autophagy in N2a cells were based only on observations of 
autophagosomes since the phagolysosomes present were 
essentially invisible when using GFP-LC3 alone (Heiseke et al 
2009).  
In addition, despite an increased autophagic flux upon infection, I 
found that PrPSc is mostly absent from autophagic vesicles, even 
when lysosomal degradation is impaired, thus excluding a fast 
lysosomal degradation in this compartment. These findings raised 
the possibility that PrPSc is not processed by the autophagic 
machinery. However if this is the case, the question arises as to 
why autophagy is induced by prion infection if it is not involved in 
PrPSc processing. One possibility is that the presence of protein 
aggregates stimulates autophagic flux as a defensive response. 
However, prions, being membrane-bound proteins, may be able to 
elude recognition by the autophagic machinery by virtue of their 
sequestration within vesicles. In addition, it could also be that the 
increased autophagic flux upon prion infection is not sufficient to 
allow an efficient PrPSc degradation. Therefore, in order to clarify 
this issue we further stimulate the autophagic flux, by using well-
known autophagy inducers, namely rapamycin, tamoxifen and 
OHT, and examine whether there was an effect on PrPSc 
clearance. I found that while a slight decrease in PrPSc levels was 
achieved upon rapamycin treatment, tamoxifen and more 
importantly OHT reduced PrPSc level up to 90%. Surprisingly, the 
measurement of the autophagic flux upon rapamycin, tamoxifen 
and OHT treatment showed that these drugs could not further 
stimulate autophagy in scrapie-infected cells. It was previously 
reported that rapamycin, by enhancing autophagy would lead to 
a moderate PrPSc degradation (Aguib et al 2009; Heiseke et al 
2009). Moreover tamoxifen and OHT were shown to stimulate 
autophagy (Samaddar 2008; de Medina 2009). The discrepancy 
with my new findings could be explained by the fact that an 
increase in GFP-LC3-positive vesicles (and hence 
autophagosomes) was previously interpreted as an increase in 
autophagy by these drugs. However, judging by the accumulation 
of both double-positive and red-only vesicles, these drugs are 
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likely interfering with the fusion between autophagosomes and 
lysosomes, thus reducing the autophagic flux.  
Consistently, by using an RNA interference approach for atg7 
gene to down-regulate the autophagic pathway, I was able to rule 
out the involvement of autophagy in tamoxifen- and OHT- 
mediated PrPSc reduction. Prevailing models in the recent 
literature propose that the amount of protease-resistant, 
aggregate-prone prion protein is maintained by a balance 
between PrPSc formation by conversion of native PrPC and its 
destruction in lysosomes, that could be autophagy-mediated. I 
have rather shown here that autophagy-mediated degradation is 
not relevant in the regulation of PrPSc levels in prion-infected 
cells, thus indicating that the mechanisms of PrPSc clearance 
observed upon tamoxifen and OHT treatment are likely 
independent from this process.   
This finding raises the question on which mechanism tamoxifen 
and, more efficiently OHT reduced PrPSc levels. It was previously 
shown that lipids, specifically cholesterol and sphingolipids, play a 
crucial role in PrPSc propagation and that changes in sub-cellular 
distribution of PrP by modulating lipid metabolism and trafficking, 
affect PrPSc levels in infected cells (Kimura et al., 2009). 
Interestingly, both tamoxifen and OHT are inhibitors of 
cholesterol biosynthesis (Campana et al., 2005; Marijanovic et al., 
2009; Lewis and Hooper, 2011; Taraboulos et al., 1995b). 
Interestingly, the drug concentrations at which these effects are 
observed are the same concentrations that were effective in 
reduction of PrPSc.  Tamoxifen has also been shown to inhibit the 
exit of cholesterol from lysosomes resulting in a lipid storage 
disease-like phenotype, characterized by an accumulation of 
cholesterol in late-lysosomal compartments (de Medina et al., 
2011, 2004, 2009). By immunofluorescence I could observe a 
similar effect of both tamoxifen and OHT on cholesterol 
trafficking in prion infected neuronal cells. Importantly, I also 
found that these treatments induced the redistribution of both 
PrPSc and PrPC towards lysosomes. This redistribution could affect 
both PrPSc replication and degradation. It has been shown that 
the ERC is an intracellular site for PrPSc conversion (Marijanovic et 
al., 2009) and it normally contain high levels of cholesterol 
(Suárez et al., 2004). Therefore, one possibility is that conditions 
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that favor endosomal degradation over endosomal recycling by 
re-routing PrPC from recycling endosomes to lysosomes could 
reduce the substrate available for its conversion. At the same 
time the rerouting of PrPSc to lysosomes would facilitate the 
elimination of the pathological prion form by the lysosomal 
system. Indeed, by treating the cells with NH4Cl in presence of 
OHT, I was able to show that a block of lysosomal degradation 
counteracted the effect of OHT and restore PrPSc levels equal to 
control. These data demonstrate that the rerouting of PrPSc in 
lysosomes leads to its degradation in this organelle.  
On the basis of these results, I propose a model in which upon 
OHT treatment cholesterol trafficking in the cell is altered leading 
to the accumulation of this lipid in lysosomes (Figure 31). This 
causes a reduction of the cholesterol content in the endosomal 
recycling compartment where can interfere with the interaction 
between PrPC and PrPSc in the endocytic pathway that is 
necessary for PrPSc replication. Moreover, OHT treatment leads to 
redirection of both PrPC and PrPSc to lysosomes, thus shifting 
equilibrium between prion production and degradation towards 
the degradation of both PrPC (thus reducing the substrate for 
conversion and PrPSc (thus leading to its clearance of prions).  
 
 
!!!!!! !
Figure 31 Schematic presentation of PrP trafficking in infected cells and upon OHT 
treatment. In infected cells PrPC and PrPSc interact at plasma membrane in cholesterol rich lipid 
domains called lipid rafts. Upon internalization both PrPC and PrPSc can recycle via endosomal 
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recycling compartment (ERC) or can be routed for degradation in lysosomes. Subcellular 
cholesterol distribution influences PrPSc trafficking in endocytic pathway. In untreated infected 
cells, majority of PrP recycles through cholesterol rich ERC supporting conversion of PrPC to 
PrPSc. Treatment with 4-hydroxy-tamoxifen (OHT) induces cholesterol accumulation in enlarged 
late endosomes PrPSc production and degradation defines cellular load of infectious prions. We 
propose that OHT-induced changes in PrPSc trafficking favor PrPSc degradation. 
 
Although these data clearly demonstrate a relocation of 
cholesterol and PrP to lysosomes, the nature of the lipids 
accumulating in lysosomes (reminiscent to a sphingolipids 
storage disease phenotype (Schulze and Sandhoff 2011) and 
whether lipid accumulation directly influenced PrPSc localization in 
this compartment remains to be determined. While autophagy is 
well known as a mechanism for directing aggregated proteins into 
lysosomes it appears that tamoxifen and OHT induce the 
trafficking of prions to lysosomes in an autophagy-independent 
fashion. In conclusion, given its ability to both reduce infectious 
prions and modify cholesterol metabolism and lipid content of the 
cell OHT represents a well-characterized, widely available 
pharmaceutical that may have applications as a broad-spectrum 
therapy for neurodegenerative diseases of protein aggregation. 
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Abstract 
 
Prion diseases are fatal 
neurodegenerative disorders involving 
the abnormal folding of a native cellular 
protein, named PrPC, to a 
malconformed aggregation-prone state, 
enriched in beta sheet secondary 
structure, denoted PrPSc. Recently, 
autophagy has garnered considerable 
attention as a cellular process with the 
potential to counteract 
neurodegenerative diseases of protein 
aggregation such as Alzheimer's 
disease, Huntington's disease, and 
Parkinson's disease. Up regulation of 
autophagy by chemical compounds 
has also been shown to reduce PrPSc in 
infected neuronal cells and prolong 
survival times in mice models. 
Consistent with previous reports we 
demonstrate that autophagic flux is 
increased in chronically infected cell 
models. However, in contrast to recent 
findings we show that autophagy is not 
causative of a reduction in scrapie 
burden. We report that in infected 
neuronal cells different compounds 
known to stimulate autophagy are 
ineffective in increasing the autophagic 
flux and in reducing PrPSc. We further 
demonstrate that the anti-prion effect of 
tamoxifen and its metabolite 4-
hydroxytamoxifen is not dependent on 
autophagy but rather depends on the 
ability of these drugs to alter the 
trafficking of both PrP and cholesterol. 
Because tamoxifen represents a well-
characterized, widely available 
pharmaceutical our data indicate that it 
may have applications in the therapy of 
prion diseases. 
 
INTRODUCTION 
 
Transmissible spongiform 
encephalopathies are infectious, 
neurodegenerative diseases involving the 
abnormal folding of the cellular prion 
protein PrPC into a pathologic conformer 
PrPSc.  This malconformed state also 
leads to its accumulation as aggregates in 
both the cytoplasm of affected neurons 
and the interstitial spaces within the brains 
of afflicted individuals (Prusiner, 1998). 
Recently, macroautophagy has been 
described as an important process in the 
pathogenesis of neurodegenerative 
diseases of protein aggregation such as 
Alzheimer's, Huntington's and Parkinson's 
disease as well as in prion diseases 
(Cherra III et al., 2010). As post-mitotic 
cells that must endure for the lifetime of an 
organism, neurons require efficient 
mechanisms to avoid accumulating toxic 
protein aggregates. It has been proposed 
that macroautophagy, often referred to 
simply as "autophagy", is one such 
mechanism (Rubinsztein et al 2007; 
(Wong and Cuervo, 2010). Recent 
evidence suggests that dysfunction in the 
autophagic pathway is common to 
numerous neurodegenerative diseases 
(Wong and Cuervo, 2010). Furthermore, 
mice engineered for neuron-specific 
knockout of the essential autophagy genes 
atg5 or atg7 present with a 
neurodegenerative phenotype 
accompanied by massive protein 
aggregate accumulation and resulting 
inexorably in death within the first few 
months of birth (Hara et al., 2006; 
Komatsu et al., 2006). Moreover up 
regulation of autophagy was shown to 
efficiently counteract neurodegeneration in 
both in vitro and in vivo models (Wong and 
Cuervo, 2010). 
The role of autophagy in prion disease in 
highly debated (Heiseke et al., 2010). 
Autophagic vacuoles were first detected in 
neuronal cell models chronically infected 
with prions (Schätzl et al., 1997). More 
recently, autophagic vacuoles were 
identified in synapses in various forms of 
human prion disease (Sikorska et al., 
2004) and it was found that they are 
formed in neuronal perikarya, neurites and 
synapses in experimentally induced 
scrapie, Creutzfeldt-Jakob disease (CJD) 
and Gerstmann-Sträussler-Scheinker 
(GSS) syndrome (Liberski et al., 2008). 
Therefore it was proposed that autophagy 
could play a disease-promoting role by 
contributing to the formation of spongiform 
(Liberski et al., 2008; Liberski and Jeffrey, 
2004). On the other hand, it has been 
demonstrated that a number of autophagy-
inducing compounds such as lithium salts, 
trehalose and rapamycin are effective at 
reducing PrPSc burden in cultured 
neuroblastoma cells (N2a) and delay the 
onset of symptoms in prion-infected mice 
in prophylactic treatment models (Aguib et 
al., 2009; Heiseke et al., 2009). Thus, 
induction of autophagy was proposed as a 
novel approach for the treatment of prion 
diseases.  
However, a more systematic analysis of 
the role of autophagy in prion infection is 
needed because the molecular 
mechanisms by which autophagy would 
be protective are still not understood. In 
particular it has to be considered that the 
majority of PrPSc resides in the endocytic 
pathway and not in the cytosol (Campana 
et al., 2005; Caughey et al., 2009). The 
availability of new tools and recent 
advances in the understanding of the 
dynamic process of autophagic flux, 
prompted us to re-examine the role of 
autophagy in prion propagation, trafficking 
and clearance. In contrast to previous 
studies, we observed a basal activation of 
autophagy in all neuronal cell models 
examined, independent of scrapie 
infection. Furthermore, chronic scrapie 
infection results in an increase in 
autophagic flux, in the absence of any 
significant colocalization of PrPSc with 
autophagic vacuoles.  We also report that 
autophagic flux could not be further 
stimulated by autophagy-inducing 
compounds like rapamycin, previously 
shown to clear prion-infection in ScN2a 
cells. Furthermore, tamoxifen (TAM), also 
described as an autophagy inducer, 
decreases autophagic flux in scrapie-
infected cells and concomitantly reduces 
scrapie burden. Consistently, its active 
metabolite, 4-hydroxytamoxifen (OHT), is 
a more potent inhibitor of autophagic flux 
and greater inducer of prion protein 
clearance. We demonstrate that both TAM 
and OHT cause the redistribution of 
cholesterol and PrPSc to lysosomes and 
are effective in reducing PrPSc levels even 
under conditions of autophagy inhibition. 
Overall these data indicate that the 
autophagic pathway is not involved in 
prion degradation and that TAM and OHT 
stimulate clearance of PrPSc in an 
autophagy-independent manner by 
altering both prion and lipid intracellular 
trafficking.  
 
 
 
RESULTS 
 
Chronic prion infection induces 
autophagic flux in neuronal cell culture 
models 
 
To investigate the role of autophagy in 
PrPSc metabolism, we analyzed whether 
scrapie infection could affect autophagic 
flux in neuronal cell lines by comparing 
uninfected and chronically infected GT1 
and N2a cells (respectively GT1 and 
scGT1 and N2a and ScN2a cells), using 
both fluorescent microscopy and 
biochemical approaches. To monitor 
potential changes in the autophagic flux, 
we analyzed LC3, a well-known 
autophagic marker protein specifically 
associated with autophagosome 
membranes (Kabeya et al., 2000). Earlier 
work with GFP-LC3 enabled researchers 
to acquire a snapshot of the number of 
early autophagosomes forming in cells. In 
order to measure the dynamic flux of the 
autophagy pathway from early 
autophagosomes through to late 
phagolysosomes, we used the tandem 
fluorescently tagged LC3 construct (tfLC3, 
encoding for LC3 linked to both GFP and 
RFP proteins) combined with inhibition of 
lysosomal proteases. 
This tool is based on the differential 
sensitivity of GFP and RFP fluorophores to 
the acidic pH of lysosomes and is 
specifically used to monitor the 
progression of autophagy (Mizushima and 
Yoshimori, 2007). While both GFP and 
RFP signals are observable in 
autophagosomes, following the maturation 
process to phagolysosomes only the RFP 
signal remains due to the quenching of the 
GFP-linked molecule (Kimura et al., 2009). 
Therefore, in cells in which autophagy is 
not activated, LC3 shows a diffuse 
GFP/RFP pattern; when activation of 
autophagy occurs, early autophagosomes 
can be detected in the cytosol as punctae 
exhibiting fluorescence in both the green 
and red channels (double-positive 
vesicles). In contrast, the punctae 
exhibiting fluorescence only in the red 
channel (red-only vesicles) indicates the 
progression of autophagic flux from early 
autophagosomes to phagolysosomes. 
 
Quantification of labeled vesicles in control 
GT1 cells transfected with tfLC3 revealed 
that 55% of the vesicles were double-
positive autophagosomes and 45% were 
red-only phagolysosomes.  In control N2a 
cells 35% of the vesicles were double-
positive autophagosomes, while 65% of 
the vesicles were red-only 
phagolysosomes (Figure 1A and 1B). 
Thus, using this improved tool to measure 
autophagic flux, a basal activation of the 
autophagic pathway was detected in both 
neuronal cell lines, in contrast to previous 
reports in which autophagy was not 
detected in control N2a cells (Aguib et al., 
2009; Heiseke et al., 2009)(see 
discussion).  
Next, autophagic flux in infected scGT1 
and scN2a cells was assessed.  
Quantification of the number of red-only 
positive vesicles revealed a substantial 
increase in the number of 
phagolysosomes in both infected cells. 
Specifically, the percentage of red-only 
phagolysosmomes in infected scGT1 and 
scN2a cells rose from 45% to 60% and 
from 65% to 90% of all LC3-decorated 
vesicles, respectively (Figure 1A and 1B). 
These data suggest that autophagic flux is 
increased under conditions of chronic 
scrapie infection in both scGT1 and scN2a 
cells. 
 
These results were corroborated by 
western blot analysis comparing the 
endogenous levels of LC3-II in infected 
and non-infected cells, in the presence or 
absence of lysosomal protease inhibitors 
(Figure 1C). LC3-II is the post-
translationally modified form of LC3, 
associated with autophagosome 
membranes, and can be distinguished 
from is precursor LC3-I by SDS-PAGE by 
its increased electrophoretic mobility (16 
kDa for LC3-I, versus 14 kDa for LC3-II) 
(Kabeya et al., 2000). Treatment with 
lysosomal protease inhibitors partially 
inhibits the degradation of LC3-II delivered 
to lysosomes during organelle fusion, thus 
facilitating its recovery and therefore the 
assessment of the state of autophagic flux 
in a given condition (Mizushima and 
Yoshimori, 2007). As expected, we found 
a significant increase in the amount of 
LC3-II upon ammonium chloride treatment 
in both scGT1 and scN2a cells (Figure 
1C). Importantly, this increase was greater 
in the infected cells compared to 
uninfected GT1 and N2a cells consistent 
with a higher rate of autophagic flux during 
prion infection (Figure 1 A, B, C). 
To further corroborate our findings we 
analyzed autophagic flux in CAD cells, 
another neuronal cell line capable of 
propagating prions (Gousset et al., 2009; 
Marijanovic et al., 2009). A comparable 
increase in autophagic flux was observed 
in chronically infected scCAD cells 
(Supplementary Figure S1, A and B) 
confirming that autophagy is activated in 
chronically infected cells.  
In order to gain some insight into the 
mechanism and timing of this activation, 
we analyzed whether de novo prion 
infection could modulate autophagy. To 
this aim we performed a live-cell imaging 
experiment in which we followed the fate 
of newly up-taken PrPSc aggregates in 
real-time and simultaneously monitored 
autophagic flux. CAD cells transfected with 
GFP-tagged LC3 (GFP-LC3) were 
challenged with Alexa546-PrPSc, a 
fluorescent infectious scrapie preparation 
(Gousset et al., 2009), and followed by live 
microscopy for up to 12 hours post-
infection.  Similar to chronically infected 
cells, autophagy was induced upon the 
uptake of Alexa546-PrPSc infected cells, 
as shown by the appearance of GFP-LC3 
puncta. However, Alexa546-PrPSc-positive 
vesicles were clearly distinguished from 
LC3-positive autophagosomes 
(Supplementary Movie S1), suggesting 
that PrPSc was not being trafficked through 
the autophagic pathway. 
 
Autophagy does not play a major role 
in PrPSc metabolism 
The evidence indicating that autophagy 
was activated both in permanently and 
newly infected cells raised the question as 
to whether autophagy was involved in 
scrapie clearance. It was previously 
reported that treatment of infected scN2a 
cells with autophagy inducers (e.g., 
rapamycin, lithium or trehalose) decreased 
PrPSc levels in cells and delayed the 
course of disease in scrapie- infected 
mice, although with high variability (Aguib 
et al., 2009; Heiseke et al., 2009). 
The presence of high levels of PrPSc, in 
spite of increased autophagic flux in 
permanently infected cells (Supplementary 
Figure S2), along with our observations 
using fluorescent microscopy in newly 
infected cells (Supplementary Movie S1) 
suggested that either PrPSc was not being 
processed by the autophagic route or that 
this process was inefficient in reducing 
scrapie burden. Therefore, to directly test 
these hypotheses we monitored PrPSc 
levels following chemical stimulation of 
autophagy. 
Specifically, scGT1 and scN2a cells were 
treated with either rapamycin, TAM or 
OHT for 5 days and the levels of total PrP 
and PK-resistant PrPSc were examined by 
limited proteinase K digestion assay and 
western blot (Schätzl et al., 1997) to test 
the ability of these drugs to reduce PrPSc 
(Figure 2, A and C). Interestingly, we 
found that TAM and particularly OHT, 
were very efficient in PrPSc clearance (80-
90%), while rapamycin caused only a 
moderate and not very consistent (see 
also Figure 5) decrease in the PrPSc 
fraction (10-20%) in both cell lines (Figure 
2, B and D). 
 
In order to understand whether the scrapie 
clearance obtained by the various 
treatments was due to stimulation of 
autophagy we monitored the activation of 
autophagic flux in ScGT1 and scN2a cells 
transfected with tfLC3 after treatment with 
rapamycin, TAM and OHT for 5 days. 
Unexpectedly, quantification of the number 
of autophagosomes and phagolysosomes 
in scGT1 cells revealed that the 
percentage of double-positive 
autophagosomes and red-only 
phagolysosomes (approximately 40% and 
60%, respectively) among the treated cells 
was similar to what was observed for the 
untreated controls (Figure 3, A). This 
indicated that none of the drugs were able 
to increase autophagic flux beyond the 
baseline established in infected cells. This 
result was confirmed independently using 
a biochemical approach in which LC3-II 
levels were measured by western blot. 
Indeed, no increase in LC3-II levels were 
observed between control and treated 
scGT1 cells upon inhibition of lysosomal 
proteolysis (Figure 3, B). In particular, it 
should be noted that the higher LC3-II 
levels found in OHT-treated cells was not 
significantly increased by co-treatment 
with lysosomal inhibitors, suggesting an 
inhibition of autophagic flux in this 
condition (Figure 3).  Consistent with 
previous findings in scN2a cells (Heiseke 
et al., 2009), we observed a moderate 
increase in the number of 
autophagosomes per cell under the 
different drug treatments (Figure 3, A). 
This observation may explain why 
previous groups using GFP-LC3 have 
reported an increase in autophagy with 
these treatments (Aguib et al., 2009; 
Heiseke et al., 2009). However, similar to 
scGT1cells, the percentage of 
phagolysosomes was unaffected or even 
reduced compared to the untreated cells 
(Figure 3A). Similar results were obtained 
in scCAD cells (Supplementary Figure S1, 
C and D). These data suggest that while 
the chemical treatments are capable of 
reducing cellular prion burden, none of 
these agents were able to increase 
autophagic flux (Figure 3, A; 
Supplementary Figure S1, C and D); 
furthermore, in the case of OHT 
autophagic flux was actually inhibited. In 
contrast with previous reports, our results 
indicated that rapamycin reduces scrapie 
burden in infected cells modestly, while 
TAM and OHT are more potent prion-
reducing agents. Furthermore, neither 
microscopy nor biochemical approaches 
supported a role for these chemicals in 
stimulating autophagic flux in prion-
infected cells (Figure 3). These data 
suggest that the effect of the above 
compounds on the PrPSc levels is 
independent of autophagy stimulation.  
To further examine these findings we 
compared the subcellular localization of 
PrPSc and LC3-decorated structures in 
infected cells both at the steady state and 
following the different treatments (Figure 
4, A). Specifically, we performed 
quantitative immunofluorescence after 
GND treatment (Marijanovic et al., 2009) 
to examine the respective subcellular 
localizations of LC3-decorated autophagy-
associated structures and PrPSc. We found 
that only a minor fraction of PrPSc (6%) 
colocalized with endogenous LC3 in 
permanently infected scGT1 cells (Figure 
4, B). Furthermore, the amount of PrPSc in 
LC3-positive vesicles did not significantly 
increase upon rapamycin, TAM or OHT 
treatments (Figure 4, B). Similar results 
were obtained in scCAD cells 
(Supplementary Figure S3, A and B). To 
rule out fast lysosomal degradation as a 
possible cause for the lack of PrPSc 
localization in phagolysosomes we 
blocked the activity of lysosomal proteases 
using Bafilomycin A1 (Figure 4, A). 
However, despite this treatment, we could 
not observe any statistically valid increase 
in localization of PrPSc in autophagosomes 
in scGT1 cells (Figure 4, B) supporting the 
hypothesis that the reduction in PrPSc 
observed upon the different treatments is 
not due to autophagy. 
To directly rule out the involvement of 
autophagy in PrPSc degradation, we used 
an RNAi approach. To this aim, we 
challenged scGT1 cells with siRNA 
targeting Atg7, an essential autophagic 
gene, in two subsequent rounds of 
transfection in order to maintain low levels 
of Atg7 during a 5-day treatment with 
rapamycin, TAM or OHT. As depicted in 
Figure 5, Atg7 down-regulation was 
achieved (up to 90%) and under these 
conditions, LC3-II could not be detected, 
suggesting that the autophagic pathway 
was efficiently inhibited.  Next, total PrP 
and PrPSc levels were assessed in the 
contest of Atg7 knockdown (Figure 5, A). 
While the rapamicin treatment did not give 
a consistent reduction of PrPSc, it was 
striking that both TAM and to a greater 
extent OHT treatments were still capable 
of decreasing PrPSc levels while PrP levels 
remained stable. Indeed, the magnitude of 
the TAM- and OHT-mediated decrease of 
scrapie in Atg7-depleted cells was 
indistinguishable from that of cells co-
treated with scrambled control siRNA 
(Figure 5, B). Further evidence from this 
experiment arguing against a role for 
autophagy in prion degradation was that 
no increase in PrPSc was observed in 
infected cells even after prolonged 
treatment with anti-Atg7 siRNA alone 
(Figure 5, A, lanes 1 and 5 of the PK 
treated extracts). 
 
 
OHT and TAM causes redistribution of 
both PrPSc and cholesterol to 
lysosomes  
 
Since the data did not support a role for 
autophagy in reducing the PrPSc fraction, 
we sought to uncover the mechanism by 
which TAM and OHT could exert such 
effects. TAM and OHT can perturb 
cholesterol trafficking (Suárez et al., 2004; 
de Medina et al., 2004, 2011). 
Furthermore, it is established that 
interference with cholesterol and 
sphingolipid efflux from lysosomes 
reduces cellular scrapie (Taraboulos et al., 
1995; Baron et al., 2002). Therefore, we 
hypothesized that perturbation of 
subcellular cholesterol trafficking by TAM 
and OHT were responsible for their anti-
prion effects. 
To test this hypothesis we examined 
cholesterol distribution in TAM and OHT 
treated cells compared to untreated scGT1 
cells by filipin staining. In contrast to the 
diffuse filipin staining observed in 
untreated cells, both TAM and OHT 
treatments resulted in a punctate staining 
pattern, partially colocalizing with LAMP1, 
a marker of late endosomes (Figure 6). 
These data indicate that these drugs can 
perturb subcellular lipid trafficking resulting 
in the accumulation of cholesterol in late 
endosomal compartments. 
To determine if this treatment resulted in 
the rerouting of PrPSc to lysosomes, we 
quantified the fraction of PrPSc in 
lysosomes upon exposure to TAM and 
OHT. Specifically, scGT1 cells were 
treated with either TAM or OHT for 3 days 
and, after fixation, permeabilization and 
guanidine-hydrochloride treatment, the 
samples were immunostained for PrPSc 
and LAMP1 and the percentage of 
colocalisation between the two was 
evaluated (Figure 7). Quantification of the 
two signals revealed that PrPSc was 
enriched in lysosomes in both TAM and 
OHT treated cells. The higher effect was 
observed following OHT treatment, with 
around 30% colocalising with LAMP1 
compared to the 10% observed in the 
control untreated cells (Figure 7, B). This 
result implicated lysosomal proteases in 
the degradation of PrPSc. 
To address this question experimentally, 
lysosomal degradation was inhibited using 
NH4Cl and the effect on PrPSc levels in 
OHT treated cells was analyzed by WB 
(Figure 8). We reasoned that if the 
observed decrease in PrPSc levels 
induced by OHT treatment was due to 
lysosomal degradation, inhibition of this 
process should restore PrPSc levels. 
Accordingly, we were able to show that 
treatment with lysosomal inhibitors 
counteracted the anti-prion effect of OHT 
(Figure 8). Indeed, this treatment led to an 
increase in PrPSc fraction and prevented 
the clearance induced by OHT.  These 
data indicate that OHT treatment caused 
the accumulation of both cholesterol and 
PrPSc in lysosomes and resulted in the 
degradation of the latter in this 
compartment. Since PrPSc failed to 
accumulate in LC3-positive structures 
even in the context of lysosomal protease 
inhibition (Figure 4), this indicated that 
scrapie was being trafficked to and 
degraded into lysosomes in an autophagy-
independent manner. 
Next, to analyze the fate of PrPSc 
aggregates in real-time upon OHT-
treatment a live-imaging approach was 
employed. To this end, CAD cells were 
challenged with Alexa546-PrPSc and 
loaded with Lysotracker Green (to stain 
lysosomes) and then followed for up to 
12h. It was observed that newly 
endocytosed PrPSc colocalized with 
lysotracker-labelled lysosomes after being 
internalized, supporting a role for this 
compartment in PrPSc degradation upon 
OHT treatment (Supplementary Movie 
S2). 
Overall, these data point towards 
autophagy-independent involvement of the 
lysosomal proteolysis pathway in PrPSc 
degradation upon OHT treatment. In 
addition, we found that upon OHT 
treatment a fraction of non-infectious PrPC 
was relocated to lysosomes 
(Supplementary Figure S4), suggesting 
that this drug could also perturb the 
trafficking of the substrate of the PrPSc 
conversion process. In conclusion, these 
results show that OHT targets PrPSc to 
lysosomes where it gets degraded and 
support the hypothesis that the variation in 
the cholesterol distribution influence both 
the trafficking and the metabolism of PrPSc 
(Lewis and Hooper, 2011; Campana et al., 
2005). 
 
Discussion 
 
When first observed, autophagy was 
considered to be only a cytopathological 
feature associated with cell death 
(Baehrecke, 2005). The field has 
advanced considerably with the 
development of new tools created to better 
study the phenomenon and the 
predominant current view is that 
autophagy in many contexts is 
cytoprotective. It has only been recently 
appreciated that autophagy is the most 
efficient mechanism by which cytosolic 
protein aggregates are targeted for 
destruction by enzymatic hydrolysis in 
lysosomes (Yang and Klionsky, 2009). 
Cellular quality control by autophagy is 
particularly important in neurons, where 
the content of aggregated proteins and 
damaged organelles cannot be reduced by 
distribution to daughter cells. Therefore, it 
is not surprising that various failures in the 
autophagic pathway are connected to 
neurodegenerative disorders such as 
Alzheimer’s, Parkinson’s and Huntington’s 
disease (Wong and Cuervo, 2010). 
Prevailing models in the recent literature 
propose that the amount of protease-
resistant, aggregate-prone prion protein is 
maintained by a balance between PrPSc 
formation by conversion of native PrPC 
and its destruction in lysosomes, which 
could be mediated by the autophagic 
pathway.  In favor of this hypothesis, the 
appearance of multi-vesicular bodies and 
autophagic vacuoles has been reported in 
both prion-infected, neuronal cells in 
culture (Schätzl et al., 1997) and in brain 
biopsies from prion-infected patients 
(Liberski et al., 2008; Sikorska et al., 
2004). Furthermore, stimulation of 
autophagy by chemical compounds such 
as rapamycin, lithium salts and trehalose 
is able to reduce protease-resistant PrPSc 
in cultured cells (Aguib et al., 2009; 
Heiseke et al., 2009). These observations 
imply a protective role for autophagy in 
prion infection. Alternatively, it was 
proposed that autophagy may contribute 
to the spongiform changes that are a 
pathological hallmark of prion affected 
brains, and may be activated by apoptosis 
(Liberski et al., 2008; Liberski and Jeffrey, 
2004; Sikorska et al., 2004). These 
contradictory findings raised the question 
of the biological role of autophagy in prion 
infection and disease and prompted us to 
look more closely into the molecular 
interplay between autophagy, prion 
propagation, trafficking and clearance. 
The first clue of an altered autophagic 
pathway in different neurodegenerative 
settings is the presence of an abnormal 
number of autophagosomes in affected 
neurons (Kegel et al., 2000; Nixon et al., 
2005). In prion diseases an increased 
number of autophagosomes have been 
reported in infected neuronal cells and 
brain tissue (Liberski et al., 2008; Sikorska 
et al., 2004; Schätzl et al., 1997). Here we 
have confirmed and extended these 
finding by showing elevated levels of basal 
autophagy in uninfected neuronal cells 
and demonstrated that chronic scrapie 
infection additionally induces autophagic 
flux, but not autophagy per se (Figure 1; 
Supplementary Figure S1, A and B). 
These results were in contrast with 
previous reports in which basal levels of 
autophagy could not be detected in non-
infected N2a cells (Aguib et al., 2009; 
Heiseke et al., 2009). The most likely 
reason for this discrepancy was the 
different tool used in this study to monitor 
autophagy, namely, tandem fluorescent 
LC3 (tf-LC3) containing both GFP and 
RFP. This construct enables one to 
distinguish autophagosomes from 
phagolysosomes based on the presence 
of only red fluorescence in the acidic 
phagolysosomal compartment (Kimura et 
al., 2009). Therefore, earlier studies 
reporting no basal autophagy in N2a cells 
were based only on observations of 
autophagosomes since the 
phagolysosomes present were essentially 
invisible when using GFP-LC3 alone.  
We also report that although chronic 
scrapie infection increases autophagic 
flux, PrPSc is mostly absent from 
autophagic vesicles, even when lysosomal 
degradation is impaired (Figure 4). This 
observation raised the possibility that 
PrPSc is not processed by the autophagic 
machinery. In fact, when Alexa546-
labelled PrPSc was added to cells 
transfected with GFP-LC3 and analyzed 
by live imaging we could observe a clear 
induction of autophagy but no 
colocalisation of Alexa 546-PrPSc with 
LC3-decorated vesicles (Supplementary 
Movie S1). This suggests that PrPSc is 
able to escape autophagy during primary 
infection. Recently, similar observations 
were made in cells harboring mutant Htt in 
which cargo recognition failure by the 
autophagic pathway was detected (Li et 
al., 2010). One unanswered question from 
this study was: why is autophagy induced 
by prion infection despite its lack of 
involvement in its processing? It is 
possible that the presence of protein 
aggregates stimulates autophagic flux as a 
defensive response. However, prions, 
being membrane-bound proteins, may be 
able to elude recognition by the 
autophagic machinery by virtue of their 
sequestration within vesicles. In addition, it 
was found that autophagy could not be 
further enhanced in scrapie-infected cells 
with drugs like rapamycin (Figure 3; 
Supplementary figure S1, C and D), 
previously described as inducers of 
autophagy. Surprisingly, while screening 
for drugs that could modify the autophagy 
program we observed that in contrast to 
previous reports (de Medina et al., 2009) 
TAM and its metabolite OHT actually 
reduce autophagic flux. This discrepancy 
could be explained by the fact that an 
increase in GFP-LC3-positive vesicles 
(and hence autophagosomes) was 
previously interpreted as an increase in 
autophagy by these drugs. However, 
judging by the accumulation of both 
double-positive and red-only vesicles 
(Figure 3), these drugs are likely 
interfering with the fusion between 
autophagosomes and lysosomes, thus 
reducing the autophagic flux (Figure 3).  
Interestingly, while we did not detect an 
increase of PrPSc in autophagosomes, we 
did observe increased PrPSc clearance 
upon TAM and OHT treatment. This 
indicates that the mechanisms of PrPSc 
clearance by these compounds are likely 
independent of autophagy (Figure 2). This 
hypothesis was tested directly using a 
gene-silencing approach. Consistent with 
the microscopy data, inhibition of 
autophagy using anti-atg7 siRNA did not 
affect the ability of TAM and OHT to 
reduce PrPSc content in infected cells 
(Figure 5). Furthermore, prolonged 
knockdown of Atg7 did not lead to an 
accumulation of PrPSc above untreated 
cells as would be expected if it was being 
degraded by autophagy. Overall these 
observations argue against a major 
contribution of autophagy-mediated 
degradation in the regulation of PrPSc 
levels both in de novo or permanent 
infections.  
Ruling out a major involvement of 
autophagy in scrapie clearance raised the 
question as to what was the mechanism 
by which TAM and OHT reduced PrPSc 
levels. We and others have previously 
shown that lipids, specifically cholesterol 
and sphingolipids, play a crucial role in 
PrPSc propagation and that changes in 
sub-cellular distribution of PrP by 
modulating lipid metabolism and 
trafficking, affect PrPSc levels in infected 
cells (Campana et al., 2005; Marijanovic et 
al., 2009; Lewis and Hooper, 2011; 
Taraboulos et al., 1995). Interestingly, 
both TAM and OHT are inhibitors of 
cholesterol biosynthesis (de Medina et al., 
2011, 2004, 2009). Interestingly, the drug 
concentrations at which these effects are 
observed are the same concentrations that 
were required for reduction of PrPSc.  TAM 
has also been shown to inhibit the exit of 
cholesterol from lysosomes resulting in a 
lipid storage disease phenotype, 
characterized by the accumulation of 
cholesterol-laden late 
endosomes/lysosomes (Suárez et al., 
2004). We observed a similar effect of 
both TAM and OHT on cholesterol 
trafficking in our cellular models (Figure 6). 
Importantly, these treatments induced the 
redistribution of PrPSc and PrPC towards 
lysosomes (Figure 6 and Supplementary 
Figure S4), which could affect both PrPSc 
replication and degradation. Indeed 
endocytic compartments, specifically the 
endosomal recycling compartment, 
normally containing high levels of 
cholesterol (Wüstner et al., 2002; Hao et 
al., 2002), was shown to be an intracellular 
site for PrPSc conversion (Marijanovic et 
al., 2009). Therefore, conditions that favor 
endosomal degradation over endosomal 
recycling by re-routing PrPC from recycling 
endosomes to lysosomes could reduce its 
conversion and should facilitate the 
elimination of the pathological prion form 
by the lysosomal system. In this case, the 
prediction would be that inhibition of 
lysosomal degradation should counteract 
the effect of OHT. Indeed, when we 
blocked lysosomal degradation using 
NH4Cl in OHT-treated cells, higher levels 
of PrPSc were observed (Figure 8). Thus, 
by redirecting PrPSc to lysosomes, OHT 
most likely interferes with the interaction 
between PrPC and PrPSc in the endocytic 
pathway, which is necessary for PrPSc 
replication thus shifting equilibrium 
towards PrPSc degradation (Figure 9). PrP 
and cholesterol distribution suggests that 
TAM and OHT could trigger the 
accumulation of different lipids in the 
lysosomal pathway. Such a mechanism for 
reducing scrapie recalls reports on 
sphingolipid storage diseases (Schulze 
and Sandhoff, 2011). However, the nature 
of the lipids accumulating in lysosomes 
and whether lipid accumulation directly 
influenced PrPSc localization in this 
compartment remains to be determined. 
While autophagy is well known as a 
mechanism for directing aggregated 
proteins into lysosomes it appears that 
TAM and OHT induce the trafficking of 
prions to lysosomes in an autophagy-
independent fashion. In conclusion, given 
its ability to both reduce infectious prions 
and modify cholesterol metabolism and 
lipid content of the cell TAM represents a 
well-characterized, widely available 
pharmaceutical that may have applications 
as a broad-spectrum therapy for 
neurodegenerative diseases of protein 
aggregation. 
MATERIALS AND METHODS 
 
Chemicals and antibodies 
Rapamycin, TAM, OHT and Bafilomycin 
A1 were all purchased from Sigma. SAF32 
and Sha31 anti-prion antibodies were 
purchased from SpiBio. Anti-tubulin 
monoclonal antibodies and anti-ATG7 
were from Sigma. All the fluorescently 
labelled secondary antibodies, as well as 
Lysotracker® green were purchased from 
Invitrogen (Molecular Probes). Anti-
LAMP1 antibodies were purchased from 
BD Pharmingen ™. Anti-LC3 monoclonal 
antibody, used for western blotting, was 
from nanoTools and anti-LC3 polyclonal 
antibody, used for immunofluorescence, 
was purchased from MBL International. 
Fluorescently labelled PrPSc (Alexa546-
PrPSc) was prepared as previously 
described (Gousset et al., 2009). 
 
Cell lines 
GT1-1 cells (gift of Dr. Mellon P., 
University of California, San Diego, USA) 
were infected with RML prion strain (gift of 
Dr. Korth K., Heinrich Heine University, 
Dusseldorf, Germany). N2a cells and 
scN2a cells (infected with 22L prion strain) 
were provided by Dr.Korth K.  
Non-infected and prion-infected GT1-1 
and N2a cells were maintained in 
Dulbecco’s modified Eagle’s medium 
(DMEM) (Invitrogen) supplemented with 
10% of fetal calf serum (FCS). CAD and 
scCAD (infected with 139A prion strain) 
were both gifts of Dr. Laude H. (Institut 
National de la Recherche Agronomique, 
Jouy-en-Josas, France) and were cultured 
in Opti-MEM (Invitrogen) with addition of 
10% FBS. 
 
Plasmids, siRNAs and transfection 
procedures 
The tandem fluorescently- tagged (with 
both GFP and RFP) LC3 (Tf-LC3) and 
GFP-LC3 plasmids were a kind gift from 
Dr. Ballabio A. (Telethon Institute of 
Genetis and Medicine (TIGEM), Naples, 
Italy) and Dr. Yoshimori T. (Research 
Institute for Microbial Diseases, Osaka 
University, Osaka, Japan). ATG7 siRNA 
predesigned ON TARGETplus 
SMARTpool and siGENOME RISC-Free 
Control siRNA were both purchased from 
Dharmacon.  
GT1-1 and scGT1 cells were transfected 
at 50% confluence using FuGENE6 
(Roche Diagnostic) for DNA constructs 
according to manufacturer’s protocol.  To 
downregulate ATG7, 100 nM 
concentration of oligo was used with 10 µl 
of HiPerFect (Quiagen) per 60 mm dish. 
Hyperfect reagent was mixed with siRNA 
in DMEM without FBS, incubated for 10 
min at room temperature and added to the 
cells. 
Transfection of both non-infected and 
infected CAD and N2a cells with DNA 
constructs was done using Lipofectamine 
2000 (Invitrogen), according to producer’s 
protocol.  
When detection of PrPSc levels was 
performed, downregulation and 
overexpression of the proteins were 
maintained for a 5-day period. Therefore in 
all the experiments siRNA and plasmids, 
except of pEGFP were transfected twice 
(a second round of transfection was 
performed 3 days post-transfection). 
 
Treatment of ScGT1 and scN2a cells 
with different drugs 
Rapamycin, TAM, OHT were reconstituted 
according to manufacturer’s instructions. 
All the drugs were used in DMEM + 10% 
FCS at the final concentration of 2 µM for 
Rapamycin, and 5 µM concentration for 
TAM and OHT. During the 3 or 5-day 
treatment, medium containing the different 
drugs was changed every 2 days. 5M 
stock concentration of NH4Cl from powder 
(Sigma) was prepared in sterile Ultra-pure 
MilliQ water. 
When needed, Bafilomycin A1 or NH4Cl, 
respectively at 100 !M and 15 mM 
concentration were added to the 
Rapamycin, TAM or OHT 5 day treatment 
for 2 days starting from the 4th day of the 
different treatments. 
 
Protein analysis by western blotting 
Cells grown in 60 mm dishes after the 
different treatments were lysed in 500 µl of 
Lysis buffer (0,5% triton X-100, 0,5% 
DOC, 100 mM NaCl, 10 mM Tris-HCl pH 
8). To analyze PrPSc levels, 250 µg of 
protein/lysate were treated with 5 µg of 
Proteinase K (PK) for 30 min at 37°C. This 
step allows detecting PrPSc content only, 
because of its partial resistance to PK 
(Prusiner et al 1984). The protein content 
was then methanol-precipitated overnight 
at -20°C and centrifuged at 13000g for 30 
minutes. After drying at 100°C, the pellet 
was resuspended and denatured in 
Laemmli buffer before SDS-PAGE and 
western blot with the Sha31 anti-PrP 
antibody. All the other proteins, including 
total PrP, were analysed by western 
blotting from 20 or 40 µg of total lysate. 
HRP-conjugated secondary antibodies 
and ECL™ reagents from Amersham (GE 
Healthcare) were used for detection. 
 
Immunofluorescence 
For immunofluorescence analysis cells 
grown on coverslips into a 24 well plate for 
3 days were carefully washed with PBS, 
fixed with 2% PFA for 30 minutes and 
permeabilized with 0,1% of Triton X-
100/PBS. A denaturation step with 6M 
guanidine-hydrochloride for 10 min was 
performed after permeabilization to detect 
PrPSc in infected cells (Taraboulos et al., 
1990), when needed. Cells were then 
blocked in 2% BSA/PBS, immunolabelled 
with primary and secondary antibodies 
and mounted with Aqua/Poly Mount 
(Polysciences). 
In order to label endogenous LC3, cells 
were differently treated as previously 
described (Kimura et al., 2009). 
When filipin staining was used, cells were 
fixed with 4% PFA for 60 min and blocked 
with 0,2% BSA/PBS. Filipin (250 µg/ml) 
was added to blocking solution and 
additional 30 min incubation was 
performed after incubation with secondary 
antibodies.  
 
Fluorescence Microscopy 
Immunofluorescence micrographs were 
acquired by high-resolution wide-field 
microscope Marianas (Intelligent Imaging 
Innovations) using 63x oil objective. All Z-
stacks were acquired with Z-steps of 0.27 
µm. The auto-scaling (min/max) of signal 
detection was used to record only maximal 
signal intensities when PrPSc was analysed 
(Marijanovic et al., 2009).  
In the live experiments, CAD cells plated 
on ibidi dishes were either transfected with 
GFP-LC3 plasmid or incubated with of 
LysoTracker (1:1000 dilution) for 30 min at 
37°C prior to be challenged with 1 µl/dish 
of sonicated Alexa546-PrPSc. The time-
lapse movies were acquired with 
Biostation IM (from Nikon) and a wide-field 
microscope (Zeiss Axiovert 200M) 
controlled by Axiovision software.  
 
Image processing and quantification 
Raw data (both images and movies) were 
processed with Image J software. The 
constrained iterative algorithm in 
Slidebook 4.2 software (Intelligent Imaging 
Innovations) was used to deconvolve the 
images. Colocalization was quantified by 
intensity correlation coefficient-based 
(ICCB) analysis using JACoP (Bolte and 
Cordelières, 2006). Statistical analysis of 
the correlation of the intensity values of 
both green and red pixels or blue and red 
pixels in dual-channel image was 
performed using Pearson’s and Menders’s 
coefficient and Van Steensel’s approach 
(van Steensel et al., 1996).  
 
Statistical analysis 
All data were statistically validated by 
Student’s T-test. The differences were 
considered significant when p<0.05. 
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FIGURES LEGEND 
 
Figure 1. Autophagic flux in non 
infected and prion-infected GT1 and 
N2a cells 
(A) Both non infected and infected GT1 
and N2a cells were transfected with Tf-
LC3 construct and analysed by 
fluorescence microscopy. Activation of 
autophagy is signalled by LC3-positive 
vesicles (both green and red labelled); 
appearance of red puncta-only indicate 
progression of autophagic flux. Scale bars 
10 µm (B) The quantification results are 
presented as % of both green and red 
(autophagosomes) and only-red vesicles 
(phagolysosomes) per cell (mean ± s.e.m, 
n=3). (C) Endogenous levels of LC3-II in 
infected and non infected cells either 
treated (+) or not (-) with lysosomal 
inhibitors revealed by monoclonal anti-LC3 
antibody (clone 2G6) on western blot 
(mean ± s.e.m, n=3). Quantified results 
were normalized for tubulin. Note that both 
fluorescence microscopy and biochemical 
approach confirmed an activation of 
autophagic flux during prion infection in 
both cell lines. 
 
Figure 2. TAM and OHT treatment are 
able to reduce PrPSc levels in both 
scGT1 and scN2a cells 
(A-C) ScGT1 and scN2a cells were treated 
with the different compounds for 5 days 
and levels of PrPSc (PK+) and total PrP 
(PK-) were detected on western blot by 
using Sha31 anti-PrP antibody. Tubulin 
levels represent control for equal loading. 
(B-D) Quantification results of PrPSc levels 
upon different treatments are presented as 
% of untreated cells where PrPSc levels 
are considered to be 100%  (mean ± 
s.e.m, n=3).  
 
Figure 3. Effect of rapamycin, TAM and 
OHT treatment on autophagic flux in 
scGT1 and scN2a cells 
(A) scGT1 and scN2a cells transfected 
with Tf-LC3 were subjected to a 4h 
treatment with the different drugs and then 
analysed  by fluorescence microscopy. 
The quantification results are presented as 
% of both green and red and only-red 
vesicles per cell (mean ± s.e.m, n=3). 
Scale bar 10 µm (B) Endogenous levels of 
LC3-II (normalized for tubulin) were 
compared in between scGT1 cells 
untreated and treated for 5 days with 
either rapamycin, tamoxifen and HO-
tamoxifen in presence (+) or absence (-) of 
lysosomal proteases inhibitors (mean ± 
s.e.m, n=3).  The lysosomal proteases 
treatment clearly shows an inhibition of the 
autophagic flux when HO-tamoxifen was 
added to the cells.  
 
Figure 4. PrPSc found in 
autophagosomes do not change upon 
different treatments in scGT1 cells 
(A) scGT1 cells were treated for 3 days 
with either rapamycin, TAM and OHT in 
presence (+) or absence (-) of 100 !M 
concentration of Bafilomycin A1 and then 
subjected to a double 
immunofluorescence with a polyclonal 
anti-LC3 antibody and Saf32 anti-prion 
mAb. 6M guanidine-hydrochloride 
treatment prior immunolabelling was used 
to reveal PrPSc epitopes. Yellow color 
shows colocalization between PrPSc and 
LC3-positive vesicles. Scale bars 10 µm. 
(B) The quantification results (mean ± 
s.e.m, n=50) are presented as % of total 
signal of PrPSc (in red) colocalizing with 
autophagosomes (green). Insets represent 
magnification of the boxex areas. Note 
that only a minor fraction of PrPSc has 
been found in LC3-positive vesicles and 
both different treatments and lysosomal 
proteases inhibition do not increase its 
presence in these organelles.  
 
Figure 5. ATG7 down-regulation in 
scGT1 cells does not block PrPSc 
clearance upon rapamycin, TAM and 
OHT treatment 
(A) scGT1 cells transfected with either 
control oligo (ctr oligo) or siRNA for ATG7 
were treated for 5 days with rapamycin, 
TAM and OHT and then subjected to lysis. 
ATG7, LC3-II and total PrP (PK-) levels 
were analyzed by western blot.  To 
measure PrPSc levels (PK+), lysed were 
additionally subjected to proteinase K 
limited proteolysis assay prion analysis. 
Tubulin has been used as a control for 
equal loading. (B) The quantification 
results (mean ± s.e.m, n=3) are presented 
as % of total PrPSc signal in untreated cells 
transfected with ctr oligo. 
 
Figure 6. Cholesterol redistributes to 
lysosomes upon TAM and OHT 
treatment in scGT1 cells 
scGT1 cells were treated with either 
rapamycin, TAM and OHT for 5 days and 
distribution of cholesterol war examined by 
filipin staining (in blue). 
Immunofluorescence with LAMP1 Ab (in 
green) was used to evaluate the presence 
of cholesterol in lysosomes. Note that 
upon TAM and OHT treatment cholesterol 
partially accumulates in lysosomes as 
depicted by arrowheads in the inset 
showing the colocalisation between filipin 
and LAMP1.  
 
Figure 7. PrPSc localisation in 
lysosomes increases upon OHT 
treatment 
(A) Differences in PrPSc fraction in 
lysosomes were examined. scGT1 cells 
were treated for 3 days with either 
rapamycin, TAM and OHT and then 
subjected to a double 
immunofluorescence with anti-LAMP1 Ab 
(to stain lysosomes) and Saf32 anti-prion 
mAb (after 6M Gnd-HCl treatment to 
reveal PrPSc). (B) The quantification 
results (mean ± s.e.m, n=50) are 
presented as % of total signal of PrPSc (in 
red) colocalizing with lysosomes (green). 
Insets represent magnification of the 
boxes areas. Scale bars 10 µm.  
 
Figure 8.  PrPSc is degraded in 
lysosomes upon OHT treatment 
scGT1 cells were treated for 5 days with 
OHT in presence (+) or absence (-) of 
NH4Cl. PrPSc (PK+) and total PrP (PK-) 
were analysed by western blot. Tubulin 
levels represent control from equal 
loading. Quantification results of PrPSc 
levels are presented as % of untreated 
cells where PrPSc levels are considered to 
be 100% (mean ± s.e.m, n=3). Note that 
lysosomal proteases inhibition counteracts 
the effect of OHT treatment restoring 
PrPSc levels.  
 
Figure 9. Schematic presentation of PrP 
trafficking in infected cells and upon 
OHT treatment 
In infected cells PrPC and PrPSc interact at 
plasma membrane in cholesterol rich lipid 
domains called lipid rafts. Upon 
internalization both PrPC and PrPSc can 
recycle via endosomal recycling 
compartment (ERC) or can be routed for 
degradation in lysosomes. Subcellular 
cholesterol distribution influences PrPSc 
trafficking in endocytic pathway. In 
untreated infected cells, majority of PrP 
recycles through cholesterol-enriched 
ERC supporting conversion of PrPC to 
PrPSc. Treatment with 4-hydroxy-tamoxifen 
(OHT) induces cholesterol accumulation in 
enlarged late endosomes. PrPSc 
production and degradation define cellular 
load of infectious prions. We propose that 
4-hydroxy-tamoxifen-induced changes in 
PrPSc trafficking favor PrPSc degradation. 
 
SUPPLEMENTARY INFORMATIONS 
 
Supplementary Figure S1. Autophagic 
flux in uninfected and prion-infected 
CAD cells and effect of rapamycin, TAM 
and OHT treatment on autophagic flux 
in scCAD cells 
(A) Both non infected and infected CAD 
cells were transfected with Tf-LC3 contruct 
and analysed by fluorescence microscopy. 
Scale bars 10 µm. (B) The quantification 
results are presented as % of both green 
and red (autophagosomes) and only-red 
vesicles (phagolysosomes) per cell (mean 
± s.e.m, n=30). As observed for GT1 and 
N2a cells, the autophagic flux increases 
upon infection. (C) scCAD cells 
transfected with Tf-LC3 were subjected to 
a 4h treatment with the different drugs and 
then analysed by fluorescence 
microscopy. (D) The quantification results 
are presented as % of both green and red 
(autophagosomes) and only-red vesicles 
(phagolysosomes) per cell (mean ± s.e.m, 
n=30). Scale bars 10 µm. Note that the 
autophagic flux is not further increased by 
autophagy inducers. 
 
Supplementary Figure S2. Proteinase K 
limited proteolysis assay on uninfected 
and infected GT1 and N2a cells 
Both infected and non infected GT1 and 
N2a cells were lysed and subjected to 
proteinase K limited proteolysis assay. 
PrPSc levels (PK+) were detected on 
western blotting by using Sha31 anti-PrP 
antibody. 
 
Supplementary figure S3. PrPSc 
localisation in autophagosomes by 
immunofluorescence and its clearance 
upon rapamycin, TAM and OHT 
treatment in scCAD cells 
(A) scCAD cells were treated for 3 days 
with either rapamycin, TAM and OHT and 
then subjected to a double 
immunofluorescence with a polyclonal 
anti-LC3 antibody and Sha31 anti-prion 
mAb. 6M guanidine-hydrochloride 
treatment prior immunolabelling was used 
to reveal PrPSc epitopes. Yellow color 
shows colocalization between PrPSc and 
LC3-positive vesicles. Scale bars 10 µm. 
(B) The quantification results (mean ± 
s.e.m, n=50) are presented as % of total 
signal of PrPSc (in red) colocalizing with 
autophagosomes (green). Insets represent 
magnification of the boxex areas. Scale 
bars 10 µm. Note that only a minor fraction 
of PrPSc has been found in LC3-positive 
vesicles in untreated control and upon 
different treatments. (C) scCAD cells were 
treated with the different compounds for 5 
days and levels of PrPSc (PK+) and total 
PrP (PK-) were detected on western blot 
by using Sha31 anti-PrP antibody. Tubulin 
levels represent control for equal loading. 
(D) Quantification results of PrPSc levels 
upon different treatments are presented as 
% of untreated cells where PrPSc levels 
are considered to be 100%  (mean ± 
s.e.m, n=3).  
  
Supplementary figure S4. Upon OHT 
treatment also a fraction of PrPC 
relocates to lysosomes in scGT1 cells 
Presence of PrPC in lysosomes was 
evaluated. scGT1 cells were treated for 3 
days with OHT and then subjected to a 
double immunofluorescence with anti-
LAMP1 Ab (to stain lysosomes) and 
Sha31 anti-PrP mAb (after Gnd-HCl 
treatment to reveal PrPSc epitopes). Note 
that while in control untreated cells PrPC is 
mainly distributed at the level of the golgi 
compartment, upon OHT treatment it 
partially relocated to lysosomes as 
suggested by a more scattered signal and 
the quantitative colocalisation analysis. 
Quantification results (mean ± s.e.m, 
n=50) are presented as % of total signal of 
PrPC (in red) colocalising with lysosomes 
(green). Scale bars 10 µm. 
 
Supplementary Movie S1. Alexa546-
PrPSc newly up-taken does not 
colocalises with GFP-LC3 in CAD cells 
The fate of newly up-taken fluorescently-
labelled PrPSc was followed in real-time up 
to 12h post-infection. CAD cells 
transfected with GFP-LC3 plasmid were 
challenged with Alexa546-PrPSc and time-
lapse movies were acquired with Time-
lapse imaging Biostation IM system from 
Nikon (temperature, humidity and CO2 
controlled). Single Z-stacks were taken for 
each time point every 5 minutes up to 12h. 
Note that despite activation of autophagy 
upon infection (as shown by the punctuate 
LC3 signal) Alex546-PrPSc particles were 
clearly distinguished from LC3-positive 
autophagosomes.  
 
Supplementary Movie S2. Alexa546-
PrPSc newly up-taken colocalises with 
lysotracker labelled lysosomes in OHT 
treated scCAD cells 
Analysis of the fate of PrPSc aggregates in 
real-time upon OHT treatment by a live-
imaging approach. CAD cells were 
challenged with Alexa546-PrPSc and 
loaded with Lysotracker green (to stain 
lysosomes). Movies were recorded in a 
microscope chamber using a wield-field 
Axiovert microscope for live imaging (with 
temperature control and supplemented 
with CO2); Z-stacks of 1 µm were taken for 
each time point every 5 minutes up to 12h. 
Newly uptaken PrPSc colocalises with 
lysosomal compartment after being 
internalized where it undergoes 
degradation. 
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PROJECT 2: 
Characterization of PrPSc spreading from cell-to-cell by 
Tunneling Nanotubes (TNTs) in a prion infected 
neuronal cell model 
 
 
2.1 Objectives 
 
a) Characterization of the sub-cellular compartments allowing 
the vesicular trafficking of PrPSc inside TNTs connecting 
CAD cells;  
b) Role of both cellular and pathological PrP isoforms on TNT 
formation and transfer; 
c) Role of Myosin-X in TNT formation, TNT-mediated transfer 
and PrPSc spreading from cell-to-cell.  
 
 
2.2 Results 
 
Objective a: 
Characterization of the sub-cellular compartments 
responsible of the vesicular trafficking of PrPSc in TNT 
formed between CAD cells  
 
o Specific background 
 
Tunneling nanotubes are long thin actin-containing bridges that 
do not contact the substratum while connecting remote cells. 
They have been found in many cell types in culture acting as 
conduits for cytosolic and membrane-bound molecules, organelles 
and spreading of pathogens (Hurtig et al 2010). As already 
mentioned above (section 1.7), membrane-specific dyes, markers 
of endo-lysosomal pathway or specific intra-cellular organelle 
dyes have observed traveling between cells along these tubular 
connections (Gurke et al 2008). In addition, the TNT-mediated 
transfer seems to be selective, as different components seem to 
be selectively transferred by different cell types (Gerdes et al 
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2007). Particularly, PrPSc has been found to hijack these 
intercellular structures to spread from cell to cell (Gousset et al 
2009; Langevin et al 2010). However one of the major questions 
that needs to be addressed is through which mechanism PrPSc is 
transferred through TNTs. Specifically is not known whether PrPSc 
is transferred as cytosolic aggregate or within vesicles of a 
specific origin. PrPSc appears to have a wide distribution inside the 
cells. Some earlier reports have shown that the majority of PrPSc 
is intracellular (Taraboulos et al 1990), sequestered within 
lysosomes of prion-infected N2a cells (Borchelt et al 2002; 
Caughey et al 1991; McKinley et al 1991) with little localization 
at the cell surface (Vey et al 1996). More recent reports describe 
accumulation of PrPSc either in the perinuclear Golgi region of 
neurons in scrapie-infected transgenic mice (Barmada et al 
2005), in the late endosomal compartment of infected GT1-7, 
N2a and CAD neuronal cells (Pimpinelli et al 2005; Marijanovic et 
al 2009; Veith et al 2009; Arnold et al 1995; Gousset et al 
2009), at the cell surface and on early endocytic and recycling 
vesicles of hippocampal neurons (Caughey and Raymond 1991; 
Jeffrey et al 1992). Interestingly, prion accumulation in the 
endosomal recycling compartment (ERC) can stimulate PrPSc 
production, thus pointing towards a role for the recycling 
endosomes as an intracellular site for prion conversion. These and 
other evidences from our laboratory contributed to show that 
the ERC is one preferential site of prion conversion (Marijanovic 
et al 2009). Of interest, by using fluorescence video-microscopy 
to follow the transfer of fluorescently labelled PrPSc, Gousset et 
al. (2009) referred that after internalization Alexa- PrPSc was 
found moving inside TNTs towards a connected cell. Along with 
other observations this may indicate that a significant portion of 
PrPSc is conveyed in transport vesicles. Given that a fraction of 
PrPc cycles between the plasma membrane and the endosomal 
system, these vesicles may be of endocytic origin. This is in 
agreement with the idea that the endosome is an important 
compartment for the conversion of PrPc to PrPSc. Therefore, given 
the importance of intracellular organelles in the trafficking of 
PrPSc, in the second part of my thesis I have investigated which 
types of vesicles/organelles are present in TNTs connecting CAD 
cells and whether any of those was responsible of the trafficking 
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of PrPSc from one cell to another. This information is necessary to 
better understand the mechanism of prion spreading and will 
allow eventually the development of new therapeutic approaches 
for prion diseases. 
 
o Results 
 
In order to characterize the sub-cellular organelles that traffic via 
TNTs formed between CAD cells, a catecholaminergic mouse 
neuronal cell line (Qi et al 1997), we first used a fluorescence 
microscopy approach to detect the presence of different sub-
cellular organelles in TNT structures by using different organelle 
specific markers. For this purpose we plated CAD cells on Ibidi 
dishes (ready to use supports for microscopy) in a well-spaced 
manner that favor the formation of TNT, as previously shown 
(Gousset et al 2009). As already mentioned in the section 2.1.1 
of this chapter, PrPSc has been found inside the cell along the 
endocytic pathway and in the Golgi in different cell systems. 
Therefore we decided to look specifically at the presence of 
these organelles in TNTs (Table 2). 
 
Sub-cellular 
Organelle 
Organelle marker 
and tool used for 
detection 
Presence in 
TNT 
ENDOCYTIC 
RECYCLING 
COMPARTMENT (ERC) 
AND RECYCLING 
VESICLES 
Anti-Vamp1,2,3 Ab; 
pGFP-Rab11; pGFP-
Vamp3 YES 
LYSOSOMES Anti-LAMP1 Ab YES 
EARLY ENDOSOMES Anti-EEA1 Ab YES 
Cis- and medial Golgi Anti-Giantin Ab NO 
Trans-Golgi Network Anti-Furin Convertase 
Ab NO 
Trans-Golgi Carriers pRFP-Rab6 NO 
Table 2 Different organelle markers used to detect specific sub-cellular organelles in TNT 
structures. Tools used (either antibodies or fluorescently labeled protein markers) are indicated 
in the central column. In the third one, presence/absence of these sub-cellular compartments in 
TNTs is reported. 
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 Therefore we examined the presence of early endosome, ERC, 
lysosomes, Golgi and Golgi-associated carriers by 
immunofluorescence after labelling the cells with specific 
antibodies or transfection with fluorescently labelled proteins (as 
described in the Material and Methods section). As depicted in 
Figure 32, (panels A, B and C, red signal), Golgi markers used to 
detect cis- and medial- Golgi, Trans-Golgi network or Trans-Golgi 
carriers were detected inside the cell body of CAD cells but were 
not present in TNT structures. On the other hand, we were able 
to detect vesicles of endo-lysosomal origin in TNTs. Particularly, 
the presence of ERC was assessed by both immunolabelling and 
transfection with GFP-tagged versions of Rab11 and Vamp3, two 
specific markers of this compartment (Maxfield and Mc Graw 
2004) (Figure 32, D and H). 
 
 
!
Figure 31 Identification of different sub-cellular compartments in TNTs of CAD cells. CAD 
cells were either transfected with plasmids harboring fluorescently labelled specific proteins or 
processed for immunofluorescence with specific antibodies as indicated in the different panels. 
Arrowheads indicate the presence of signals in TNTs. Red signals in the panel A, B and C 
correspond to RFP-Rab6, Anti-Giantin and Anti-Furin Convertase (FC) antibodies. Images 
indicate transfer respectively of ERC (D, E and H), Lysosomes (F) and Early Endosomes (G) 
via TNTs.  
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This finding suggests that TNTs formed in between CAD cells are 
able to transport different types of endocytic vesicles, 
particularly recycling endosomes (Figure 32, E) and early 
endosomes (Figure 32, G). Additionally, we could confirm the 
presence of lysosomes in TNT structures (Figure 2.1, F), by using 
Lysotracker ® probe as previously shown (Gousset et al 2009). 
The Golgi compartment has been found to travel in between 
TNTs of astrocytes (Wang et al 2011) and in bridging conduits of 
macrophages (Kadiu and Gendelman 2011). We could not detect 
this compartment in the TNTs of CAD cells, thus highlighting the 
fact that these intercellular structures are functionally 
heterogeneous as different components seem to be selectively 
transferred by different cell types (Gerdes et al 2007).   
 
The next step was to analyze the presence of PrPSc in ERC, early 
endosomes and lysosomes that we had observed travelling in 
TNTs. In order to determine the involvement of these 
compartments in PrPSc intercellular trafficking, we have analyzed 
by quantitative immunofluorescence the nature of the organelles 
transferring PrPSc in TNTs in infected CAD (scCAD) cells. By using 
QUIA (Figure 33), a specifically designed software (for reference 
see the Material and Methods section), we measured the degree 
of colocalisation between a specific organelle marker and PrPSc in 
TNT. Specifically, we performed a double immunolabelling with 
either anti-LAMP1, anti-Vamp1,2,3 and anti-EEA1 together with 
anti-PrP Sha31 antibodies after a denaturing step with Gnd-HCl 
6M to expose PrPSc epitopes for the antibody binding (as 
described in the Material and Methods section) (Figure 33).  
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Figure 32 Colocalisation between PrPScand different sub-cellular organelles in TNT-like 
structures of scCAD cells.  Immunofluorescence was performed after a denaturing step with 
Gnd-HCl to expose PrPSc epitopes  to Sha31 anti-PrP antibody. Anti-EEA1 Ab for early 
endosomes (A), anti-LAMP1 Ab for lysosomes (B) and anti-Vamp1, 2,3 for ERC (C) were used 
to specifically label these sub-cellular compartments. White square in Overlay column indicate 
the enlargement (Inset). 
 
Z-stacks of 0.27 μm were taken with a Perkin-Elmer fast confocal 
spinning-disk microscope from the top to the bottom of the dish 
in order to acquire the entire volume of TNT-connected cells with 
a short time of acquisition in order to protect thin TNT 
structures. After processing, the images were analysed with QUIA 
software and the percentage of colocalisation of PrPSc with the 
different organelle markers was evaluated. Figure 2.3 shows an 
example of the analysis performed with the QUIA software. In 
brief, the image file is loaded into the software and a Region Of 
Interest (ROI) containing the TNT structure is manually selected. 
A “Spot detection” function is then used to select signals on 
both channels (red for PrPSc signal and green for the specific 
organelle marker) (Figure 34, A) followed by the colocalisation 
step (Figure 34, B) and the output (Figure 34, C) consisting of 
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an excel file with the number of spots in each channel and the 
percentage of colocalisation in the ROI.  
 
!
Figure 33 QUIA Software interface. A Region Of Interest (ROI) is manually selected on a 
given image and within it spots on both channels are detected (A) and then colocalised (B). An 
excel file gives the output of the analysis containing the total number of vesicles in both 
channels and the % of colocalisation between the two (C). 
 
Given the peculiarity of the ROI and the high sensitivity requested 
for this analysis QUIA software has been a fundamental tool to 
precisely detect and quantitate signals deriving from both PrPSc 
particles and different sub-cellular compartments in TNT 
structures.  
Indeed, as shown in Figure 35, by quantitative colocalisation 
analysis we found that the percentage of PrPSc colocalising with 
early endosomes and lysosomes in TNT is respectively around 
22% and 32%, while a major fraction (around 50%) seems to 
colocalise with the recycling compartment. As described before 
the ERC is one of the intracellular compartments for PrPSc 
production (Marijanovic et al 2009). Therefore, taken together 
these results show that PrPSc particles travel via TNT mainly in 
the organelle in which they are produced. However different 
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‘elements’ of the endocytic pathway are important for the 
trafficking of PrPSc inside the cell where it can either meet PrPC for 
further conversion (ERC) or been degraded in acidic 
compartments  (lysosomes). This new finding that PrPSc can be 
transported in endocytic vesicles (ERC, early endosomes and 
lysosomes) in TNT structures of CAD cells attributes an 
important role of these organelles as vehicle for the spreading of 
PrPSc from cell-to-cell. 
 
 
                 !
Figure 34 Quantitation of the colocalisation between PrPSc and the different organelle 
markers in TNT structures. The percentage of PrPSc particles colocalising respectively with 
EEA1 (for early endosomes), LAMP1 (for lysosomes) and Vamp1, 2, 3 (for recycling 
compartment) was evaluated. n represents the number of total vesicles counted deriving from 
three independent experiments. 
 
Therefore, exploring the mechanisms by which cells are induced 
to form TNTs and specifically how the transfer of vesicles is 
regulated, within these structures, is essential for a better 
understanding the mechanism of PrPSc spreading.  These 
informations would also contribute to the development of novel 
therapeutical approaches for prion disease. 
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Objective b: 
Role of both cellular and pathological PrP isoforms on 
TNT formation and transfer 
 
Since TNTs have been shown to transfer selective components 
dependently on the cell line, we then asked whether the cellular 
prion protein itself, PrPC, could somehow play a role in TNT 
formation and transfer of endocytic vesicles or the presence of 
its pathological counterpart, PrPSc, leads to a stimulation of TNT 
formation. 
 
 
o Specific background 
 
A plethora of cellular functions have been attributed to PrPC but 
as already mentioned in the introduction (section 1.4) its 
physiological role appears to be redundant and is not yet fully 
understood (Westergard 2007). Of particular interest the recent 
findings showing that PrPC is implicated in cell adhesion (Málaga-
Trillo et al., 2009), focal adhesion formation and filopodial 
extensions (Málaga-Trillo et al., 2009). These findings point 
towards an additional role of PrPC in cytoskeleton dynamics and 
remodeling, and in cell-to-cell communication. Therefore, by using 
cell culture models of prion infection we have investigated the 
potential role of PrPSc in TNTs formation and transfer of vesicles. 
Interestingly, it has been reported that cells undergo a rapid 
increase in intracellular reactive oxygen species (ROS) following 
exposure to infectious brain homogenates, in a prion protein 
(PrP) dependent manner. Furthermore, ROS production correlated 
with internalization and increased levels of intracellular PrPSc 
(Haigh et al 2011).  It is important to note that Wang and 
colleagues (2010) have shown that stress induced by hydrogen 
peroxide (H2O2) treatment led to an increase in TNT formation in 
both astrocytes and neurons suggesting that TNT formation 
might be directly induced by stress. Finally, as already mentioned 
above (section 7 of the introduction) TNT-mediated HIV 
spreading led to an increase in the number of connections both in 
macrophages (Kadiu et al 2011a) and T-cells (Sowinski et al 
2008). As these data suggested a role for PrP in TNT formation 
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which might be induced either by stress activation or by its 
putative role in actin remodeling and cell adhesion (Malaga-Trillo 
2009; Schoch et al 2009), we attempted to explore the effect 
that prions could have on TNTs number.  
 
 
o Results 
 
To analyse the effect of PrPC on the number of TNTs we 
transfected a fluorescent version of PrPC full-length (GFP-PrPWT) 
in CAD cells and used cells transfected with GFP-vector as 
control. After fixation, CAD cells were stained with WGA-
rhodamine in order to visualize and manually count TNT 
structures. By fluorescence microscopy it appeared that GFP-
PrPWT transfected cells have an increased number of protrusions 
and in several of them PrPC was decorating the membranes 
(Figure 36, A).  
 
 
!
Figure 35 Effect of GFP-PrPWT over-expression on TNTs number in CAD cells. (A) CAD 
cells either transfected with GFP-vector or GFP-PrPWT were fixed and labelled with WGA-
rhodamine (in red) and HCS cell mask (in blue) in order to detect both TNT structures and cell 
body. Scale bar 10 µm. Note that GFP-PrPWT over-expressing cells are more enriched in 
cellular protrusion compared to control. (B) The relative percentage of TNT-connected cells 
upon GFP-PrPWT over-expression compared to GFP-vector transfected cells was evaluated. 
(mean ± s.e.m, n=3). 
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By counting the number of cells connected by TNTs in GFP-
PrPWT transfected CAD cells we could quantitatively evaluated 
whether over-expression of PrPC was affecting TNT formation 
between CAD cells, compared to control cells. Interestingly, we 
Page | !#)"
found that over-expression of GFP-PrPWT on average increased 
the relative percentage of cells connected by TNTs by around 
40% (Figure 36, B).  
These networks of TNT structures observed between cells could 
potentially increase the frequency of transfer of different cellular 
components. Hence, to determine whether TNT structures 
formed in CAD cells upon over-expression of GFP-PrPWT were 
functional and therefore were able to support vesicular transfer, 
we analyzed the transfer of endocytic vesicles (section 2.1). In 
order to assess this, we set up a flow cytometry assay that 
would allow us to detect the transfer of DiD-labelled vesicles 
TNT-mediated in CAD cells (as detailed in the Material and 
Methods section). In Figure 37, a schematic containing the 
experimental design is illustrated.  
 
 
 
!
Figure 36 Schematic of the DiD-vesicle transfer assay by Flow cytometry. The three main 
steps are summarized. Step 1 represents the loading step of donor cells (that can be also 
transfected with different GFP-tagged proteins of interest); in the step2, donor cells are co-
cultured with CFP-vector transfected cells, in order to discriminate in between the two 
populations. After co-culture overnight the cells are the passage of DiD-vesicle from the donor 
to the acceptor cells is evaluated (Step3). 
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In brief, donor cells were loaded with the lipid dye DiD that binds 
to the plasma membrane and, after internalization, allows staining 
of intracellular vesicles of different origin (Figure 37, Step 1). 
Finally, donor cells are mixed over-night with acceptor cells 
transfected with CFP-vector (Figure 37, Step 2). Then the 
amount of DiD labeled vesicles transferred from the donor cells 
to the recipient CFP-transfected cells is quantified by Flow 
cytometry (Figure 37, Step 3).  
As already shown, CAD cells transfected with GFP-vector (e.g. 
control cells) can form functional TNTs (panel A of Figure 36). 
Indeed we were able to detect and quantify the transfer of DiD 
vesicles from the donor to the acceptor cells by flow cytometry 
in this condition (Figure 38, A and E), similar to what was already 
described (Bukoreshtliev et al 2009).  
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Figure 37 Flow Cytometry assay of DiD-vesicle transfer from GFP-vector transfected 
donors to CFP-vector transfected acceptors. Different co-culture systems are schematized. 
(A) DiD-labelled, GFP-vector positive (in green) are mixed with CFP-vector recipient CAD cells 
(in violet), (B) DiD-labelled, GFP-vector positive (in green) are fixed prior mixing, (C) a filter 
separate DiD-labelled, GFP-vector positive (in green) cells from CFP-vector recipient CAD cells 
and (D) supernatant deriving from a DiD-labelled, GFP-vector positive (in green) overnight 
culture is used to feed CFP-vector recipient CAD cells. In (E), the percentage of DiD-vesicle 
transfer in (B), (C) and (D) conditions has been quantified as relative transfer compared with 
condition in (A) corresponding to the first histogram. (mean ± s.e.m, n=3). 
 
Additional controls were made to demonstrate that the DiD 
transfer detected is an active mechanism, driven by TNT and, 
thus, involving cell-to-cell contact (Gousset et al., 2009 and 
Langevin et al., 2010). In order to verify this, we co-cultured DiD-
vesicle loaded donor cells with CFP-vector transfected cells in 
different co-culture conditions, as illustrated in Figure 38 and 
described below. 
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• Co-culture 1 (B): fixed DiD-vesicle loaded donor CAD cells 
(dead cells) + CFP-vector transfected CAD cells (live cells). 
This control has been made to exclude any transfer of 
vesicles deriving from cells debris up-taken by acceptor 
cells.   
• Co-culture 2 (C): DiD-vesicle loaded donor CAD cells + CFP-
vector transfected CADs separated by a filter. This control 
has been made to reveal whether cell-to-cell contact was 
required. 
• Co-culture 3 (D): CFP-vector transfected CAD cultured 
overnight in the culture medium of DiD-vesicle loaded 
donor CAD cells. This control has been made to exclude 
transfer mediated by secretion or exosomes. 
By quantifying the percentage of transfer of DiD-vesicles from 
GFP-vector transfected donor cells to CFP-vector positive cells, 
we found that when donor cells are either fixed (Figure 38, B), 
separated by a filter (Figure 38, C) or when the recipient cells are 
in contact only with the supernatant of the donor cells (Figure 
38, C), the relative transfer of DiD-vesicle compared to control is 
between 2% and 7% and therefore not significant (Figure 38, E).  
 
We next determined the effect that over-expression of GFP-PrP in 
donor cells might play in the transfer of DiD-labelled vesicle. As 
depicted in Figure 39, we found that GFP-PrPWT transfected in 
donor cells did not increase DiD-vesicle transfer, as the 
percentage of relative transfer is equal to control condition with 
an average of 104.2%.  
 
 
!
Figure 38 Effect of GFP-PrPWT over-expression on DiD-vesicle transfer TNT-mediated in 
CAD cells. The relative percentage of DiD-vesicle transfer upon GFP-PrPWT over-expression 
compared to GFP-vector transfected cells was evaluated (mean ± s.e.m, n=3). 
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Taken together these results show that the increase in TNTs 
number mediated by over-expression of PrPC (Figure 39, A and B) 
did not lead to an increase in the trafficking of endocytic vesicle 
in CAD cells through TNTs. This result highlighted the fact that 
possible candidate factors might be implicated in TNT-mediated 
transfer and can have different roles in the process, either 
structural (e.g., building up the membrane structure) or 
functional (e.g., as part of the machinery that allows and drives 
the transfer of material within the membrane). PrPC seems to 
have a structural function, which we are currently trying to 
address (see discussion, paragraph 2.3). 
 
The next step was to evaluate the effect of prion infection on 
TNTs formation. To test whether PrPSc infection could induce TNT 
formation in order to increase its spreading the proportion of 
cells having TNT structures in control or infection conditions was 
quantified (Figure 40).  
 
 
!
Figure 39 PrPSc infection induces TNT-formation by increasing the number of connected 
scCAD cells. (A) CAD cells chronically infected with the prion strain 139A (ScCAD,) or 
uninfected CAD cells were labeled with WGA-rhodamine (in red) and HCS cell mask (blue) after 
fixation and images were acquired to evaluate the number of TNT-connected cells. (B) 
Quantitation of TNT-connected scCAD cells compared to non infected CAD cells (mean ± 
S.E.M., n=3).  
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Thus, we compared the number cells connected via TNTs in the 
case of non-infected CAD with chronically infected CAD (ScCAD) 
cells. We found that the number of TNT-connected cells was 
increased of about 28% in the case of prion infection, Those data 
indicate that, at least in vitro, PrPSc could potentially accelerate 
its spreading through direct induction of TNT formation.  
Overall, these results show that both cellular prion protein PrPC 
and PrPSc infection can lead to increased number of TNT 
structures in CAD cells. In addition, PrPC over-expression does not 
increase DiD-vesicle transfer, thus indicating that its function is 
either structural or not sufficient to drive transfer of cellular 
components in between cells. Further investigations in order to 
unravel the role of PrPC and the mechanism by which PrPSc 
infection can possibly increase TNT-formation are required and 
will be examined in the discussion section of this chapter 
(paragraph 2.4).  
 
 
 
Objective c: 
Role of Myosin-X in TNT formation, TNT-mediated 
transfer and PrPSc spreading from cell-to-cell 
 
Understanding both the mechanism of TNT formation and of 
vesicular transfer is fundamental for unraveling and hamper prion 
spreading, thus, in the last part of my thesis I focused on the 
potential role of specific molecules in TNT formation and TNT-
mediated transfer. Specifically I analyzed the possible 
involvement of the unconventional actin-binding motor Myosin-X 
in these processes.  
 
o Specific Background 
 
The fact that most TNTs in neuronal cells arise from the 
extension of filopodia-like protrusions toward neighboring cells 
suggested that actin polymerization plays an important role in 
TNT formation. In addition, since filopodia-like protrusions are 
critical for TNT formation in neuronal cells (Bukoretshliev et al., 
2009), it is likely that factors involved in filopodia formation also 
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play a role in TNT biogenesis. In particular we have analyzed the 
role that the unconventional actin-binding protein Myosin-X might 
play in both the formation of TNT-like structures and its function 
in transfer of materials in neuronal cells. Indeed Myo-X and its 
effects on filopodia formation have been well studied (Berg and 
Cheney, 2002).  In particular, over-expression of full length Myo-
X in a number of cell types, including CAD cells, has led to an 
increase in both the number and the length of filopodia (Sousa 
and Cheney 2005). Also, it was shown that over-expression of 
Myo-X specifically increased dorsal filopodia (Bohil et al 2006), 
suggesting that it could play a role in de novo formation of TNT-
like structures because it would lead to the extensions of 
filopodia, unattached to the substratum, toward recipient cells. 
Hence, in the last part of my work I wanted to understand 
whether this protein could play a role in TNT formation and the 
spreading of PrPSc from cell-to-cell. This part of my work has been 
done in collaboration with Dr Karine Gousset (Unité de trafic 
membranaire & pathogénèse, Institut Pasteur, Paris). 
 
 
o Results 
 
First, to analyze the effect of Myo-X on TNT formation, we 
transfected a GFP-tagged version of the full-length protein (GFP-
Myo-X) in CAD cells and by fluorescence microscopy we analyzed 
TNT structures, as previously described. Upon over-expression of 
GFP-MyoX, numerous TNT-like structures were observed (Figure 
2.41, A).  
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Figure 40 Effect of GFP-Myo-X over-expression on both TNT formation and transfer of 
DiD-vesicle in CAD cells. (A) CAD cells either transfected with GFP-vector or GFP-Myo-X 
were fixed and labelled with WGA-rhodamine (in red) and HCS cell mask (in blue) in order to 
detect both TNT structures and cell body. Scale bar 10 µm. Note that GFP-Myo-X over-
expressing cells are more enriched in cellular protrusion compared to control. (B) The relative 
percentage of TNT-connected cells upon GFP-Myo-X over-expression compared to GFP-vector 
transfected cells was evaluated. (mean ± s.e.m, n=3) (C) The relative percentage of DiD-vesicle 
transfer upon GFP-Myo-X over-expression compared to GFP-vector transfected cells was 
evaluated (mean ± s.e.m, n=3). 
 
To quantify this result, we compared the number of TNT-like 
structures observed in CAD cells over-expressing GFP-Myo-X with 
cells over-expressing GFP vector as a control. We determined 
that over-expression of GFP-Myo-X on average increased the 
relative percent of cells with TNT-like structures by over 50% 
(Figure 41, B). Also, as shown in Figure 41 (panel A) GFP-Myo-X 
is predominantly present within these structures and can move 
back and forth over time in live-imaging experiments (data not 
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shown). We then asked whether these networks of tubes 
observed between cells could potentially increase the frequency 
of transfer in between cells. Thus, in order to determine whether 
TNT-like structures formed upon over-expression of GFP-Myo-X 
are functional TNTs (e.g., allow the intercellular transfer of 
vesicles), we quantify the transfer of DiD-labeled vesicles in our 
neuronal cell system by using the flow cytometry assay 
previously set up (as schematized in Figure 37).  For these 
experiments, donor cells were loaded with the lipid dye DiD and 
mixed with CFP-transfected acceptor cells overnight. As 
expected from our previous studies, normal CAD cells transfected 
with GFP-vector (e.g., control cell) formed functional TNTs and 
transferred DiD vesicles from the donor cells to the acceptor cells 
(Figure 41, C, column 1). Interestingly, when we over-expressed 
GFP-Myo-X in donor cells we observed a relatively large increase 
(around 72%) in the transfer of DiD-labeled vesicles compared to 
the control (Figure 41, C, column 2).  It is important to note that 
in these experiments, on average, the transfection rate efficiency 
of GFP-Myo-X is much lower (about 1/6) compared to the control 
GFP-vector.  This means that by flow cytometry, the transfer 
efficiency of the cells over-expressing GFP-Myo-X is largely 
underestimated.  To demonstrate that the transfer detected 
upon GFP-MyoX over-expression was the results of an active 
intercellular transfer mechanism and did not come from DiD-
labeled vesicles in the supernatant, we repeated the flow 
cytometry assays with either fixed donor cells or in co-cultures 
separated by filters (Figure 38, Gousset et al., 2009 and 
Langevin et al., 2010).  As shown in Figure 42, no significant 
transfer of DiD-labeled vesicles could be detected in either fixed 
cells or in co-cultures separated by a filter in either GFP-vector or 
GFP-Myo-X transfected cells.   
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Figure 41 DiD-vesicle transfer mediated by GFP-Myo-X transfected cells is an active 
mechanism. The relative percentage of DiD-vesicle transfer upon GFP-Myo-X over-expression 
compared to GFP-vector transfected cells was evaluated (column 1 and 2). Additional controls 
with either fixed donor CAD cells (transfected with GFP-vector or GFP-Myo-X) prion mixing with 
acceptor CAD cells (column 3 and 4) and mixed population separated by a filter (mean ± s.e.m, 
n=3). Note that the last two cases DiD-vesicle transfer is not considerable. 
 
These results suggest that the transfer of vesicles observed by 
flow cytometry is an active mechanism that correlates with the 
number of TNT-connected cells present in culture. To further 
characterize the role of Myo-X over-expression on the formation 
and functionality of TNTs, we next determined whether its 
expression in donor cells or in acceptor cells would affect vesicle 
transfer.  Thus, we repeated these experiments using co-cultures 
where both the donor cells and the acceptor cells were 
transfected with GFP-Myo-X (Figure 41, C, column 3) or in co-
cultures where only the acceptor cells were transfected with GFP-
Myo-X (Figure 41, C, column 4) and compared the results with 
control cells (Figure 41, C, column 1) or donor cells transfected 
with GFP-Myo-X (Figure 41, C, column 2). The results clearly 
demonstrate that over-expression of GFP-Myo-X in the acceptor 
cells had little effect in the transfer of vesicles from donor cells 
(Figure 41, C, columns 3 and 4). These experiments suggest that 
in CAD cells, the transfer of vesicles is uni-directional, going from 
the cell that extend the filopodial protrusion towards a recipient 
cells establishing the connection.  Overall, they demonstrate that 
over-expression of GFP-Myo-X in donor cells leads to an increase 
in functional TNTs, thus resulting in the enhancement of the 
transfer of DiD-labeled vesicles to the recipient cells. 
Since CAD cells already have endogenous levels of Myo-X in order 
to better characterize the effects of Myo-X expression on TNT 
formation and transfer we then attempted to knock-down Myo-X. 
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Using Myo-X shRNA lentiviral particles (as described in the 
Material and Methods section) we were able to reduce Myo-X 
expression levels up to 83% (Figure 43, A).  Next, we analyzed 
the effect of Myo-X down regulation on the number of TNT-
connected CAD cells.  We found that while the relative number of 
cells with TNTs decreased in Myo-X down-regulated cells 
compared to the control CAD cells (Figure 43, B), TNTs were still 
present in the down-regulated cultures.  This could be because 
(1) we were unable to efficiently silence Myo-X gene expression, 
(2) CAD cells are able to form TNTs cell dislodgement (Gousset 
et al 2009), a process that might not require Myo-X or (3) Myo-X 
can enhance de novo TNT formation but is not a limiting factor.  
 
 
!
Figure 42 Effect on TNT formation and DiD-vesicle transfer of Myo-X down-regulation in 
CAD cells. (A) Western blot with anti-Myo-X antibodies in CAD cells down-regulated for Myo-X 
gene with Myo-X shLentiviral particles (B) The relative percentage of DiD-vesicle transfer in 
Myo-X downregulated cells (shRNA Myo-X) compared to CAD cells treated with scramble 
shRNA lentiviral particles as control (shTNA CTR) was evaluated (mean ± s.e.m, n=3) (C) Myo-
X rescue experiment. The relative percentage of DiD-vesicle transfer upon GFP-Myo-X over-
expression in shRNA Myo-X CAD cells compared to GFP-vector transfected shRNA CTR cells 
was evaluated (mean ± s.e.m, n=3). 
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Next, we analyzed the effects of down-regulation of Myo-X on 
the transfer of DiD-vesicles by flow cytometry to determine what 
types of structures were affected.  By quantifying the relative 
percentage of vesicle transfer in Myo-X down regulated cells 
compared to control cells, we found a decrease of over 20 % in 
the transfer of DiD-labeled vesicles when Myo-X was down-
regulated (Figure 43, C, column 1 and 2). In addition, when GFP-
MyoX was transfected in Myo-X down-regulated cells, the transfer 
of vesicles could not only be rescued but also increased by 
almost 17% compared to control cells GFP-vector positive 
(Figure 43, C, column 3 and 4). This demonstrates that Myo-X 
expression allowed the formation of efficient functional TNTs. 
As stated above, GFP-Myo-X is enriched within TNTs and is able 
to move back and forth along the tubes.  The forward movement 
of Myo-X to the tips of filopodia was shown to be dependent 
upon its molecular motor activity, while its rearward transport 
take advantage of actin retrograde flow (Berg and Cheney, 
2002). To determine the role that either the motor domain or tail 
domain of Myo-X might play in both TNT formation and function 
we used two Myo-X mutants: (1) GFP-HMM consisting of the head 
motor domain, neck and coiled-coil regions or (2) GFP-Headless 
containing the neck, coiled coil and tail regions of Myo-X (Berg 
and Cheney 2002).  Thus, we first expressed both mutants in 
CAD cells and compared them to GFP-Myo-X over-expression 
(Figure 44).   
 
 
Page | !%+"
!
Figure 43 Effect of GFP-HMM-Myo-X and GFP-Headless-Myo-X on both TNT formation 
and DiD-vesicle transfer in CAD cells. (A) CAD cells either transfected with either GFP-Myo-
X, GFP-HMM-Myo-X or GFP-Headless-Myo-X were fixed and labelled with WGA-rhodamine (in 
red) and HCS cell mask (in blue) in order to detect both TNT structures and cell body. Scale bar 
10 µm. (B) The relative percentage of TNT-connected cells upon GFP-Myo-X, GFP-HMM-Myo-
X or GFP-Headless-Myo-X over-expression compared to GFP-vector transfected cells was 
evaluated (mean ± s.e.m, n=3) (C) The relative percentage of DiD-vesicle transfer upon GFP-
Myo-X, GFP-HMM-Myo-X or GFP-Headless-Myo-X over-expression compared to GFP-vector 
transfected cells was evaluated (mean ± s.e.m, n=3). 
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As previously described (Berg and Cheney, 2002), both GFP-Myo-
X and GFP-HMM are able to localize at the tips of filopodia, 
whereas GFP-Headless is cytosolic (Figure 44, A).  Since both 
mutants could be transfected in CAD cells and behaved as 
expected (Berg and Cheney, 2002), we next determined the 
effects of over-expression of these constructs on TNT formation.  
Interestingly, even though GFP-HMM is able to behave in filopodia 
in a similar fashion to the full length GFP-Myo-X construct, its 
over-expression in CAD cells is not sufficient to increase the 
relative number of cells with TNTs (Figure 44, B, column 3).  
Similarly, the over-expression of the tail domain alone GFP-
Headless, did not increase TNT formation in CAD cells (Figure 44, 
B, column 4).  These experiments suggest that the motor and 
the tail domains of Myo-X are both necessary for TNT formation.   
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Next, to further characterize the effect of over-expression of 
these mutants on TNT function we analyzed the transfer of DiD-
vesicles by flow cytometry (Figure 44, C).  In agreement with the 
fact that the TNTs number was not increased, we found that 
neither constructs were able to increase the transfer of DiD-
vesicles, to the levels observed with GFP-Myo-X (Figure 44, C).   
It is of interest to note that these constructs did not have the 
same rate of transfection efficiency in CAD cells.  On average, 
GFP-Headless and GFP-HMM were 2 and 4.5 times more efficiently 
expressed compared to GFP-Myo-X, suggesting that the effect of 
full length GFP-Myo-X might have been under-estimated by its 
lower transfection efficiency. Overall, these experiments suggest 
that while the motor domain might play a role in bringing Myo-X 
to the tip of filopodia and thus to the point of attachment with 
an adjacent cell, the tail domain of Myo-X might play a critical role 
in the binding and/or fusion of the tubes, possibly by binding to 
necessary components. 
Therefore, to further narrow down which part of the tail domain 
of Myo-X might be critical for the formation of TNTs, we next 
decided to analyze mutations within the FERM domain located at 
the end of the Myo-X tail (Berg and Cheney 2002).  As already 
described in the introduction (section 1.8) FERM domains are 
thought to serve as a link between cytoskeletal components and 
integral membrane proteins (Chishti et al., 1998).  In the case of 
Myo-X, the FERM domain was shown to bind to integrins (Zhang 
et al., 2004).  In their study, Zhang and colleagues demonstrated 
that both F2 and F3 subdomains of the FERM domain were 
necessary for the binding of integrins to Myo-X.   Thus, we 
decided to analyze the effects of over-expression of the deletion 
mutants GFP-Myo-X-!F2 and GFP-Myo-X-!F3 lacking either the F2 
or F3 lobes respectively (Zhang et al., 2004).  We first analyze 
the localization of these mutants in transfected CAD cells (Figure 
45, A).   
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Figure 44 Effect of GFP-Myo-X-!F2 and GFP-Myo-X-!F3 on TNT formation and DiD-
vesicle transfer in CAD cells. (A) CAD cells either transfected with either GFP-Myo-X, GFP-
Myo-X –$F2 or GFP-Myo-X- $F3 were fixed and labelled with WGA-rhodamine (in red) and 
HCS cell mask (in blue) in order to detect both TNT structures and cell body. Scale bar 10 µm. 
(B) The relative percentage of TNT-connected cells upon GFP-Myo-X, GFP-Myo-X –$F2 or 
GFP-Myo-X- $F3 over-expression compared to GFP-vector transfected cells was evaluated 
(mean ± s.e.m, n=3) (C) The relative percentage of DiD-vesicle transfer upon GFP-Myo-X, 
GFP-Myo-X –$F2 or GFP-Myo-X- $F3 over-expression compared to GFP-vector transfected 
cells was evaluated (mean ± s.e.m, n=3). 
 
We found that similar to Myo-X full-length both mutants could be 
found at the tips of filopodia or within TNTs (Figure 45, A). 
However, while GFP-Myo-X and GFP-Myo-X-!F3 were both able to 
increase the number of CAD cells with TNTs (Figure 45, B, 
column 2 and 3), GFP-Myo-X-!F2 was not (Figure 45, B, column 
4).  We then studied at the effects of these mutations in the 
transfer of DiD-labeled vesicles by flow cytometry. As can been 
seen in the panel C in Figure 45, we determined that both full 
length and GFP-Myo-X-!F3 enhanced the transfer of DiD-labeled 
vesicles but not GFP-Myo-X-!F2 in agreement with the 
quantification of TNT-connected cells. Since both lobes are 
simultaneously necessary for the binding of Myo-X to integrins, 
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our results suggest that integrins are not necessary for TNT 
formation and function.  While integrins are important for 
attached filopodia extension, they are not necessary for the 
formation of dorsal filopodia (Bohil et al., 2006).  Thus, this 
further suggests that dorsal filopodia could potentially be the 
precursor of TNT structures.  Importantly, our data specifically 
identify the F2 lobe of the FERM domain as a necessary 
subdomain of Myo-X for both TNT formation and function, likely 
by binding to critical cargo proteins.  Thus, it will be important to 
identify the binding partner(s) of F2 critical for TNT formation. 
So far, our data suggest that Myo-X expression is able to 
enhanced TNT formation and improve the intercellular transfer of 
vesicles. The question I wanted to answer next was if Myo-X was 
involved in the transfer of PrPSc between cells. Indeed I have 
shown that PrPSc travels within TNTs in endocytic vesicles 
(section 2.1 of this chapter). Therefore, we decided to analyze 
whether Myo-X expression in chronically prion infected CAD 
(scCAD) cells could also affect the transfer of PrPSc particles to 
recipient CAD cells. Thus, we set up a microscopy experiment, in 
which we quantified the transfer of PrPSc aggregates, (revealed 
by the anti-PrP antibody Sha31 after Gnd-HCl treatment), from 
ScCAD donor cells transfected with GFP-vector or GFP-Myo-X, to 
recipient CAD cells transfected with GFP-PML, a nuclear marker 
(Figure 46).   
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Figure 45 Transfer of PrPSc via TNTs in CAD cells by fluorescence microscopy. scCAD 
donor cells were transfected either with GFP-vector as control or GFP-Myo-X (in green). CAD 
recipient cells were transfected with GFP-PML (a nuclear marker) in order to discriminate them 
from scCAD. Both population were mixed overnight and the transfer of PrPSc was evaluated by 
immunolabelling with Sha31 anti-PrP antibody after Gnd-HCl treatment (to expose PrPSc 
epitopes).  
 
In these experiments, GFP-PML was used as a tool to identify the 
acceptor cells and the PrPSc particles were quantified using the 
QUIA Software for spot detection (as described in the Material 
and Methods section).  Analysis of the data clearly demonstrated 
that over-expression of GFP-Myo-X led to a drastic increase in the 
transfer PrPSc particles from scCAD cells to naïve CAD cells 
(Figure 47).  
 
!
Figure 46 Effect of Myo-X over-expression on transfer of PrPSc via TNTs in CAD cells. (A) 
Detection of the transfer of PrPSc particles (by using Sha31 antibody) via TNTs in control 
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condition (scCAD donor cells transfected with GFP-vector) and after over-expression of GFP-
MyoX. CAD recipient cells are transfected with GFP-PML (a nuclear marker). White circles and 
arrowheads indicate obtained PrPSc passage from the donors scCAD cells to the acceptor CAD 
cells. (B) Quantification of the percentage of transfer by Count Spots with QUIA software. (mean 
± s.e.m, n=3). 
  
In conclusion these data show that Myo-X is able to induce TNT 
formation and to regulate the transfer of vesicle and, more 
interestingly, the transfer of PrPSc particles.  
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2.3 Discussion 
 
Prion diseases are characterized by the presence of prions, 
proteinaceous aggregates, mainly constituted by a misfolded 
protein, PrPSc. The central event in prion pathogenesis is the 
conformational change of the cellular protein, PrPC, in its 
pathological counterpart, PrPSc (Prusiner, 1998). As discussed 
above (in the section 1.6 of the Introduction), at the different 
stages of its lethal journey to the central nervous system, PrPSc is 
transferred from one cell to another and this passage can involve 
several mechanisms, not mutually exclusive, probably depending 
on cell type, the infectious strain and the host. These 
mechanisms include cell-to-cell contact, exosomes and GPI-
painting (Kanu et al., 2002; Fevrier et al., 2004; and Baron et al., 
2006). More recently it has been shown that intercellular 
membranous channels, called tunneling nanotubes (TNT), are 
hijacked by PrPSc for intercellular spread (Gousset et al., 2009; 
Langevin et al 2009). In this context, in the second part of my 
PhD work I focused on better characterizing TNT-mediated 
trafficking of PrPSc in between neuronal CAD cells, as a model of 
prion infection. I also tried to individuate potential factors that 
could be involved in TNT formation and resulting transfer of PrPSc 
in particular.  
PrPSc has been found mainly intracellular, and particularly all along 
the endocytic pathway (Campana et al 2005). Moreover, like 
PrPC, PrPSc is a GPI-anchored protein. Both proteins could travel 
via TNTs surfing the surface or inside the channel, as cytosolic 
aggregates or within vesicular structures. In particular, I 
investigated the presence of PrPSc in different sub-cellular 
organelles in TNTs. To this aim, by fluorescence microscopy, I 
first evaluated the presence of different subcellular 
compartments in TNTs, namely early endosomes, lysosomes, 
recycling vesicles, Golgi apparatus and trans-Golgi carriers. While I 
could not detect Golgi and Golgi-associated vesicles in these 
structures, I found that early endosomes, lysosomes and 
recycling vesicles were trafficked in TNTs. I then further analyzed 
the presence of PrPSc in early endosomes, lysosomes and 
recycling vesicles inside TNTs. By a specifically designed 
quantitative localization analysis (QUIA software, Figure 34), I 
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found that similar to what can be found in the cell body, PrPSc can 
travel in TNTs in early endosomes and lysosomes but it is 
preferentially enriched in the endocytic recycling compartment 
(Figure 33 and Figure 35). This is particular interesting as the 
ERC is also an intracellular site for prion conversion (Marijanovic 
et al 2009). Therefore my data suggest that PrPSc exploits 
endocytic traffic through tunneling nanotubes for its intercellular 
spread. Similar to PrPSc, it has also been recently reported that 
HIV particles can spread, both surfing on or inside TNTs in 
primary macrophages (Eugenin et al 2009).  Recently, a more 
detailed characterization of HIV-carriers mediating the transfer of 
the virus along TNTs bridging macrophages has been made 
(Kadiu et al 2011a). The authors also identified the composition 
of TNTs by proteomic analysis following isolation from cell bodies. 
Interestingly they found several organelle markers, including 
endo-lysosomal and recycling compartments, inside TNTs and 
some of them colocalizing with the viral proteins Env and Gag, 
thus confirming a role for these intracellular organelles in HIV 
intercellular trafficking (Kadiu et al 2011a). Comparing intra- and 
inter-cellular trafficking of PrPSc with the current knowledge in the 
HIV field could improve our understanding and help in 
characterizing intercellular spreading of prions.  
Moreover, these new findings showing that PrPSc trafficking in 
tunneling nanotubes could be associated with vesicles of 
endosomal origin, lead to some speculations and open up a series 
of new questions that could be a basis for further investigations. 
In particular, the fact that TNT structures contain F-actin as 
backbone suggests that the movement of organelles along TNTs 
is facilitated by an acto-myosin-dependent mechanism. Besides, it 
has been reported that the acto-myosin machinery used by the 
cell to move virus-containing cargoes within TNTs is 25 times 
faster than the surfing process seen for HIV and other 
retroviruses on filopodial protrusions (Sherer et al 2007), thus 
suggesting that intercellular vesicular trafficking is a more 
efficient mechanism of pathogens spreading. This leads to the 
question, which are the actin-associated motors involved in 
endocytic vesicles traffic through TNTs and, so, leading to the 
spread of PrPSc? It has been shown that Myosin Va is present in 
TNTs and partially localizes with endocytic organelles (Rustom et 
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al 2004; Gerder 2007). It is known that Myosin Va is recruited on 
to diverse organelles, such as melanosomes and secretory 
vesicles, by a mechanism involving Rab GTPase (Desnos et al 
2007). So, it would be interesting to assess the role of this 
molecular motor in driving PrPSc-containing vesicles transfer via 
TNTs in neuronal cells.  
Another intriguing question raised by these results regard the 
implication of the vesicular intercellular transport of PrPSc in prion 
infectivity. I found that PrPSc travel via TNT mainly with the 
recycling endosomes representing the apparatus for prion 
replication (Marijanovic et al 2009). Whether PrPSc particles 
spreading in vesicles through tunneling nanotubes results in a 
productive infection of a recipient cell and how the flow of these 
carriers is regulated and intersects with the intracellular pathway 
of the ‘host’ remain to be investigated. In particular, what would 
be the fate of PrPSc-enriched recycling endosomes once they get 
in a neighboring cell? To travel in different organelles can be a 
mean for PrPSc to meet, by organelle fusion, with PrPC-containing 
early or recycling endosomes from another cell and continue to 
spread by further replication by transconformation. One way to 
explore this possibility could be by following the intercellular 
trafficking of specific markers of recycling endosomes, as Rab11 
and Vamp3 (that I showed travelling via TNT, see paragraph 1.1 
of this chapter) deriving from two cells population transfected 
with either GFP- and RFP-tagged proteins by using double color 
live-imaging fluorescence technique. Subsequently, by recording 
in real-time the organelles fusion events between vesicles 
deriving from one cell population with the other, it would be 
possible to understand whether there is interaction between the 
endocytic systems of two connected cell and the fate of the 
newly obtained endocytic vesicles.  
Also, in order to evaluate the infectivity of PrPSc-enriched 
endosomes it would be interesting to purify TNTs deriving from 
co-culture between prion-infected and uninfected cells, in a 
similar way on what was recently shown for HIV virus (Kadiu et al 
2010). In addition, this could possibly allow the isolation of 
factors that are specifically present upon prion infection in TNT 
and could be potentially associated with PrPSc trafficking in these 
structures.  
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Moreover, I set up a flow cytometry assay (Figure 37) to 
quantitate DiD- vesicles TNT-mediated transfer in CAD cells 
specifically to study the effect of PrPC and Myo-X on vesicular 
trafficking in TNT (as described in paragraphs 2.2 and 2.3 of this 
chapter and further discussed below). Thus, one could imagine 
using this assay to analyze the effect of selective blocking of 
different endocytic pathways on DiD-vesicles transfer. The 
identification and subsequent dissection of the pathways that are 
implicated in intercellular- vesicular trafficking could help to find 
possible therapeutic approaches to limit PrPSc spreading by 
controlling its exit from an host cell or by impairing its trafficking 
to the neighboring cells. 
 
Next I have analyzed factors that could be involved in formation 
of TNTs and in the spreading of prions through these channels. 
Because TNTs formed in between CAD cells can derive from 
filopodia-like protrusions (Gousset et al 2009), it is likely that 
TNT formation could be driven by factors that are important for 
filopodia formation and their maintenance.  
Interestingly PrPC itself has been recently involved in cytoskeleton 
dynamic and remodeling and in cell-to-cell adhesion (Malaga-Trillo 
2009; Chiesa and Harris 2009; Schrock et al 2009). Therefore, 
we have investigated its potential role on TNTs formation and 
transfer of vesicles. Interestingly I observed that GFP-PrPWT 
transfected cells seem to extend more filopodial protrusions that 
could fuse with the ones present on remote cells leading to 
formation of TNT. By quantitate the number of TNT-connected 
cells I indeed found an increase in TNTs number in cells over-
expressing GFP-PrPWT (Figure 36). Surprisingly, this increase was 
not related to an increase in trafficking of endocytic vesicles in 
CAD cells, as I could not detect more DiD-vesicle transfer in this 
condition compared to control (Figure 39).  
This could be explained by the fact that different molecules are 
involved in TNT formation. Indeed some of them can have a 
structural role where some others a functional property (e.g., 
building up the membrane structure or be part of the machinery 
that allows and drives the transfer of material within the TNT 
membrane). In this view, one could speculate that even in 
presence of an increased number of TNT structures PrPC over-
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expression is not sufficient to increase the transfer of vesicles 
because other components that are fundamental for the process 
or a limiting step. On the other hand, the role of PrPC could be 
related more to TNT structure. For example, it has been shown 
that in zebrafish, PrP-1, an homologue of the mammalian PrPC, 
might directly mediate homophilic interactions or indirectly by 
regulating the trafficking of E-cadherins and β-catenin to the 
plasma membrane, thus promoting adherents junctions (Malaga-
Trillo, 2009). This is in agreement with previous observations 
made for mammalian PrPC in which a role for this protein in 
neurite outgrowth and cell-cell interaction, respectively in 
hippocampal neurons and neuroblastoma cells has been reported 
(Monge et al 2002; Santuccione et al 2005). On the other hand 
it has been observed that VE-Cad, an endothelium-specific 
cadherin, can be transported to the tips of filopodia in 
association to the motor protein Myosin-X in order to develop 
primary cell-cell contacts by promoting homophilic cell-cell 
junction formation (Almagro et al 2010).  Accordingly, one could 
hypothesize that PrPC can be involved in this event and 
participate in the anchoring and establishment of cell-to-cell 
contact with a neighboring cell, thus interacting with different 
partners.  
Along the same line of thinking, in the last part of my thesis work 
(paragraph 2.3 of this chapter) I explored the role of Myo-X 
molecular motor in TNT-formation and TNT-mediated transfer. 
Indeed this protein is fundamental in initiating filopodia formation 
and transporting specific cargo to its tip, that is an active site for 
actin polymerization (Berg and Cheney, 2002; Sousa and Cheney 
2005). By using both fluorescence microscopy and flow 
cytometry I found that over-expression of a fluorescently labelled 
version of Myo-X (GFP-Myo-X) increases the number of TNT-
connected cells (of around 40% more compared to control). 
Furthermore it doubles the transfer of DiD-vesicles in CAD cells 
(Figure 41). Consistently, by knocking-down Myo-X gene I 
observed an inhibitory effect on both these processes (Figure 
43). It is interesting to note that the transfer of vesicles was 
unidirectional (e.g., occurring from the cells over-expressing Myo-
X to the acceptor cells) (Figure 41), thus highlighting that critical 
intracellular signals in the TNT-sending cell can stimulate and 
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drive TNT-formation and lead to transfer of different 
components.  
These data clearly showed that Myo-X might play a pivotal role on 
TNT-mediate intercellular communication between cells. To 
further dissect the mechanism of action of Myo-X I analyzed the 
effect of the different Myo-X domains. To this aim I used 
different GFP-tagged construct mutants of the protein containing 
mutations or deletions of the different Myo-X domains (Figure 
44) and by similar experimental approaches I was able to show 
that both motor domain (that binds to actin) and tail domain 
(containing cargo-binding sites) need to be present for TNT 
formation and transfer (Figure 44). This highlights the fact that 
the tip localization of Myo-X, given by its motor domain, is not 
sufficient to drive TNT-formation and mediated-transfer and that 
binding to specific cargo proteins, as critical components of TNT 
formation machinery, is required.  
Furthermore it has been shown that both lobe 2 and 3 of the 
FERM domain of Myo-X (present in the tail) are crucial for binding 
to β-integrins (Zhang et al 2004). We hypothesized that this 
interaction might be implicated in TNT-formation mechanism. To 
verify this hypothesis, by using mutants of Myo-X lacking of lobe 
2 or 3 of FERM domain (F2 or F3), respectively GFP-Myo-X-!F2 
and GFP-Myo-X-!F3 mutants, I evaluated both the number of 
TNT-connected cells and DiD-vesicle transfer upon their over-
expression. Interestingly, I found that, while cells over-expressing 
GFP-Myo-X-!F3 showed similar properties to GFP-Myo-X wild-
type, no increase of TNT number or transfer of DiD-vesicle was 
detected in GFP-Myo-X-!F2 transfected cells (Figure 45). This 
clearly suggests that proteins that specifically bind to lobe 2 of 
the FERM domain of Myo-X, but not β-integrins, are necessary for 
both TNT formation and function. In agreement with this finding, 
it was recently shown that Myo-X over-expression is a greater 
inducer of dorsal filopodia and knock-down of Myo-X leads to a 
substantial loss of these structures (Bohil et al 2006). Dorsal 
filopodia do not contact the substratum and are independent for 
their function from integrins. Besides, Myo-X FERM mutants over-
expression do not impair the ability of Myo-X to induce dorsal 
filopodia (Bohil et al 2006), thus suggesting that this type of 
filopodia could potentially be TNT precursors. Therefore further 
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investigations are needed to identify the binding partner(s) of F2 
and, so, unravel the mechanism by which Myo-X and cooperative 
partners induce TNT-formation and transfer. In particular, it 
would be interesting to explore the possible role of VASP/Mena 
proteins in this process, as Myo-X is responsible of their 
localization to the tip of filopodia where they promote actin 
filament elongation by interacting with the plus ends and 
shielding them from the capping protein (Tokuo et al 2004). In 
this view, it could be that the actin-binding motor protein Myo-X 
is critical for delivering important factors that would 
subsequently drive elongation of the filopodial protrusions and/or 
establishment of cell-to-cell contact and passage of molecules 
through newly formed tunneling nanotubes. 
Having established that Myo-X is involved in both the formation 
and the transfer through TNTs, the question that I addressed 
next was to explore the effect that over-expression of Myo-X had 
on PrPSc transfer. Interestingly, I found that over-expression of 
Myo-X not only increases TNT numbers and vesicle transfer but it 
also almost doubles the transfer of PrPSc from prion infected CAD 
(scCAD) to naïve CAD cells (Figure 46). Consequently, 
understanding the role of Myo-X in TNT-mediated transfer could 
also allow a better characterization of the mechanism of PrPSc 
trafficking and its invasive properties in a specific host.  
In addition, I also found that PrPSc itself could increase the 
number of TNT-connected cells in scCAD cells (around 28% 
compared to uninfected cells) (Figure 40). Hijacking of TNT 
structures can be preceded by induction of TNT formation, thus 
optimizing pathogen transfer, as it has been observed for HIV 
spreading in macrophages (Sowinski et al 2008; Kadiu et al 
2011). In these reports, the authors first observed an increase in 
the number of connections in macrophages, following HIV 
infection. Therefore, together with these findings, the increase in 
TNT number upon prion infection can reflect the possibility that 
TNT induction is also a general host-response mechanism against 
pathogens that can mediate transfer of ‘protective’ factors or 
other specific signals in neighboring cells. Especially, it has been 
shown that following PrPSc infection, an early burst of reactive 
oxygen species (ROS) occurs in the brain of prion infected mice 
(Yun et al., 2006; Pamplona et al., 2008) and in in vitro cell 
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culture systems (Haigh et al 2011). It has been recently reported 
that TNTs are induced by H2O2 in rat astrocytes and neurons in a 
p53-dependent manner (Wang et al 2011). Therefore, a possible 
link between prion infection and TNT-induction could be 
envisaged. Moreover, upon H2O2-stimulation, phosphoinositide 3-
kinase (PI3-K) gene among the others is up-regulated by p53 
signalling. Curiously, Myo-X is a downstream effector of PI3-K 
during phagocytocis (Cox et al 2002) and PtdIns(3,4,5)P3 is a 
regulator of Myo-X localization to the tip of filopodia (Plantard et 
al 2010). From the data present in literature and from the 
findings presented here regarding both a role for Myo-X in TNT-
formation and an induction of TNT structures upon prion 
infection, one could be intrigued to pursue this direction and 
uncover a possible relationship in between the two. Particularly, 
would be interesting to understand how prion infection leads 
finally to TNT-induction and what is the biological meaning of this 
process, since an increase of PrPSc spreading is also observed 
when induction of TNT formation occurs? Further investigations 
are needed in order to address this important question in order 
to be able to explore my results towards both the understanding 
of the disease as which as the development of efficacious 
therapies. 
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Conclusions and Perspectives 
 
! In the first part of my PhD work I investigated the role of 
autophagy in prion disease in order to better clarify the 
mechanisms by which PrPSc is degraded. This was 
performed by using in vitro cell models of prion infection 
and combined fluorescence microscopy and biochemical 
approaches. 
 
In these experiments I found that: 
 
a) autophagy is not involved in PrPSc degradation; 
b) tamoxifen and 4-hydroxil-tamoxifen (OHT), two drugs used 
to enhance the autophagic flux, efficiently reduced PrPSc 
levels in autophagy independent manner; 
c) tamoxifen and OHT alter cholesterol trafficking and cause a 
redistribution of both PrPSc and PrPC to lysosomes, thus 
shifting the equilibrium between prion production and 
degradation towards the latter. 
 
While autophagy has been recently shown to have a role in other 
neurodegenerative diseases (by directing aggregated proteins 
into lysosomes), my data exclude a role of autophagy in prion 
degradation. On the other hand, I demonstrated that tamoxifen 
and OHT increase PrPSc degradation by re-routing the trafficking 
of prions to lysosomes independently from the autophagic 
pathway. Moreover, upon OHT treatment cholesterol trafficking in 
the cell is altered leading to the accumulation of this lipid in 
lysosomes. This is accompanied by a reduction of the cholesterol 
content in the endosomal recycling compartment that represents 
a favorable environment for PrPC-PrPSc conversion, thus shifting 
the equilibrium between prion production and degradation 
towards degradation. 
These results highlight the importance of the endosomal 
recycling compartment in prion conversion and the lipid 
environment as key elements necessary for prion replication. This 
suggests that development of new drugs able to selectively 
diverge the trafficking of both PrPC and PrPSc from the recycling 
endosomes or interfere with their mutual interaction by changing 
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cholesterol distribution could be used in experimental search for 
treatments of prion infections. Therefore, given its ability to both 
reduce infectious prions and modify cholesterol metabolism OHT 
represents a well-characterized, widely available pharmaceutical 
that may have applications as broad-spectrum therapy for 
neurodegenerative diseases of protein aggregation.  
In this view, additional experiments are needed to assess OHT 
therapeutic anti-prion efficacy in in vivo experiments. For 
example, it would be possible to deliver OHT by oral 
administration, in order to mimic a pre-clinical therapeutic 
situation, and evaluate both the reduction of PrPSc burden and 
survival times compared to control mice. 
 
! In the second part of my thesis I focused on characterizing 
the intercellular trafficking of PrPSc via Tunneling Nanotubes 
(TNTs) and on the mechanisms of TNT formation and 
function in neuronal CAD cell as a model of prion infection.  
 
By using fluorescence microscopy and flow cytometry 
techniques, I could show that: 
 
a) PrPSc particles travel via TNTs in different sub-cellular 
compartments, as early endosomes and lysosomes, and 
mainly in the endocytic recycling compartment that is also 
an intracellular site for prion conversion; 
b) PrPC over-expression increases the number of TNT 
structures but does not increase vesicle transfer; 
c) PrPSc infection can lead to an increase in TNT-like 
structures; 
d) Myo-X molecular motor is able to induce TNT formation, to 
increase the transfer of vesicle and, more interestingly, to 
increase the transfer of PrPSc particles.  
 
The identification and subsequent dissection of the pathways and 
the molecules that are implicated in intercellular vesicular 
trafficking of PrPSc could help to find possible therapeutic 
approaches to limit PrPSc spreading by controlling its exit from a 
host cell or by impairing its trafficking to the neighboring cells. 
Therefore, a better understanding of this process, together with 
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the study of structural and functional factors (as PrPC and Myo-X) 
involved in TNT formation and transfer of cellular components is 
of fundamental importance in prion biology. 
Moreover, an increasing number of papers have reported the 
involvement of TNTs in normal cellular functions as well as in 
diseases. Indeed our findings are not confined to prion disease but 
could also be extended to other pathological conditions associated 
for example with the spreading of different aggregate proteins 
(e.g., β-Amyloid), signals (e.g., death signals) and pathogens (e.g., 
HIV virus, bacteria) between different cells through TNTs. These 
data also highlight the need of multidisciplinary synergistic 
research between different fields in which TNTs have been shown 
to play a role, thus bringing a new way of looking at diseases and 
allowing the development of new strategies to fight them. 
Therefore a more accurate characterization of this type of long 
distance form of intercellular communication together with a 
better understanding of their physiological role is an intriguing and 
challenging still open question in biology.  
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